



US009464368B2

(12) **United States Patent**  
**Zussman et al.**

(10) **Patent No.:** **US 9,464,368 B2**  
(45) **Date of Patent:** **\*Oct. 11, 2016**

(54) **METHODS OF ATTACHING A MOLECULE-OF-INTEREST TO A MICROTUBE**  
(75) Inventors: **Eyal Zussman**, Haifa (IL); **Yael Dror**, Misgav (IL); **Jonathan Charles Kuhn**, Haifa (IL)  
(73) Assignee: **TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD.**, Haifa (IL)  
( \* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 2 days.  
This patent is subject to a terminal disclaimer.

(21) Appl. No.: **12/918,372**  
(22) PCT Filed: **Feb. 12, 2009**  
(86) PCT No.: **PCT/IL2009/000171**  
§ 371 (c)(1),  
(2), (4) Date: **Dec. 16, 2010**

(87) PCT Pub. No.: **WO2009/104176**  
PCT Pub. Date: **Aug. 27, 2009**  
(65) **Prior Publication Data**  
US 2011/0081394 A1 Apr. 7, 2011

#### **Related U.S. Application Data**

(60) Provisional application No. 61/064,206, filed on Feb. 21, 2008, provisional application No. 61/064,210, filed on Feb. 21, 2008, provisional application No. 61/064,204, filed on Feb. 21, 2008.  
(51) **Int. Cl.**  
**D01D 5/24** (2006.01)  
**D01F 1/08** (2006.01)  
(Continued)  
(52) **U.S. Cl.**  
CPC ..... **D01D 5/003** (2013.01); **A61K 9/0092** (2013.01); **B82Y 30/00** (2013.01); **C02F 3/102** (2013.01);  
(Continued)

(58) **Field of Classification Search**  
CPC ..... A61K 9/0092; A61K 9/00; A61K 9/48;

A61K 9/50; A61K 9/4816; A61K 9/5005;  
D01D 5/003; D01D 5/007  
See application file for complete search history.

#### (56) **References Cited**

##### U.S. PATENT DOCUMENTS

4,921,475 A 5/1990 Sibal  
5,209,734 A 5/1993 Hurley et al.

(Continued)

##### FOREIGN PATENT DOCUMENTS

AU 2007303821 4/2008  
CN 1799649 7/2006

(Continued)

##### OTHER PUBLICATIONS

Zhang et al. Biomimetic and bioactive nanofibrous scaffolds from electrospun composite nanofibers. *International Journal of Nanomedicine* 2007, vol. 2, No. 4, pp. 623-638.\*  
(Continued)


*Primary Examiner* — Shafiqul Haq

(74) *Attorney, Agent, or Firm* — The Roy Gross Law Firm, LLC; Roy Gross

#### (57) **ABSTRACT**

Provided is a method of attaching a molecule-of-interest to a microtube, by co-electrospinning two polymeric solutions through co-axial capillaries, wherein a first polymeric solution of the two polymeric solutions is for forming a shell of the microtube and a second polymeric solution of the two polymeric solutions is for forming a coat over an internal surface of the shell, the first polymeric solution is selected solidifying faster than the second polymeric solution and a solvent of the second polymeric solution is selected incapable of dissolving the first polymeric solution and wherein the second polymeric solution comprises the molecule-of-interest, thereby attaching the molecule-of-interest to the microtube. Also provided is an electrospun microtube comprising an electrospun shell, an electrospun coat over an internal surface of the shell and a molecule-of-interest attached to the microtube.

**18 Claims, 12 Drawing Sheets**  
**(6 of 12 Drawing Sheet(s) Filed in Color)**



(51) **Int. Cl.**

**A61K 9/00** (2006.01)  
**D01D 5/00** (2006.01)  
**B82Y 30/00** (2011.01)  
**C02F 3/10** (2006.01)  
**C02F 3/34** (2006.01)  
**D01D 5/247** (2006.01)  
**D01F 1/10** (2006.01)  
**D01F 8/14** (2006.01)  
**G01N 33/543** (2006.01)  
**C02F 101/18** (2006.01)  
**C02F 101/20** (2006.01)  
**C02F 101/30** (2006.01)  
**C02F 101/36** (2006.01)

(52) **U.S. Cl.**

CPC ..... **C02F 3/34** (2013.01); **C02F 3/342** (2013.01); **D01D 5/247** (2013.01); **D01F 1/10** (2013.01); **D01F 8/14** (2013.01); **G01N 33/54393** (2013.01); **C02F 2101/18** (2013.01); **C02F 2101/20** (2013.01); **C02F 2101/306** (2013.01); **C02F 2101/36** (2013.01); **C02F 2305/08** (2013.01); **Y02W 10/15** (2015.05); **Y10T 428/1393** (2015.01)

(56) **References Cited**

## U.S. PATENT DOCUMENTS

5,688,501	A	11/1997	Merril et al.
5,795,340	A	8/1998	Lang
6,537,195	B2	3/2003	Forman
6,537,241	B1	3/2003	Odland
7,066,922	B2	6/2006	Angel et al.
2001/0014394	A1	8/2001	Soane et al.
2001/0034503	A1	10/2001	Mehier
2003/0098518	A1*	5/2003	Averdug et al. .... 264/10
2003/0135158	A1	7/2003	Gonnelli
2003/0139727	A1	7/2003	Angel et al.
2004/0018226	A1	1/2004	Wnek et al.
2004/0030377	A1	2/2004	Dubson et al.
2004/0147903	A1	7/2004	Latini
2004/0223954	A1	11/2004	Bruessow et al.
2005/0180992	A1	8/2005	Belcher et al.
2006/0119015	A1	6/2006	Wehrspohn et al.
2006/0200232	A1	9/2006	Phaneuf et al.
2006/0226580	A1	10/2006	Xia et al.
2006/0228435	A1	10/2006	Andrady et al.
2009/0061496	A1	3/2009	Kuhn et al.
2010/0129656	A1	5/2010	Zussman et al.
2010/0303881	A1	12/2010	Hoke et al.
2011/0081394	A1	4/2011	Zussman et al.

## FOREIGN PATENT DOCUMENTS

EP	2079860	7/2009
WO	WO 03/000381	1/2003
WO	WO 2006/019293	2/2006
WO	WO 2006/108809	10/2006
WO	WO 2008/041183	4/2008
WO	WO 2009/104174	8/2009
WO	WO 2009/104175	8/2009
WO	WO 2009/104176	8/2009

## OTHER PUBLICATIONS

Yarin et al. Material encapsulation and transport in core-shell micro/nanofibers, polymer and carbon nanotubes and micro/nanochannels. J. Mater. Chem., 2007, vol. 17, pp. 2585-2599.\*  
 Kim et al. Controlled protein release from electrospun biodegradable fiber mesh composed of poly( $\epsilon$ -caprolactone) and poly(ethylene oxide). International Journal of Pharmaceutics 2007, vol. 338, pp. 276-283.\*

Official Action Dated Jun. 20, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/918,377.  
 Official Action Dated Feb. 14, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/311,601.  
 Response Dated Feb. 1, 2011 to Official Action of Oct. 1, 2010 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/896,130.  
 Response Dated Mar. 24, 2011 to Office Action of Oct. 13, 2010 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 200780044536.1.  
 Official Action Dated Apr. 7, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/896,130.  
 Zussman et al. "Formation of Nanofiber Crossbar in Electrospinning", Applied Physics Letters, 82(6): 973-975, Feb. 10, 2003.  
 Response Dated Aug. 2, 2011 to Official Action of Apr. 7, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/896,130.  
 Larsson et al. "Detection of Number and Viability of *E. coli* and *A. Hydrophila* With FISH Technique", Techneau, D.3.5.3, p. 1-30, Apr. 30, 2008.  
 International Preliminary Report on Patentability Dated Apr. 16, 2009 From the International Bureau of WIPO Re.: Application No. PCT/IB2007/054001.  
 International Search Report and the Written Opinion Dated Sep. 29, 2009 From the International Searching Authority Re.: Application No. PCT/IL2009/000169.  
 International Search Report and the Written Opinion Dated Sep. 29, 2009 From the International Searching Authority Re.: Application No. PCT/IL2009/000171.  
 International Search Report and the Written Opinion Dated Sep. 30, 2009 From the International Searching Authority Re.: Application No. PCT/IL2009/000170.  
 International Search Report Dated Oct. 14, 2008 From the International Searching Authority Re.: Application No. PCT/IB2007/054001.  
 Written Opinion Dated Oct. 14, 2008 From the International Searching Authority Re.: Application No. PCT/IB2007/054001.  
 Bognitzki et al. "Polymer, Metal, and Hybrid Nano- and Mesotubes by Coating Degradable Polymer Template Fibers (TUFT Process)", Advanced Materials, 12(9): 637-640, 2000.  
 Caruso et al. "Titanium Dioxide Tubes From Sol-Gel Coating of Electrospun Polymer Fibers", Advanced Materials, 13: 1577-1579, Oct. 16, 2001.  
 Dror et al. "One-Step Production of Polymeric Microtubes by Co-Electrospinning", Small, XP002497054, 3(6): 1064-1073, Jun. 4, 2007.  
 Dror et al. "Viable Encapsulation of Enzymes in Biodegradable Tubular Structures", Faculty of Mechanical Engineering, Faculty of Biology, Technion, Israel Institute of Technology, Haifa, IL, 18 P.  
 Huang et al. "Encapsulating Drugs in Biodegradable Ultrafine Fibers Through Co-Axial Electrospinning", Journal of Biomedical Materials Research, Part A, 77A: 169-179, 169, 2006.  
 Jiang et al. "A Facile Technique to Prepare Biodegradable Coaxial Electrospun Nanofibers for Controlled Release of Bioactive Agents", Journal of Controlled Release, XP005163067, 108(2-3): 237-243, Nov. 28, 2005.  
 Jiang et al. "Modulation of Protein Release From Biodegradable Core-Shell Structured Fibers Prepared by Coaxial Electrospinning", Journal of Biomedical Materials Research Part B: Applied Biomaterials, 79B: 50-57, 2006.  
 Li et al. "Direct Fabrication of Composite and Ceramic Hollow Nanofibers by Electrospinning", Nano Letters, 4(5): 933-938, 2004.  
 Li et al. "Electrospinning of Nanofibers: Reinventing the Wheel?", Advanced Materials, 16(14): 1151-1170, Jul. 19, 2004.  
 Li et al. "Electrospinning: A Simple and Versatile Technique for Producing Ceramic Nanofibers and Nanotubes", Journal of the American Ceramic Society, 89(6): 1861-1869, 2006.  
 Li et al. "Use of Electrospinning to Directly Fabricate Hollow Nanofibers With Functionalized Inner and Outer Surfaces", Small, XP002497053, 1(1): 83-86, Jan. 1, 2005.  
 Loscertales et al. "Electrically Forced Coaxial Nanojets for One-Step Hollow Nanofiber Design", Journal of the American Chemical Society, JACS, 126: 5376-5377, 2004.

(56)

**References Cited****OTHER PUBLICATIONS**

Loscertales et al. "Micro/Nano Encapsulation Via Electrified Coaxial Liquid Jets", *Science*, 295: 1695-1698, Mar. 16, 2002.

Reneker et al. "Electrospinning of Nanofibers From Polymer Solutions and Melts", *Advances in Applied Mechanics*, 41: 1-3, 103-115, 142-153, 2006.

Reznik et al. "Evolution of A Compound Droplet Attached to a Core-Shell Nozzle Under the Action of a Strong Electric Field", *Physics of Fluids*, 18: 062101-1 -062101-13, 2006.

Salalha et al. "Encapsulation of Bacteria and Viruses in Electrospun Nanofibres", *Nanotechnology*, 17: 4675-4681, 2006.

Sun et al. "Compound Core-Shell Polymer Nanofibers by Co-Electrospinning", *Advanced Materials*, XP002497055, 15(22): 1929-1932, Nov. 17, 2003.

Xie et al. "Ultra-High Surface Fibrous Membranes From Electrospinning of Natural Proteins: Casein and Lipase Enzyme", *Journal of Materials Science*, 38: 2125-2133, 2003.

Yarin et al. "Material Encapsulation and Transport in Core-Shell Micro/Nanofibers, Polymer and Carbon Nanotubes and Micro/Nanochannels", *Journal of Materials Chemistry*, XP002546457, 17(25): 2585-2599, Jul. 1, 2007. Chapter III Section (ii).

Yu et al. "Production of Submicrometer Diameter Fibers by Two-Fluid Electrospinning", *Advanced Materials*, 16(17): 1562-1566, Sep. 3, 2004.

Zhang et al. "Coaxial Electrospinning of (Fluorescein Isothiocyanate-Conjugated Bovine Serum Albumin)-Encapsulated Poly( $\epsilon$ -Caprolactone) Nanofibers for Sustained Release", *Biomacromolecules*, 7(4): 1049-1057, 2006.

Zussman et al. "Electrospun Polyacrylonitrile/Poly(Methyl Methacrylate)-Derived Turbostratic Carbon Micro-Nanotubes", *Advanced Materials*, 18: 348-353, 2006.

Official Action Dated Nov. 3, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/896,130.

Communication Pursuant to Article 94(3) EPC Dated Dec. 2, 2011 From the European Patent Office Re. Application No. 07826621.0.

Restriction Official Action Dated Dec. 23, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/311,601.

Official Action Dated Oct. 1, 2010 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/896,130.

Lee et al. "Virus-Based Fabrication of Micro- and Nanofibers Using Electrospinning", *NanoLetters*, 4(3): 387-390, 2004.

Salalha et al. "Encapsulation of Bacteria and Viruses in Electrospun Nanofibres", *Nanotechnology*, 17: 4675-4681, Aug. 30, 2006.

Theron et al. "Electrostatic Field-Assisted Alignment of Electrospun Nanofibres", *Nanotechnology*, 12: 384-390, 2001.

International Preliminary Report on Patentability Dated Sep. 2, 2010 From the International Bureau of WIPO Re. Application No. PCT/IL2009/000171.

Translation of Office Action Dated Oct. 13, 2010 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 200780044536.1.

He et al. "Recent Development of the Nanocomposites Prepared by Coaxial Jet Technology", *Acta Materialia Compositae Sinica*, 22(6): 1-8, Dec. 2005. Abstract in English.

Li et al. "Porous Ultrafine Nanofibers Having a Ultrahigh Specific Surface Area", *Chinese Science Bulletin*, 49(21): 2160-2163, Nov. 2004. Chinese Only!

International Preliminary Report on Patentability Dated Sep. 2, 2010 From the International Bureau of WIPO Re. Application No. PCT/IL2009/000171.

International Preliminary Report on Patentability Dated Sep. 2, 2010 From the International Bureau of WIPO Re.: Application No. PCT/IL2009/000169.

International Preliminary Report on Patentability Dated Sep. 2, 2010 From the International Bureau of WIPO Re.: Application No. PCT/IL2009/0001790.

Translation of Office Action Dated Mar. 1, 2012 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 200780044536.1.

Communication Pursuant to Article 94(3) EPC Dated Jul. 18, 2012 From the European Patent Office Re. Application No. 09713280.7.

Communication Pursuant to Article 94(3) EPC Dated Jul. 19, 2012 From the European Patent Office Re. Application No. 09712148.7.

Communication Pursuant to Article 94(3) EPC Dated Jul. 19, 2012 From the European Patent Office Re. Application No. 09713264.1.

Official Action Dated Aug. 27, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/311,601.

Official Action Dated Feb. 7, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/311,601.

Translation of Office Action Dated Dec. 4, 2012 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 200780044536.1.

Patent Examination Report Dated Nov. 19, 2012 From the Australian Government, IP Australia Re. Application No. 2007303821.

Official Action Dated Jun. 18, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/918,365.

Advisory Action Before the Filing of an Appeal Brief Dated May 16, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/311,601.

Restriction Official Action Dated May 9, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/918,365.

Restriction Official Action Dated Mar. 1, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/918,365.

Advisory Action Before the Filing of an Appeal Brief Dated Apr. 12, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/311,601.

Official Action Dated Apr. 8, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/918,377.

Decision to Grant a European Patent Pursuant to Article 97(1) EPC Dated Jul. 11, 2013 From the European Patent Office Re. Application No. 07826621.0.

Translation of Office Action Dated Jun. 4, 2013 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 200780044536.1.

Communication Under Rule 71(3) EPC Dated Mar. 5, 2013 From the European Patent Office Re. Application No. 07826621.0.

Communication Pursuant to Article 94(3) EPC Dated Aug. 20, 2013 From the European Patent Office Re. Application No. 09713264.1.

Advisory Action Before the Filing of an Appeal Brief Dated May 30, 2014 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/918,365.

Requisition by the Examiner Dated May 22, 2014 From the Canadian Intellectual Property Office Re. Application No. 2,664,972.

Official Action Dated Oct. 1, 2014 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/896,130.

Office Action Dated Nov. 21, 2013 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 200780044536.1 and Its Translation Into English.

Official Action Dated Jan. 17, 2014 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/918,365.

Official Action Dated Jan. 9, 2015 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/918,377.

Official Action Dated Jan. 14, 2015 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/311,601.


McCann et al. "Electrospinning of Nanofibers With Core-Sheath, Hollow, or Porous Structures", *Journal of Materials Chemistry*, 15: 735-738, 2005.

Communication Pursuant to Article 94(3) EPC Dated Aug. 23, 2013 From the European Patent Office Re. Application No. 09713280.7.

Official Action Dated Feb. 4, 2015 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/918,365.

Requisition by the Examiner and Examination Search Report Dated Jan. 23, 2015 From the Canadian Intellectual Property Office Re. Application No. 2,664,972.

\* cited by examiner



FIGs. 1A-D




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3






FIG. 4B




FIG. 4A




FIG. 5




FIG. 6

FIG. 7A





FIG. 7B






FIG. 8

Multiple Enzyme Pathways




FIG. 9






FIG. 10

# METHODS OF ATTACHING A MOLECULE-OF-INTEREST TO A MICROTUBE

## RELATED APPLICATIONS

This application is a National Phase of PCT Patent Application No. PCT/IL2009/000171 having International filing date of Feb. 12, 2009, which claims the benefit of U.S. Provisional Patent Application Nos. 61/064,210, 61/064,206 and 61/064,204 filed on Feb. 21, 2008.

The teachings of PCT/IB2007/054001 are incorporated herein by reference.

The contents of all of the above documents are incorporated by reference as if fully set forth herein.

## FIELD AND BACKGROUND OF THE INVENTION

The invention, in some embodiments thereof, relates to a method of attaching a molecule-of-interest to a microtube and, more particularly, but not exclusively, to electrospun microtubes including the molecule-of-interest attached thereto.

In nature there is an enormous variety of enzymes that catalyze reactions, some of which have industrial use. These include oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Immobilization of enzymes on solid substrates sometimes offers advantages over the use of a free enzyme. For example, immobilization can stabilize enzymes, enable better control of enzymatic reactions, allow the reuse of the enzyme and prevent enzyme loss with time. The material bearing the immobilized enzyme has a significant role in evoking these advantages both from architectural and chemical points of view.

Nanofibers and polymeric nanofibers in particular can be produced by an electrospinning process (Reneker D H., et al., 2006; Ramakrishna S., et al., 2005; Li D., et al., 2004; PCT WO 2006/106506 to the present inventors). Electrospun polymeric nanofibers have been widely used in biological applications such as scaffolds, carriers for biologically active molecules like proteins and enzymes (Xie J., et al., 2003; Zhang Y Z., et al., 2006; Jiang H., et al., 2006; and Patel A C., et al., 2006) and encapsulation of viruses and bacteria (Salalha W., et al., 2006).

Several approaches can be used to entrap or attach enzymes to electrospun fibers. One approach is to immobilize the enzyme on the outer surface of the nanofibers by either covalently attaching the desired enzyme to the functional groups of the polymer surface (Ye P., et al., 2006; Jia H., et al., 2002; Kim T G., et al., 2006) or physically absorbing the enzyme to the surface (Huang X J., et al., 2006). The second approach, which results in encapsulation of enzymes, is based on mixing the enzyme with the polymer solution prior to the electrospinning process (Xie J. and Hsieh Y-L, 2003). However, encapsulation is often associated with leaching of the enzymes, e.g., via fiber dissolution and burst releases (Zhang Y Z., et al., 2006), especially, when the host polymer is a water soluble polymer such as poly(vinyl alcohol) (PVA) or dextran. To prevent immediate dissolution of the fibers in a physiological environment (e.g., blood) and the subsequent enzyme leaching, the electrospun fibers can be crosslinked by chemical or physical agents such as glutaraldehyde or UV irradiation. Alternatively Zeng J, et al. (2005) suggested that PVA fibers can be coated with water insoluble polymers using a chemical vapor deposition (CVD). However, the organic solvents

of the water insoluble polymers are harmful to biological material and can lead to loss of enzymatic activity. To overcome this problem, Herricks et al. (2005) suggested to use surfactant-stabilized enzymes in an organic solution of polystyrene (PS) as a spinning solution. In this way the electrospun nanofibers are insoluble in water and the enzymatic activity is retained due to surfactant stabilization (Herricks T E., et al., 2005).

Sun and co-workers (Sun Z, et al., 2003) describe the production of core-shell nanofibers (i.e., filled fibers) by co-electrospinning of two polymeric solutions using a two co-axial capillaries spinneret. US patent application No. 20060119015 to Wehrspohn R., et al. describes the production of hollow fibers by introducing a liquid containing a polymer to a porous template material, and removal of the template following polymer solidification. PCT/IB/2007/054001 to the present inventors (which is fully incorporated herein by reference) discloses methods of producing electrospun microtubes (i.e., hollow fibers) which can be further filled with liquids and be used as microfluidics.

## SUMMARY OF THE INVENTION

According to an aspect of some embodiments of the present invention there is provided a method of attaching a molecule-of-interest to a microtube, the method comprising: co-electrospinning two polymeric solutions through co-axial capillaries, wherein a first polymeric solution of the two polymeric solutions is for forming a shell of the microtube and a second polymeric solution of the two polymeric solutions is for forming a coat over an internal surface of the shell, the first polymeric solution is selected solidifying faster than the second polymeric solution and a solvent of the second polymeric solution is selected incapable of dissolving the first polymeric solution and wherein the second polymeric solution comprises the molecule-of-interest, thereby attaching the molecule-of-interest to the microtube.

According to an aspect of some embodiments of the present invention there is provided a microtube comprising an electrospun shell, an electrospun coat over an internal surface of the shell and a molecule-of-interest attached to the microtube.

According to an aspect of some embodiments of the present invention there is provided a method of processing a substrate-of-interest, comprising contacting the substrate-of-interest with the microtube of the invention, wherein the molecule-of-interest is capable of processing the substrate, thereby processing the substrate-of-interest.

According to an aspect of some embodiments of the present invention there is provided a method of depleting a molecule from a solution, comprising contacting the solution with the microtube of the invention, wherein the member of the affinity pair is selected capable of binding the molecule, thereby depleting the molecule from the solution.

According to an aspect of some embodiments of the present invention there is provided a method of isolating a molecule from a solution, comprising: (a) contacting the solution with the microtube of the invention under conditions which allow binding of the molecule to the microtube via the member of the affinity pair which is selected capable of binding the molecule, and; (b) eluting the molecule from the microtube; thereby isolating the molecule from the solution.

According to an aspect of some embodiments of the present invention there is provided a method of detecting a presence of a molecule in a sample, comprising: (a) con-



3

tacting the sample with the microtube of the invention, wherein the member of the affinity pair is selected capable of binding the molecule, and; (b) detecting binding of the molecule by the member of the affinity pair; thereby detecting the presence of a molecule in the sample.

According to an aspect of some embodiments of the present invention there is provided a method of releasing a molecule-of-interest to cells of a subject in need thereof, comprising implanting in the subject the microtube of the invention, to thereby release the molecule-of-interest to cells of the subject.

According to some embodiments of the invention, the electrospun shell is formed of a first polymeric solution and the electrospun coat is formed of a second polymeric solution.

According to some embodiments of the invention, the first polymeric solution solidifies faster than the second polymeric solution.

According to some embodiments of the invention, a solvent of the second polymeric solution is incapable of dissolving the first polymeric solution.

According to some embodiments of the invention, the electrospun shell comprises a polymer selected from the group consisting of poly (ε-caprolactone) (PCL), polyamide, poly(siloxane), poly(silicone), poly(ethylene), poly(vinyl pyrrolidone), poly(2-hydroxy ethylmethacrylate), poly(N-vinyl pyrrolidone), poly(methyl methacrylate), poly(vinyl alcohol), poly(acrylic acid), poly(vinyl acetate), polyacrylamide, poly(ethylene-co-vinyl acetate), poly(ethylene glycol), poly(methacrylic acid), polylactide, polyglycolide, poly(lactide-coglycolide), polyanhydride, polyorthoester, poly(carbonate), poly(acrylonitrile), poly(ethylene oxide), polyaniline, polyvinyl carbazole, polystyrene, poly(vinyl phenol), polyhydroxyacid, poly(ε-caprolactone), polyanhydride, polyhydroxyalkanoate, polyurethane, collagen, albumin, alginate, chitosan, starch, hyaluronic acid, and whereas the electrospun coat comprises a polymer selected from the group consisting of poly(acrylic acid), poly(vinyl acetate), polyacrylamide, poly(ethylene-co-vinyl acetate), poly(ethylene glycol), poly(methacrylic acid), polylactide polyglycolide, poly(lactide-coglycolide), polyanhydride, polyorthoester, poly(carbonate), poly(ethylene oxide), polyaniline, polyvinyl carbazole, polystyrene, poly(vinyl phenol), polyhydroxyacid, alginate, starch, hyaluronic acid.

According to some embodiments of the invention, a solvent of the first polymeric solution evaporates faster than a solvent of the second polymeric solution.

According to some embodiments of the invention, the electrospinning is effected using a rotating collector.

According to some embodiments of the invention, a solvent of the second polymeric solution is capable of evaporating through the internal surface of the shell.

According to some embodiments of the invention, the second polymeric solution is capable of wetting the internal surface of the shell.

According to some embodiments of the invention, a thickness of the shell is from about 100 nm to about 20 micrometer.

According to some embodiments of the invention, an internal diameter of the microtube is from about 50 nm to about 20 micrometer.

According to some embodiments of the invention, the first and the second polymeric solutions are selected from the group consisting of: 10% poly (ε-caprolactone) (PCL) in chloroform (CHCl<sub>3</sub>) and dimethylformamide (DMF) (80:20 by weight) as the first polymeric solution and 4% poly (ethylene oxide) (PEO) in water (H<sub>2</sub>O) and ethanol (60:40

4

by weight) as the second polymeric solution, 10% PCL in CHCl<sub>3</sub> and DMF (80:20 by weight) as the first polymeric solution and 6% PEO in H<sub>2</sub>O and ethanol (60:40 by weight) as the second polymeric solution, 9% PCL in CHCl<sub>3</sub> and DMF (90:10 by weight) as the first polymeric solution and 7% PEO in H<sub>2</sub>O as the second polymeric solution, 10% PCL in CHCl<sub>3</sub> and DMF (80:20 by weight) as the first polymeric solution and 9% poly(vinyl alcohol) (PVA) in water and ethanol (50:50 by weight) as the second polymeric solution, and 10% PCL in CHCl<sub>3</sub> and DMF (90:10 by weight) as the first polymeric solution and 4% (w/w) PEO in ethanol:H<sub>2</sub>O (26:74 by weight) as a second polymeric solution.

According to some embodiments of the invention, the microtube is filled with a liquid.

According to some embodiments of the invention, the first and the second polymeric solutions are biocompatible.

According to some embodiments of the invention, the molecule-of-interest is attached to the coat over the internal surface of the shell.

According to some embodiments of the invention, the molecule-of-interest is attached to the shell of the microtube.

According to some embodiments of the invention, the molecule-of-interest comprises a polypeptide, a polynucleotide, a carbohydrate, a small molecule, or any combination thereof.

According to some embodiments of the invention, the molecule-of-interest comprises a member of an affinity pair.

According to some embodiments of the invention, the polypeptide is an enzyme.

According to some embodiments of the invention, the enzyme is alkaline phosphatase (SEQ ID NO:1 or 8) or beta-galactosidase (SEQ ID NO:2 or 9).

According to some embodiments of the invention, the first polymeric solution comprises polyethylene glycol (PEG).

According to some embodiments of the invention, the shell comprises pores.

According to some embodiments of the invention, the shell prevents diffusion of the molecule-of-interest there-through.

According to some embodiments of the invention, the substrate-of-interest comprises incorporating the substrate-of-interest in a synthesis reaction catalyzed by the molecule-of-interest.

According to some embodiments of the invention, the substrate-of-interest comprises incorporating the substrate-of-interest in a catabolism reaction catalyzed by the molecule-of-interest.

According to some embodiments of the invention, the method further comprising collecting the solution following the contacting.

According to some embodiments of the invention, the solution comprises blood.

According to some embodiments of the invention, the affinity pair is selected from the group consisting of an enzyme and a substrate, a hormone and a receptor, an antibody and an antigen, a polypeptide and a polynucleotide, a polynucleotide and a cognate polynucleotide, a polypeptide and a metal ion, a polypeptide and a carbohydrate.

According to some embodiments of the invention, a therapeutically effective amount of the molecule-of-interest is capable of treating a pathology in the subject.

According to some embodiments of the invention, the molecule-of-interest comprises a polypeptide, and whereas a therapeutically effective amount of the polypeptide is capable of treating a pathology in the subject.

According to some embodiments of the invention, the pathology is selected from the group consisting of a metabolic disorder, an endocrine disease, an autoimmune disease, and cancer.

According to some embodiments of the invention, the polypeptide is selected from the group consisting of insulin (SEQ ID NO:6), phenylalanine hydroxylase (PAH) (SEQ ID NO:3), dystrophin (SEQ ID NO:4), beta-glucosidase (GBA) (SEQ ID NO:5), and ceruloplasmin ferroxidase (CP) (SEQ ID NO:7).

Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.

In the drawings:

FIGS. 1A-D are images depicting high resolution scanning electron microscope (HRSEM) micrographs of (a) Type 1 fibers with alkaline phosphatase (AP); (b) Type 2 fibers with AP; (c) Type 1 fibers with beta-galactosidase ( $\beta$ -GAL); and (d) Type 2 fibers with  $\beta$ -GAL;

FIGS. 2A-C are graphs (FIGS. 2a-b) and a picture (FIG. 2C) depicting the progress of the AP reactions with time for enzymes attached to (e.g., encapsulated within) the electrospun fibers and the free enzyme in the solution forming the coat over the internal surface of the shell (also referred to herein as a core solution) prior to the electrospinning. FIG. 2A—the progress of the alkaline phosphatase reaction over 2500 minutes; FIG. 2B—inset, the progress of the reaction through over the first 300 minutes; Note that the enzymatic reaction of the enzyme encapsulated within type 2 electrospun microtubes is faster than that of enzyme encapsulated within type 1 electrospun microtubes. FIG. 2C—a photograph of a piece of mat (Type 1) immersed in the assay solution. The presence of the yellow reaction product, p-nitrophenol, is apparent; the reaction substrate was p-nitrophenyl phosphate;

FIG. 3 is a histogram depicting the relative activity of AP enzyme for different types of fibers (type 1 and type 2) and in dwelling buffers. Mat—the electrospun fibers (microtubes) with the attached (encapsulated) enzymes; rinsing buffer—the buffer used to only rinse the fibers, without any additional incubation time; 24 hrs. buffer—the buffer following incubation of the fibers therein for 24 hours; 72 hrs. buffer—the buffer following incubation of the fibers therein

for 72 hours; core solution—the enzyme in the core solution prior to the electrospinning process.

FIGS. 4A-B are graphs depicting the progress of the  $\beta$ -GAL reactions with time for the two types of electrospun fibers and the free enzyme in the core solution. The substrate was ortho-nitrophenyl galactoside. FIG. 4A—the progress of the  $\beta$ -GAL reactions over 5000 minutes as measured by the amount of ortho-nitrophenol generated; FIG. 4B—inset of the graph of FIG. 4a, the progress of the  $\beta$ -GAL reactions over the first 50 minutes;

FIG. 5 is a graph depicting the  $\beta$ -GAL reaction versus time for the mat and buffers for Type 2 fibers;

FIG. 6 is a histogram depicting the relative activity of the  $\beta$ -GAL and AP for different types of fibers;

FIGS. 7A-B are fluorescence microscope micrographs depicting Type 1 fibers with AP (FIG. 7A) and  $\beta$ -GAL (FIG. 7B). Size bars: 100  $\mu$ m (FIG. 7A) and 50  $\mu$ m (FIG. 7B).

FIG. 8 is a schematic illustration depicting the desorption process of the molecule-of-interest from the microtube of the invention. The molecule-of-interest (e.g., a protein, an enzyme) is attached to the coat over the internal surface of the shell. Following contacting the microtube with a solution, the solution enters the microtube via the pores (an exemplary pore is marked by arrow No. 3) by a capillary rise (see arrow No. 1) and gradually wets and fills the microtube inner volume. The desorption of the molecule-of-interest from the internal surface of the microtube shell (which depends mainly on the rate of the release of the molecule-of-interest from the polymer) is shown by arrow No. 2.

FIG. 9 depicts a multi-step enzymatic reaction performed using encapsulated molecules-of-interest (enzymes 1-4). Enzyme 1 (enz1) catalyzes the conversion of compound A to B; Enzyme 2 (enz2) catalyzes the conversion of compound B to C; Enzyme 3 (enz3) catalyzes the conversion of compound C to D; Enzyme 4 (enz4) catalyzes the conversion of compound D to E.

FIG. 10 is a schematic presentation depicting Atrazine degradation by the isolated *Pseudomonas* ADP enzymes: AtzA (atrazine chlorohydrolase, e.g., GenBank Accession No. NP\_862474), AtzB (hydroxyatrazine hydrolase, e.g., GenBank Accession No. NP\_862481), AtzC(N-isopropylammelide isopropylamino hydrolase, e.g., GenBank Accession No. NP\_862508), AtzD (cyanuric acid amidohydrolase, e.g., GenBank Accession No. NP\_862537), AtzE (biuret hydrolase, e.g., GenBank Accession No. NP\_862538) and AtzF (allophanate hydrolase, e.g., GenBank Accession No. AAK50333) which are attached to the microtube of the invention.

#### DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION

The present invention, in some embodiments thereof, relates to methods of attaching a molecule-of-interest to a microtube and, more particularly, but not exclusively, to electrospun microtubes which include a molecule-of-interest attached thereto which can be used in various therapeutic, diagnostic, purification and synthesis applications.

Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.

While reducing the invention to practice, the present inventors have uncovered that a molecule-of-interest can be attached to electrospun microtubes. Thus, as is shown in

FIGS. 1*a-b* and described in Example 1 of the Examples section which follows, two types of electrospun microtubes containing active molecules-of-interest (e.g., enzymes such as alkaline phosphatase or beta-galactosidase) were formed: Type 1 microtubes which exhibit a non-porous shell, and Type 2 microtubes which exhibit a porous shell due to the presence of PEG in the polymeric solution forming the shell. The enzymatic activity contained within the microtubes was at the same order of magnitude as that of the polymeric solution prior to the electrospinning process (FIGS. 2*a-b*, 3, 4*a-b* and 6; Examples 1-3 of the Examples section which follows) indicating that surprisingly the process of production did not compromise the functionality of the delicate protein material incorporated into the tube. In addition, as is shown in FIG. 3 and described in Example 2 of the Examples section which follows, both the porous and non-porous microtubes were capable of releasing enzymes attached thereto. Moreover, during the electrospinning process, some of the alkaline phosphatase enzyme migrated to the outer surface of the microtube shell and was released therefrom into the aqueous environment (FIG. 3, Example 2), while the  $\beta$ -GAL enzyme remained within the internal surface of the shell (FIG. 5, Example 3). In addition, as is further described in Example 3 of the Examples section which follows, the activity of the enzymes attached to the internal surface of the shell was increased in the presence of a porous shell which enabled the passage of substrates therethrough (FIGS. 4*a-b*). These results support the use of the microtubes of the invention as micro-reactors (e.g., bioreactors) for various synthesis, hydrolysis, isolation and purification reactions.

According to an aspect of the invention there is provided a method of attaching a molecule-of-interest to a microtube. The method is effected by co-electrospinning two polymeric solutions through co-axial capillaries, wherein a first polymeric solution of the two polymeric solutions is for forming a shell of the microtube and a second polymeric solution of the two polymeric solutions is for forming a coat over an internal surface of the shell, the first polymeric solution is selected solidifying faster than the second polymeric solution and a solvent of the second polymeric solution is selected incapable of dissolving the first polymeric solution and wherein the second polymeric solution comprises the molecule-of-interest, thereby attaching the molecule-of-interest to the microtube.

As used herein the term "microtube" refers to a hollow tube having an inner diameter of e.g., about 200 nm to about 50  $\mu$ m and an outer diameter of e.g., about 0.5  $\mu$ m to about 100  $\mu$ m.

According to some embodiments of the invention the thickness of the microtube shell can vary from a few nanometers to several micrometers, such as from about 100 nm to about 20  $\mu$ m, e.g., from about 200 nm to about 10  $\mu$ m, from about 100 nm to about 5  $\mu$ m, from about 100 nm to about 1  $\mu$ m, e.g., about 500 nm.

According to some embodiments of the invention the internal diameter of the microtube shell can vary from a few nanometers to several micrometers, such as from about 50 nm to about 50  $\mu$ m, e.g., from about 100 nm to about 20  $\mu$ m, from about 200 nm to about 10  $\mu$ m, from about 500 nm to about 5  $\mu$ m, from about 1  $\mu$ m to about 5  $\mu$ m, e.g., about 3  $\mu$ m.

According to some embodiments of the invention, the microtube may have a length which is from about 0.1 millimeter (mm) to about 20 centimeter (cm), e.g., from about 1-20 cm, e.g., from about 5-10 cm.

As used herein the term "attaching" refers to the binding of the molecule-of-interest to the polymer(s) comprised in

the microtube of the invention via covalent or non-covalent binding (e.g., via an electrostatic bond, a hydrogen bond, a van-Der Waals interaction) so as to obtain an absorbed, embedded or immobilized molecule-of-interest to the microtube of the invention.

According to some embodiments of the invention, the length (L) of the microtube can be several orders of magnitude higher (e.g., 10 times, 100 times, 1000 times, 10,000 times) than the microtube's diameter (D). Accordingly, a molecule-of-interest which is attached to such a microtube is referred to as being entrapped or encapsulated within the microtube.

According to some embodiments of the invention, covalent attachment of the molecule-of-interest can be via functional groups such as SH groups, amino groups, carboxyl groups which are added to the polymer(s) forming the microtube.

As used herein the phrase "co-electrospinning" refers to a process in which at least two polymeric solutions are electrospun from co-axial capillaries (i.e., at least two capillary dispensers wherein one capillary is placed within the other capillary while sharing a co-axial orientation) forming the spinneret within an electrostatic field in a direction of a collector. The capillary can be, for example, a syringe with a metal needle or a bath provided with one or more capillary apertures from which the polymeric solution can be extruded, e.g., under the action of hydrostatic pressure, mechanical pressure, air pressure and/or high voltage.

The collector serves for collecting the electrospun element (e.g., the electrospun microtube) thereupon. Such a collector can be a rotating collector or a static (non rotating) collector. When a rotating collector is used, such a collector may have a cylindrical shape (e.g., a drum), however, the rotating collector can be also of a planar geometry (e.g., an horizontal disk). The spinneret is typically connected to a source of high voltage, such as of positive polarity, while the collector is grounded, thus forming an electrostatic field between the dispensing capillary (dispenser) and the collector. Alternatively, the spinneret can be grounded while the collector is connected to a source of high voltage, such as with negative polarity. As will be appreciated by one ordinarily skilled in the art, any of the above configurations establishes motion of a positively charged jet from the spinneret to the collector. Reverse polarity for establishing motions of a negatively charged jet from the spinneret to the collector are also contemplated.

For electrospinning, the first polymeric solution is injected into the outer capillary of the co-axial capillaries while the second polymeric solution is injected into the inner capillary of the co-axial capillaries. In order to form a microtube (i.e., a hollow structure, as mentioned above), the first polymeric solution (which is for forming the shell of the microtube) solidifies faster than the second polymeric solution (also referred herein as a core polymeric solution, and is for forming a coat over the internal surface of the shell). In addition, the formation of a microtube also requires that the solvent of the second polymeric solution be incapable of dissolving the first polymeric solution.

The solidification rates of the first and second polymeric solutions are critical for forming the microtube. For example, for a microtube of about 100  $\mu$ m, the solidification of the first polymer (of the first polymeric solution) can be within about 30 milliseconds (ms) while the solidification of the second polymer (of the second polymeric solution) can be within about 10-20 seconds. The solidification may be a result of polymerization rate and/or evaporation rate.

According to some embodiments of the invention, the solvent of the first polymeric solution evaporates faster than the solvent of second polymeric solution (e.g., the solvent of the first polymeric solution exhibits a higher vapor pressure than the solvent of the second polymeric solution).

According to some embodiments of the invention, the rate of evaporation of the solvent of the first polymeric solution is at least about 10 times faster than that of the solvent of the second polymeric solution. The evaporation rate of the solvent of the first polymeric solution can be at least about 100 times faster or at least about 1000 times faster than the evaporation rate of the solvent of second polymeric solution. For example, the evaporation of chloroform is significantly faster than the evaporation of an aqueous solution (water) due to the high vapor pressure at room temperature of the chloroform (195 mmHg) vs. that of the aqueous solution (23.8 mmHg).

When selecting a solvent of the second polymeric solution which is incapable of dissolving the first polymeric solution (i.e., a non-solvent of the first polymeric solution), the polymer of the first polymeric solution can solidify (e.g., through precipitation) and form a strong microtube shell which does not collapse, and is characterized by an even thickness. According to some embodiments of the invention, the first polymeric solution (e.g., the solvent of the first polymer) is substantially immiscible in the solvent of the second polymeric solution.

The solvent of the second polymeric solution may evaporate while the polymer (of the second polymeric solution) forms a thin layer on the internal surface of the shell.

According to some embodiments of the invention, the solvent of the second polymeric solution is capable of evaporating through the internal surface of the shell.

The flow rates of the first and second polymeric solutions can determine the microtube outer and inner diameter and thickness of shell. Non-limiting examples of microtubes generated by electrospinning using different flow rates are shown in Table 1 hereinbelow.

TABLE 1

Effect of the flow rates of the two polymeric solutions during electrospinning on microtube diameter and thickness of shell						
System No.	System: First polymeric solution/ Second polymeric solution	Flow rates (ml/hr)	R Outer Fiber radius (μm)	d Shell thickness (μm)	V Voltage (kV)	Electro-static field kV/cm
M5	First polymeric solution	4	3.0-4.5	0.5 ± 0.1	8.5	0.43
	Second polymeric solution	0.5				
M10	First polymeric solution	10	2.3-4.0	1.0 ± 0.1	8	0.5
	Second polymeric solution	0.3				
M11	First polymeric solution	10	3-6	1.0 ± 0.1	9	0.56

TABLE 1-continued

Effect of the flow rates of the two polymeric solutions during electrospinning on microtube diameter and thickness of shell						
System No.	System: First polymeric solution/ Second polymeric solution	Flow rates (ml/hr)	R Outer Fiber radius (μm)	d Shell thickness (μm)	V Voltage (kV)	Electro-static field kV/cm
	Second polymeric solution	2				

Table 1: Electrospinning was performed with the following solutions: First polymeric solution (for forming the shell) was 10% PCL in CHCl<sub>3</sub>/DMF (8:2 weight/weight); Second polymeric solution (for forming the coat) was 4% PEO in H<sub>2</sub>O/EtOH (6:4, weight/weight). PCL used was PCL 80 K; PEO used was PEO 600 K. The temperature during electrospinning was 22-26° C. The relative humidity during electrospinning was 58%, 52% and 53% for systems M5, M10 and M11, respectively. The flow rates were measured in milliliter per hour (ml/hr); the outer microtube radius (R) and the shell thickness (d) were measured in microns (μm). The voltage was measured in kilo volt (kV), and the electrostatic field was measured in kV per centimeter (cm). The resulting tubes were hollow (good tubes in systems M5 and M11, and mostly good in system M10).

As used herein the phrase “polymeric solution” refers to a soluble polymer, i.e., a liquid medium containing one or more polymers, co-polymers or blends of polymers dissolved in a solvent. The polymer used by the invention can be a natural, synthetic, biocompatible and/or biodegradable polymer.

The phrase “synthetic polymer” refers to polymers that are not found in nature, even if the polymers are made from naturally occurring biomaterials. Examples include, but are not limited to, aliphatic polyesters, poly(amino acids), copoly(ether-esters), polyalkylenes oxalates, polyamides, tyrosine derived polycarbonates, poly(iminocarbonates), polyorthoesters, polyoxaesters, polyamidoesters, polyoxaesters containing amine groups, poly(anhydrides), polyphosphazenes, and combinations thereof.

Suitable synthetic polymers for use by the invention can also include biosynthetic polymers based on sequences found in naturally occurring proteins such as those of collagen, elastin, thrombin, fibronectin, or derivatives thereof or, starches, poly(amino acids), poly(propylene fumarate), gelatin, alginate, pectin, fibrin, oxidized cellulose, chitin, chitosan, tropoelastin, hyaluronic acid, polyethylene, polyethylene terephthalate, poly(tetrafluoroethylene), polycarbonate, polypropylene and poly(vinyl alcohol), ribonucleic acids, deoxyribonucleic acids, polypeptides, proteins, polysaccharides, polynucleotides and combinations thereof.

The phrase “natural polymer” refers to polymers that are naturally occurring. Non-limiting examples of such polymers include, silk, collagen-based materials, chitosan, hyaluronic acid, albumin, fibrinogen, and alginate.

As used herein, the phrase “co-polymer” refers to a polymer of at least two chemically distinct monomers. Non-limiting examples of co-polymers include, polylactic acid (PLA)-polyethyleneglycol (PEG), polyethylene glycol terephthalate (PEGT)/polybutylene terephthalate (PBT), PLA-polyglycolic acid (PGA), PEG-polycaprolactone (PCL) and PCL-PLA.

As used herein, the phrase “blends of polymers” refers to the result of mixing two or more polymers together to create a new material with different physical properties.

The phrase “biocompatible polymer” refers to any polymer (synthetic or natural) which when in contact with cells, tissues or body fluid of an organism does not induce adverse effects such as immunological reactions and/or rejections,

## 11

cellular death and the like. It will be appreciated that a biocompatible polymer can also be a biodegradable polymer.

According to some embodiments of the invention, the first and the second polymeric solutions are biocompatible.

Non-limiting examples of biocompatible polymers include polyesters (PE), PCL, Calcium sulfate, PLA, PGA, PEG, polyvinyl alcohol, polyvinyl pyrrolidone, Polytetrafluoroethylene (PTFE, teflon), polypropylene (PP), polyvinylchloride (PVC), Polymethylmethacrylate (PMMA), polyamides, segmented polyurethane, polycarbonate-urethane and thermoplastic polyether urethane, silicone-polyether-urethane, silicone-polycarbonate-urethane collagen, PEG-DMA, alginate, hydroxyapatite and chitosan, blends and copolymers thereof.

The phrase "biodegradable polymer" refers to a synthetic or natural polymer which can be degraded (i.e., broken down) in the physiological environment such as by proteases or other enzymes produced by living organisms such as bacteria, fungi, plants and animals. Biodegradability depends on the availability of degradation substrates (i.e., biological materials or portion thereof which are part of the polymer), the presence of biodegrading materials (e.g., microorganisms, enzymes, proteins) and the availability of oxygen (for aerobic organisms, microorganisms or portions thereof), lack of oxygen (for anaerobic organisms, microorganisms or portions thereof) and/or other nutrients. Examples of biodegradable polymers/materials include, but are not limited to, collagen (e.g., Collagen I or IV), fibrin, hyaluronic acid, polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), polydioxanone (PDO), trimethylene carbonate (TMC), polyethyleneglycol (PEG), collagen, PEG-DMA, alginate, chitosan copolymers or mixtures thereof.

According to some embodiments, the polymeric solution can be made of one or more polymers, each can be a polymer or a co-polymer such as described hereinabove.

According to some embodiments of the invention, the polymeric solution of the invention is a mixture of at least one biocompatible polymer and a co-polymer (either biodegradable or non-biodegradable).

## 12

According to some embodiments of the invention, the first polymeric solution for forming the shell can be made of a polymer such as poly (ε-caprolactone) (PCL), polyamide, poly(siloxane), poly(silicone), poly(ethylene), poly(vinyl pyrrolidone), poly(2-hydroxy ethylmethacrylate), poly(N-vinyl pyrrolidone), poly(methyl methacrylate), poly(vinyl alcohol), poly(acrylic acid), poly(vinyl acetate), polyacrylamide, poly(ethylene-co-vinyl acetate), poly(ethylene glycol), poly(methacrylic acid), polylactide, polyglycolide, poly(lactide-coglycolide), polyanhydride, polyorthoester, poly(carbonate), poly(acrylonitrile), poly(ethylene oxide), polyaniline, polyvinyl carbazole, polystyrene, poly(vinyl phenol), polyhydroxyacid, poly(caprolactone), polyanhydride, polyhydroxyalkanoate, polyurethane, collagen, albumin, alginate, chitosan, starch, hyaluronic acid, and blends and copolymers thereof.

According to some embodiments of the invention, the second polymeric solution for forming the coat over the internal surface of the shell can be made of a polymer such as poly(acrylic acid), poly(vinyl acetate), polyacrylamide, poly(ethylene-co-vinyl acetate), poly(ethylene glycol), poly(methacrylic acid), polylactide, polyglycolide, poly(lactide-coglycolide), polyanhydride, polyorthoester, poly(carbonate), poly(ethylene oxide), polyaniline, polyvinyl carbazole, polystyrene, poly(vinyl phenol), polyhydroxyacid, alginate, starch, hyaluronic acid, and blends and copolymers thereof.

During the formation of the microtube shell (e.g., following the solidification of the first polymeric solution) the second polymeric solution flows within the internal surface of the shell.

According to some embodiments of the invention, the second polymeric solution is selected capable of wetting the internal surface of the shell.

Various polymeric solutions which are known in the art as capable of wetting other polymeric surfaces (for forming the shell) can be used. Following is a non-limiting list of pairs of polymeric solutions in which the second polymeric solution is capable of wetting the internal surface of the shell formed by the first polymeric solution.

TABLE 2

Pairs of polymeric solutions for producing the microtube of the invention	
First polymeric solution forming the shell	Second polymeric solution capable of wetting the internal surface of the shell
10% poly (ε-caprolactone) (PCL); in chloroform (CHCl <sub>3</sub> ) and dimethylformamide (DMF) (80:20 by weight)	4% poly(ethylene oxide) (PEO); in water (H <sub>2</sub> O) and ethanol (60:40 by weight)
Nylon 6,6 in formic acid 7 to 12 wt %	4% poly(ethylene oxide) (PEO); in water (H <sub>2</sub> O) and ethanol (60:40 by weight)
Poly(L-lactide-co-glycolide) (PLGA 10:90) in hexafluoroisopropanol (HFIP) concentrations ranging from 2 to 7 weight % solution.	4% poly(ethylene oxide) (PEO); in water (H <sub>2</sub> O) and ethanol (60:40 by weight)
Poly(L-lactide-co-glycolide) (PLGA 15:85) hexafluoroisopropanol (HFIP) concentrations ranging from 2 to 7 weight % solution.	4% poly(ethylene oxide) (PEO); in water (H <sub>2</sub> O) and ethanol (60:40 by weight)
poly(lactide-co-glycolide) (PLGA; l-lactide/glycolide — 50/50) 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) concentrations ranging from 2 to 7 weight % solution.	4% poly(ethylene oxide) (PEO); in water (H <sub>2</sub> O) and ethanol (60:40 by weight)
polyglycolide (PGA) in chloroform 3-10 weight % solution.	9% poly(vinyl alcohol) (PVA); in water and ethanol (50:50 by weight)
poly(L-lactide) (PLA) in chloroform 3-10 weight % solution.	9% poly(vinyl alcohol) (PVA); in water and ethanol (50:50 by weight)

TABLE 2-continued

Pairs of polymeric solutions for producing the microtube of the invention	
First polymeric solution forming the shell	Second polymeric solution capable of wetting the internal surface of the shell
Segmented polyurethane in DMF and THF (80:20 by weight)	9% poly(vinyl alcohol) (PVA); in water and ethanol (50:50 by weight)
Polyurethane in DMF and tetrahydrofuran, THF (80:20 by weight)	9% poly(vinyl alcohol) (PVA); in water and ethanol (50:50 by weight)
PLGA (poly lactic-co-glycolic acid); in chloroform and DMSO (dimethyl sulfoxide) in chloroform and DMSO (80:20 by weight).	9% poly(vinyl alcohol) (PVA); in water and ethanol (50:50 by weight)
10% PCL in CHCl <sub>3</sub> /DMF (80:20 by weight)	6% PEO in H <sub>2</sub> O/EtOH (60:40 by weight)
9% PCL in CHCl <sub>3</sub> /DMSO (90:10 by weight)	7% PEO in H <sub>2</sub> O
10% PCL in CHCl <sub>3</sub> /DMF (80:20 by weight)	9% PVA in ethanol/water (50:50 by weight)
10% PCL 80 K CHCl <sub>3</sub> :DMF (90:10 by weight)	4% (w/w) PEO 600 K; in ethanol:H <sub>2</sub> O (26:74 by weight)
10% PCL 80 K + 1% PEG 6 K CHCl <sub>3</sub> :DMF (90:10 by weight)	4% (w/w) PEO 600 K; in ethanol:H <sub>2</sub> O (26:74 by weight)

Table 2 (cont.). The polymers forming the solutions and the solvents are provided by weight ratios, i.e., a weight/weight (w/w) ratio.

According to some embodiments of the invention, the first and the second polymeric solutions are selected from the group consisting of: 10% poly (ε-caprolactone) (PCL) in chloroform (CHCl<sub>3</sub>) and dimethylformamide (DMF) (80:20 by weight) as the first polymeric solution and 4% poly (ethylene oxide) (PEO) in water (H<sub>2</sub>O) and ethanol (60:40 by weight) as the second polymeric solution, 10% PCL in CHCl<sub>3</sub> and DMF (80:20 by weight) as the first polymeric solution and 6% PEO in water and ethanol (60:40 by weight) as the second polymeric solution, 9% PCL in CHCl<sub>3</sub> and DMF (90:10 by weight) as the first polymeric solution and 7% PEO in water as the second polymeric solution, 10% PCL in CHCl<sub>3</sub> and DMF (80:20 by weight) as the first polymeric solution and 9% poly(vinyl alcohol) (PVA) in water and ethanol (50:50 by weight) as the second polymeric solution and 10% PCL in CHCl<sub>3</sub> and DMF (90:10 by weight) as the first polymeric solution and 4% (w/w) PEO in ethanol:H<sub>2</sub>O (26:74 by weight) as a second polymeric solution.

To enable a flow of a liquid-of-interest within the microtube, i.e., along the coat polymer covering the internal surface of the shell (which originates from the second polymer solution), the surface (thin film) formed by the coat polymer should be designed such that it can be wetted by the liquid-of-interest. The ability to wet (wettability) polymer films by liquids is known in the art. For example, silicone oil or water can wet a surface made of a PEO polymer. It will be appreciated that the wettability of the coat polymer covering the internal surface of the shell can be controlled (e.g., improved) for example by attaching functional groups such as hydroxyl groups (OH) which increase the hydrophilicity of the coat by a plasma treatment [see Thurston R M, Clay J D, Schulte M D, Effect of atmospheric plasma treatment on polymer surface energy and adhesion, *Journal of Plastic Film & Sheeting* 23 (1): 63-78 January 2007; which is incorporated within by reference].

As is further discussed hereinabove and in the Examples section which follows, for certain applications the microtube shell may comprise pores, thus creating a “breathing” tube. Methods of forming “breathing” microtube (i.e., microtubes with pores in the shell thereof) are described in PCT/IB2007/054001 to the present inventors, which is fully incorporated herein by reference. Briefly, “breathing” tubes

can be formed by the inclusion of a high percent (e.g., at least 80%) of a volatile component such as tetrahydrofuran (THF), chloroform, acetone, or trifluoroethanol (TFE) in the first polymeric solution forming the shell, and/or by the inclusion of a water-soluble polymer such as polyethylene glycol (PEG) in the first polymeric solution forming the shell so that the first polymeric solution comprises a blend of polymers in which one is water-soluble and the other is water-insoluble (e.g., a blend of PEG and PCL). Alternatively, “breathing” microtubes can be formed by inducing pores in the shell after the completion of the electrospinning process, essentially as described in PCT WO 2006/106506 to the present inventors, which is fully incorporated herein by reference, such as by passing an electrical spark or a heated puncturing element through the electrospun shell, or by using a pulsed or continuous laser beam through the electrospun shell.

According to some embodiments of the invention, the first polymeric solution comprises PEG for inducing pores in the shell. For example, to generate pores greater (>) than 150 nm in diameter, the first polymeric solution may include about 4% PEG MW 35 kDa. Similarly, to generate pores smaller (<) than 150 nm in diameter, the first polymeric solution may include about 2% PEG MW 6 kDa.

The microtube shell of the invention can be designed such that it enables the passage of certain molecules (e.g., a substrate of an enzyme) while preventing the passage of other molecules (e.g., a certain enzyme), depending on the geometry (pore size) and/or the electrical charge of the molecules with respect to the geometry (length and radius), surface energy, electrical charge of the nanopore(s) of the shell, and the viscosity and surface tension of the liquid containing the molecules (e.g., the substrate of the enzyme). In addition, the porosity and pore size of the shell can control the release of the molecule-of-interest which is attached to the microtube. For example, a higher porosity and/or pore size can result in increased rate of release of the molecule-of-interest.

Alternatively, the microtube shell can be made such that it prevents diffusion or any passage of the molecule-of-interest therethrough (i.e., substantially devoid of pores, or with pores smaller than the molecule-of-interest).

## 15

As mentioned, the second polymeric solution comprises the molecule-of-interest. Such a molecule (or molecules) can be any naturally occurring or synthetic molecule such as a polypeptide, a polynucleotide, a carbohydrate or a polysaccharide, a lipid, a drug molecule, a small molecule (e.g., a nucleotide base, an amino acid, a nucleotide, an antibiotic, a vitamin or a molecule which is smaller than 0.15 kDa), or any combination thereof. The molecule-of-interest can be produced by recombinant DNA technology or by known synthesis methods such as solid phase.

According to some embodiments of the invention, the molecule-of-interest comprises a polypeptide such as an enzyme. Such polypeptides (e.g., enzymes) can be naturally occurring (e.g., mammals such as primates, rodents and Homo sapiens, plants, fungi, protozoa, bacteria and viruses) or synthetic (e.g., derived from in vitro evolution) and can be selected according to the desired application.

The following non-limiting list of enzymes can be attached to the microtube of the invention: DNA polymerase (EC 2.7.7.7), DNase (EC 3.1.11.4), RNA polymerase (EC 2.7.7.6), DNA ligase (EC 6.5.1.1), RNA ligase (EC 6.5.1.3), alcohol dehydrogenase (EC 1.1.1.1), homoserine dehydrogenase (EC 1.1.1.3), acetoin dehydrogenase (EC 1.1.1.5), glycerol dehydrogenase (EC 1.1.1.6), L-xylulose reductase (EC 1.1.1.10), L-arabinol 2-dehydrogenase (EC 1.1.1.13), L-idoitol 2-dehydrogenase (EC 1.1.1.14), mannitol-1-phosphate 5-dehydrogenase (EC 1.1.1.17), mannitol 2-dehydrogenase (EC 1.1.1.138), glucose oxidase (EC 1.1.3.4), L-sorbose oxidase (EC 1.1.3.11), lactate-malate transhydrogenase (EC 1.1.99.7), formaldehyde dehydrogenase (EC 1.2.1.1), aryl-aldehyde dehydrogenase (EC 1.2.1.29), aldehyde oxidase (EC 1.2.3.1), pyruvate synthase (EC 1.2.7.1), cortisone  $\alpha$ -reductase (EC 1.3.1.4), lathosterol oxidase (EC 1.3.3.2), D-proline reductase (EC 1.4.4.1), dihydrofolate reductase (EC 1.5.1.3), methylenetetrahydrofolate reductase (NADPH) (EC 1.5.1.20), cystine reductase (NADH) (EC 1.6.1.4), cob(II) alamin reductase (EC 1.6.99.9), sulfite reductase (EC 1.8.1.2), cytochrome-c oxidase (EC 1.9.3.1), NADH peroxidase (EC 1.11.1.1), homogentistate 1,2-dioxygenase (EC 1.13.11.5), *Photinus*-luciferin 4-monooxygenase (1.13.12.7), anthranilate 3-monooxygenase (EC 1.14.13.35), steroid 9 $\alpha$ -monooxygenase (EC 1.14.99.25), mercury(II) reductase (EC 1.16.1.1), nicotinamide N-methyltransferase (EC 2.1.1.1), thymidylate synthase (EC 2.1.1.45), site-specific DNA-methyltransferase (adenine-specific) (EC 2.1.1.72), tryptophan 2-C-methyltransferase (EC 2.1.1.106), glycine formiminotransferase (EC 2.1.2.4), aspartate carbamoyltransferase (EC 2.1.3.2), transaldolase (EC 2.2.1.2), arylamine N-acetyltransferase (EC 2.3.1.5), arginine N-succinyltransferase (EC 2.3.1.109), phosphorylase (EC 2.4.1.1), glycosaminoglycan galactosyltransferase (EC 2.4.1.74), thymidine phosphorylase (EC 2.4.2.4),  $\beta$ -galactoside  $\alpha$ -2,6-sialyltransferase (EC 2.4.99.1), galactose-6-sulfurylase (EC 2.5.1.5), aspartate transaminase (2.6.1.1), hexokinase (EC 2.7.1.1), choline kinase (EC 2.7.1.32), acetate kinase (EC 2.7.2.1), creatine kinase (EC 2.7.3.2), adenylate kinase (EC 2.7.4.3), nucleotide pyrophosphokinase (EC 2.7.6.4), sulfate adenyltransferase (ADP) (EC 2.7.7.5), aryl sulfotransferase (EC 2.8.2.1), carboxylesterase (3.1.1.1), acetyl-CoA hydrolase (EC 3.1.2.1), alkaline phosphatase (3.1.3.1), phosphodiesterase I (EC 3.1.4.1), dGTPase (EC 3.1.5.1), steryl-sulfatase (EC 3.1.6.2), exodeoxyribonuclease I (EC 3.1.11.1), ribonuclease T1 (EC 3.1.27.3),  $\alpha$ -amylase (EC 3.2.1.1), purine nucleosidase (EC 3.2.2.1), epoxide hydrolase (EC 3.3.2.3), lysyl aminopeptidase (EC 3.4.11.15), carboxypeptidase A2 (EC 3.4.17.15), trypsin (EC 3.4.21.4), glutaminase (EC 3.5.1.2), barbiturase (EC

## 16

3.5.2.1), ATP deaminase (EC 3.5.4.18), inorganic pyrophosphatase (EC 3.6.1.1), oxaloacetase (EC 3.7.1.1), oxalate decarboxylase (EC 4.1.1.2), mandelonitrile lyase (EC 4.1.2.10), isocitrate lyase (4.1.3.1), fumarate hydratase (EC 4.2.1.2), pectate lyase (EC 4.2.2.2), histidine ammonia-lyase (EC 4.3.1.3), cyanate lyase (4.3.99.1), cysteine lyase (EC 4.4.1.10), DDT-dehydrochlorinase (EC 4.5.1.1), adenylate cyclase (EC 4.6.1.1), alanine racemase (5.1.1.1), tartrate epimerase (EC 5.1.2.5), retinal isomerase (EC 5.2.1.3), L-rhamnose isomerase (EC 5.3.1.14), prostaglandin-D synthase (EC 5.3.99.2), phosphoglucomutase (EC 5.4.2.2), lanosterol synthase (EC 5.4.99.7), DNA topoisomerase (EC 5.99.1.2), tyrosine-tRNA ligase (EC 6.1.1.1), acetate-CoA ligase (EC 6.2.1.1), acetylcholinesterase (EC 3.1.1.7), butyrylcholinesterase (EC 3.1.1.8) and glutathione synthase (EC 6.3.2.3).

According to an embodiment of the invention, the enzyme which is attached to the microtube is alkaline phosphatase (e.g., SEQ ID NO:1 or 8; EC 3.1.3.1) or beta-galactosidase (e.g., SEQ ID NO:2 or 9; EC 3.2.1.23).

The term "polynucleotide" as used herein refers to a single stranded or double stranded oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes polynucleotides composed of naturally-occurring bases, sugars and covalent internucleoside linkages (e.g., backbone) as well as polynucleotides having non-naturally-occurring portions which function similarly to respective naturally-occurring portions.

The polynucleotide which is attached to the microtube of the invention can be generated according to any oligonucleotide synthesis method known in the art such as enzymatic synthesis, liquid phase or solid phase synthesis (using a commercially available equipment from, for example, Applied Biosystems). Equipment and reagents for executing solid-phase synthesis are commercially available from, for example, Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the capabilities of one skilled in the art and can be accomplished via established methodologies as detailed in, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Md. (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988) and "Oligonucleotide Synthesis" Gait, M. J., ed. (1984) utilizing solid phase chemistry, e.g. cyanoethyl phosphoramidite followed by deprotection, desalting and purification by for example, an automated trityl-on method or HPLC. Liquid phase synthesis of oligonucleotides can be performed using methods known in the art (see for example, Bonora G M, et al., 1998, Biol. Proced. Online. 1: 59-69; Padiya K J and Salunkhe M M., 2000, Bioorg. Med. Chem. 8: 337-42). It will be appreciated that for the preparation of multiple labeled polynucleotides, a large scale oligonucleotide synthesis can be utilized essentially as described elsewhere (Anderson N G. et al., Appl Biochem Biotechnol. 1995 July-September; 54 (1-3):19-42; Rahmann S., Proc IEEE Comput Soc Bioinform Conf. 2002; 1:54-63).

Additionally or alternatively, the polynucleotide which is attached to the microtube of the invention can be generated by recombinant DNA techniques using any known DNA replication or transcription system (e.g., using bacterial cells, eukaryotic cells).

As mentioned, the molecule-of-interest can be a drug molecule. Such a drug can be any synthetic, chemical or biological molecule.

Non-limiting examples of biological drug molecules include antisense oligonucleotides, Ribozymes, DNazymes, siRNA, receptor agonists, antagonists, hormones, growth factors and antibodies. Non-limiting examples of which chemical drug molecules include chemotherapy agents, Paclitaxel (Taxol®), radiation seed particles (e.g., see Hypertext Transfer Protocol://World Wide Web (dot) oncura (dot) com), as well as natural or synthetic vitamins.

The molecule-of-interest which is attached to the microtube of the invention can be labeled. Such a label can be an intrinsic property of the molecule-of-interest (e.g., as in the case of green fluorescent protein) or can be a label which is attached to the molecule-of-interest using known methods. For example, the label can be a fluorescent labeling in which a fluorophore (i.e., an entity which can be excited by light to emit fluorescence) or a radio-isotope is conjugated via a linker or a chemical bond to the molecule-of-interest. Alternatively, the molecule-of-interest can be indirectly labeled via a covalently conjugated enzyme (e.g., horse radish peroxidase) and a covalently conjugated substrate (e.g., o-phenylenediamine) which upon interaction therebetween yield a colorimetric or fluorescent color.

The molecule-of-interest can also comprise a member of an affinity pair, which is capable of reversibly or non-reversibly binding with high affinity (e.g., less than  $10^{-7}$  M, e.g., less than  $10^{-8}$  M, less than  $10^{-9}$ , less than  $10^{-10}$  M) to a specific molecule. For example, the affinity pair can be an enzyme-substrate pair, a polypeptide-polypeptide pair (e.g., a hormone and receptor, a ligand and receptor, an antibody and an antigen, two chains of a multimeric protein), a polypeptide-small molecule pair (e.g., avidin or streptavidin with biotin, enzyme-substrate), a polynucleotide and its cognate polynucleotide such as two polynucleotides forming a double strand (e.g., DNA-DNA, DNA-RNA, RNA-DNA), a polypeptide-polynucleotide pair (e.g., a complex formed of a polypeptide and a DNA or RNA e.g., aptamer), a polypeptide-metal pair (e.g., a protein chelator and a metal ion), a polypeptide and a carbohydrate (leptin-carbohydrate), and the like.

The molecule-of-interest, which is comprised within the second polymeric solution, can be attached to the coat over the internal surface of the shell. For example, as shown in FIG. 5 and described in Example 3 of the Examples section which follows, most of the  $\beta$ -GAL enzymatic activity was detected inside the microtube, demonstrating the attachment of the enzyme to the coat over the internal surface of the shell.

During the electrospinning process some molecules-of-interest which are comprised within the second polymeric solution may migrate to the outer surface of the shell (i.e., mixed with the first polymeric solution) depending on their charge state, size and geometry. For example, as shown in FIG. 3 and described in Example 2 of the Examples section which follows, some of the alkaline phosphatase activity was detected in the rinsing buffer of the microtube.

According to some embodiments of the invention attachment of the molecule-of-interest is performed following microtube formation. For example, the microtube can be soaked with a solution containing the molecule-of-interest. The molecule-of-interest can diffuse through the shell pores and enter the inner lumen of the microtube. In addition, the microtube can be covalently attached to the molecule-of-interest (e.g., via SH groups).

Regardless of the method of production, the present invention provides a microtube which comprises an electrospun shell, an electrospun coat over an internal surface of the shell and a molecule-of-interest attached to the microtube.

As used herein, the phrase "electrospun shell" refers to a hollow element of a tubular shape, made of one or more polymers, produced by the process of electrospinning as detailed above.

As used herein the phrase "electrospun coat" refers to a thin layer covering the internal surface of the shell of the microtube of the invention which is made of one or more polymers by the process of electrospinning as detailed above.

One of ordinary skill in the art will know how to distinguish an electrospun object from objects made by means which do not comprise electrospinning by the high orientation of the macromolecules, the skin (e.g., shell) morphology, and the typical dimensions of the microtube which are unique to electrospinning.

The microtube of the invention can be an individual (e.g., single or separated) microtube or can form part of a plurality (e.g., an aligned array) of microtubes which can be either connected to each other or separated (as single, not-connected microtubes).

For the production of a single microtube a fork like clip is attached to the edge of the rotating disk. The disk is rotated for 1-2 seconds and individual microtubes are formed between the sides of the clip. In a similar way individual electrospun fibers were collected (see E. Zussman, M. Burman, A. L. Yarin, R. Khalfin, Y. Cohen, "Tensile Deformation of Electrospun Nylon 6,6 Nanofibers," *Journal of Polymer Science Part B: Polymer Physics*, 44, 1482-1489, 2006, herein incorporated by reference in its entirety).

Alternatively, when using a rotating collector, a plurality of microtubes can be formed and collected on the edge of the collector as described elsewhere for electrospun fibers (A. Theron, E. Zussman, A. L. Yarin, "Electrostatic field-assisted alignment of electrospun nanofibers," *Nanotechnology J.*, 12, 3: 384-390, 2001; herein incorporated by reference in its entirety).

The plurality of microtubes can be arranged on a single layer, or alternatively, the plurality of microtubes define a plurality of layers hence form a three dimensional structure. The microtubes can have a general random orientation, or a preferred orientation, as desired. For example, when the fibers are collected on a cylindrical collector such as a drum, the microtubes can be aligned predominantly axially or predominantly circumferentially. Different layers of the electrospun microtubes can have different orientation characteristics. For example, without limiting the scope of the present invention to any specific ordering or number of layers, the microtubes of a first layer can have a first predominant orientation, the microtubes of a second layer can have a second predominant orientation, and the microtubes of third layer can have general random orientation.

The microtube of the invention can be available as a dry fibrous mat(s) (e.g., as spun dry microtubes) or as a wetted mat(s) (e.g., following immersing or filling the microtube with a liquid).

The microtube of the invention which is attached to the molecule-of-interest may be configured as or in a microfluidics device. "Lab-on-a-chip" is described in a series of review articles [see for example, Craighead, H. Future lab-on-a-chip technologies for interrogating individual molecules. *Nature* 442, 387-393 (2006); deMello, A. J. Control and detection of chemical reactions in microfluidic systems. *Nature* 442, 394-402 (2006); El-Ali, J., Sorger, P. K. &



Jensen, K. F. Cells on chips. *Nature* 442, 403-411 (2006); Janasek, D., Franzke, J. & Manz, A. Scaling and the design of miniaturized chemical-analysis systems. *Nature* 442, 374-380 (2006); Psaltis, D., Quake, S. R. & Yang, C. H. Developing optofluidic technology through the fusion of microfluidics and optics. *Nature* 442, 381-386 (2006); Whitesides, G. M. The origins and the future of microfluidics. *Nature* 442, 368-373 (2006); Yager, P. et al. Microfluidic diagnostic technologies for global public health. *Nature* 442, 412-418 (2006)] each of which is fully incorporated herein by reference].

According to some embodiments of the invention, the liquid which fills in, flows in or surrounds the microtube enables the desorption (detachment) of the molecule-of-interest from the microtube (e.g., from the polymer included in the coat over the internal surface of the shell). According to some embodiments of the invention the desorption process facilitates the interaction between the molecule-of-interest and a substrate. According to some embodiments of the invention the desorption process enables the flow and/or the release of the molecule-of-interest within and/or from the microtube.

According to some embodiments of the invention, the molecule-of-interest which is attached to the microtube of the invention remains active, i.e., maintains the activity, or at least a portion thereof, which it possessed prior to the attachment (e.g., of the same molecule-of-interest before electrospinning, or when not-attached to the microtube). The term "activity" as used herein refers to any of a catalytic activity, kinetics, and/or affinity to a substrate, a ligand or an affinity member of the molecule. Such an activity can be any biological activity such as catalysis, binding (with a specific affinity), hybridization, chelation, degradation, synthesis, catabolism, hydrolysis, polymerization, transcription, and the like.

As used herein the phrase "at least a portion of the activity" refers to at least about 10%, at least about 20-50%, e.g., more than about 50%, e.g., more than about 60%, e.g., more than about 70%, e.g., more than about 75%, e.g., more than about 80%, e.g., more than about 90%, e.g., more than about 95% of the activity which the molecule-of-interest possessed prior to the attachment to the microtube.

For example, as mentioned before and described in the Examples section which follows, the enzymes contained within the microtubes preserved the specific activity to their substrates at a kinetic which is comparable (i.e., within the same order of magnitude) to that of the enzyme in the polymeric solution prior to electrospinning.

The microtube of the invention which is attached to an active molecule-of-interest can be used in various applications which require the attachment of active molecules (e.g., enzymes, DNA, RNA) to a support and optionally also the controlled release therefrom.

According to some embodiments of the invention, the microtube of the invention is attached to more than one type of molecule-of-interest. The combination of molecules can be selected according to the intended use. For example, several molecules (e.g., enzymes) which are involved in complex reactions (e.g., processing of a substrate or a mixture of substrates) can be used.

Thus, according to an aspect of the invention, there is provided a method of processing a substrate-of-interest. The method is effected by contacting the substrate-of-interest with the microtube of the invention, wherein the molecule-of-interest is capable of processing the substrate, thereby processing the substrate-of-interest.

As used herein the term "processing" refers to a catalytic activity performed by the molecule-of-interest which is attached to the microtube on its cognate substrate.

According to some embodiments of the invention, such a process can concomitantly incorporate of the substrate-of-interest in a synthesis reaction catalyzed by the molecule-of-interest.

For example, the microtube of some embodiments the invention can be used as a micro-reactor (e.g., bioreactor) for chemical transition reactions requiring high concentrations of several enzymes. As described in Example 4 of the Examples section which follows and schematically illustrated in FIG. 9, the microtube of the invention can be attached to certain molecules (enzymes in this case), which together catalyze a multi-step synthesis reaction (e.g., cascade) which converts an initial substrate (e.g., compound A) to an end-product (e.g., compound E). As mentioned, the selective shell of the microtube can be designed such that it prevents the leakage (escape by diffusion) of the intermediate compounds (e.g., compounds B, C and D) therethrough and thus enables sufficiently high concentrations of such compounds as needed for the synthesis of the end product. The local concentration of the intermediate molecules formed from the initial substrate (entrapped at the time of spinning or externally added after electro spinning to the formed microtube) are about 2-10 orders of magnitude greater than the concentrations formed in an open system. Thus, the microtube of some embodiments of the invention exhibits a great kinetic advantage in multi-step reactions as compared to an open system. Microtubes are in this way similar to living cells which function on the same principle.

For example, to synthesize an indole-glycerol phosphate, an intermediate compound in tryptophan synthesis within cells, a microtube of some embodiments of the invention can be attached to the enzymes anthranilate-phosphoribosyl transferase (EC 2.4.2.18), phosphoribosylanthranilate isomerase (EC 5.3.1.24) and indole-3-glycerol-phosphate synthase (EC 4.1.1.18), and the reaction commences when anthranilate and phosphoribosyl-pyrophosphate interact with the attached enzymes. The substrates (anthranilate and phosphoribosyl-pyrophosphate) can be either added externally to the reaction medium (within which the microtube is placed) or can be attached to the microtube by mixing them within the second polymeric solution. When the substrates are supplied externally, pores of about 2-20 nm in diameter should exist in the shell to allow diffusion of anthranilate and phosphoribosyl-pyrophosphate therethrough.

According to some embodiments of the invention, such a process can be the incorporation of the substrate-of-interest in a catabolism reaction catalyzed by the molecule-of-interest.

A catabolism reaction can be the degradation (e.g., by hydrolysis) of a toxic molecule for the purpose of detoxification (e.g., detoxifying water) or decomposition of an unwanted molecule. Examples include, but are not limited to, the removal of the chlorine entity from atrazine (see FIG. 10) and the degradation of cyanide resulting from silver mining.

According to an aspect of the invention, there is provided a method of depleting a molecule from a solution. The method is effected by contacting the solution with the microtube of the invention, wherein the member of the affinity pair (which is attached to the microtube) is selected capable of binding the molecule (which is to be removed), thereby depleting the molecule from the solution.

According to an embodiment of the invention, the method further comprising collecting the solution following the contacting.

As used herein the phrase “depleting” refers to removing an amount e.g., at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, e.g., 99%, e.g., 100% of the molecule from the solution.

According to some embodiments of the invention, the depletion (removal) of the molecule from the solution is effected within a short time period, such as within minutes (e.g., 1-30 minutes), hours (e.g., 1-10 hours) or several days (e.g., 1-5 days).

As used herein the phrase “contacting” refers to enabling the interaction between the molecule and the member of the affinity pair, which is attached to the microtube, for a time period which is sufficient for depleting the molecule from the solution. Such a contact can take place while the solution is passing through (e.g., via capillary forces) the end(s) of the hollow structure of the microtube and/or through the shell pores. Additionally or alternatively, such a contact between the molecule and the member of the affinity pair can take place by incubating the microtube in the solution (e.g., by placing the microtube in a container including the solution).

The solution can be any water-based solution which includes inorganic or organic molecules, such as a biological sample or a sample from a non-living source such as stream or ocean waters. As used herein the phrase “biological sample” refers to any sample derived from a living organism such as plant, bacteria or mammals, and can include cells or alternatively be cell-free (i.e., include only a biological fluid). For example, a biological sample of an individual can include body fluids such as blood or components thereof (e.g., white blood cells, red blood cells, coagulation factors, leukocytes, neutrophils, serum, plasma), cerebrospinal fluid, urine, lymph fluids, and various external secretions of the respiratory, intestinal and genitourinary tracts, tears, saliva, milk, amniotic fluid and chorionic villi, a tissue biopsy, a tissue section, a malignant tissue, and the like. The sample can be derived from the individual and be further tested in vitro or ex vivo, or alternatively, can be not physically removed from the subject (e.g., for in situ detection and/or diagnosis).

According to some embodiments of the invention, the solution is an aqueous solution such as a drinking water, a groundwater and/or an industrial waste water. According to some embodiments of the invention, the microtube of the invention forms part of an aqueous system designed for treatment of the aqueous solution (e.g., for depleting, eliminating or removing toxic moieties therefrom).

For example, to remove a certain metal ion (e.g., copper, gold, nickel, zinc, lead, mercury, cadmium, silver, iron, manganese, palladium, and platinum) from water, the microtube of the invention can be attached to a water soluble ethylene dichloride ammonia polymer, which contains dithiocarbamate salt groups and is capable of chelating the metal ion (U.S. Pat. No. 5,346,627). Thus, by contacting the water with the microtube the ethylene dichloride ammonia polymer binds to the metal ion and removes it from the water. Water collected after being in contact with the microtube is substantially devoid of the metal ion. Alternatively, these metal ions may be removed by attaching a protein chelator of such metal ions to the microtube.

Alternatively, to remove a ligand (e.g., a hormone, a substrate, a co-factor or a vitamin such as biotin) from a solution containing a biological sample, the microtube can

be attached to a polypeptide which is member of an affinity pair such as an enzyme, a hormone or streptavidin, and following contacting the solution with the microtube, the ligand remains attached to the microtube while the solution is substantially devoid of the ligand (e.g., includes less than 0.5%, e.g., less than 0.1%, e.g., less than 0.01% of the ligand).

According to some embodiments of the invention, the molecule which is to be removed from the solution comprises an antigen and the member of the affinity pair comprises the antibody capable of specifically binding the antigen.

For example, the microtube of the invention can be used to remove virus particles from a blood sample. Briefly, an anti-virus antibody (e.g., anti-HIV antibodies such as those described in Tullis, R H., et al., *Therapeutic Apheresis and Dialysis*, 6: 213-220) can be attached to the microtube and a blood sample containing the virus particles (e.g., HIV particles) can be in contact with the microtube such that the virus particles bind to their respective antibodies and the collected blood sample (after being in contact with the microtube) is substantially devoid of the viral particles.

The member of the affinity pair which is attached to the microtube of the invention can be also used to isolate a molecule from a solution.

According to an aspect of the invention, there is provided a method of isolating a molecule from a solution. The method is effected by: (a) contacting the solution with the microtube of the invention under conditions which allow binding of the molecule to the microtube via the member of the affinity pair which is selected capable of binding the molecule, and (b) eluting the molecule from the microtube, thereby isolating the molecule from the solution.

As used herein the term “isolating” refers to physically separating the molecule from the solution or its other components by binding the molecule to the member of the affinity pair that is attached to the microtube and eluting the bound molecule therefrom. As used herein the term “eluting” refers to dissociating the bound molecule from the microtube. Those of skills in the art are capable of adjusting the conditions required for eluting (e.g., releasing) the molecule from the microtube and/or separating the molecule from the other member of the affinity pair.

As is further described in Example 5 of the Examples section which follows, the present inventors have envisaged the use of the microtube of the invention, which is attached to a member of an affinity pair, as a biosensor, for the detection of molecules in a sample. Such a biosensor can be advantageous over known open field biosensors (e.g., sensors in which the member of the affinity pair is conjugated to a solid support not having a tubular structure, such as a flat support) due to the increased ratio between the size of the microtube surface (which attaches the member of the affinity pair) and the volume of the sample being in contact therewith.

According to an aspect of the invention, there is provided a method of detecting a presence of a molecule in a sample. The method is effected by (a) contacting the sample with the microtube of the invention, wherein the member of the affinity pair is selected capable of binding the molecule, and; (b) detecting binding of the molecule by the member of the affinity pair, thereby detecting the presence of a molecule in the sample.

As used herein the phrase “detecting binding” refers to identifying a change in the concentration, conformation, spectrum or electrical charge of the molecule in the sample and/or the member of the affinity pair that is attached to the

microtube following the binding therebetween. Identification of such binding can be performed using methods known in the art such as following the fluorescence or the color of the sample, radioactivity in the sample, the electrical conductivity of the sample and the like.

As mentioned hereinabove and described in Example 2 of the Examples section which follows, the microtube of the invention can release the molecule-of-interest attached thereto (a releasing apparatus).

The microtube of some embodiments the invention (e.g., a microtube made of biocompatible polymers) can be implanted in a subject in need thereof.

As used herein the phrase a "subject in need thereof" refers to any animal subject e.g., a mammal, e.g., a human being which suffers from a pathology (disease, disorder or condition) which can be treated by the molecule that is attached to or flows through the microtube of the invention.

The term "treating" as used herein refers to inhibiting, preventing or arresting the development of a pathology and/or causing the reduction, remission, or regression of a pathology. Those of skill in the art will understand that various methodologies and assays can be used to assess the development of a pathology, and similarly, various methodologies and assays may be used to assess the reduction, remission or regression of a pathology.

Methods of implanting grafts such as the microtube of the invention into a subject are known in the art. For example, the microtube can be implanted subcutaneously, intradermally, or into any body cavity (e.g., abdomen), as well as into the vascular system (using e.g., a hollow catheter delivery system). Alternatively, the microtube of the invention can be connected to a body conduit (e.g., a blood vessel such as a vein or an artery) such that it enables the flow of a fluid therethrough.

For example, the microtube of the invention which is capable of depleting a molecule from a solution as described above, can be connected to a blood vessel of the subject. For example, the proximal end of the microtube (or of a plurality of microtubes) can be connected to a feeding blood vessel and the distal end of the microtube(s) can be connected to a receiving blood vessel. Such a configuration can be used, for example, for hemodialysis and depletion of a specific molecule (e.g., a virus particle such as HIV, hepatitis virus such as HCV) from the blood stream of the subject.

In addition, a microtube which is attached to a drug molecule can be implanted in a subject in need thereof to thereby release a therapeutically effective amount of the drug to cells of the subject.

As used herein the phrase "therapeutically effective amount" means an amount of the molecule-of-interest (e.g., the drug, the active molecule) effective to prevent, alleviate or ameliorate symptoms of a pathology or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art.

For example, in case the molecule-of-interest comprises a polynucleotide, such a polynucleotide can be used in gene therapy applications to either increase an expression level or activity of a desired polypeptide needed for treating the pathology, or to decrease or inhibit the expression level of a polynucleotide causing the pathology (e.g., antisense technology). Alternatively, the polynucleotide can be used to immunize the subject by inducing an immune response thereagainst.

Alternatively, in case the molecule-of-interest is a polypeptide, such a polypeptide can be used in a subject in need of polypeptide therapy, such as a subject having a decreased

or no activity of the polypeptide (e.g., due to a genetic disease, auto-antibodies, pathogen infection, degeneration or a decrease in tissue functioning), as well as for other therapeutic applications such as immunization with the polypeptide.

Non-limiting examples of pathologies which require polypeptide therapy and can be treated using the microtube of the invention include, metabolic disorders such as phenylketonuria (PKU), Gaucher disease, muscular dystrophy [Duchenne (DMD) and Becker (BMD) Muscular Dystrophies], Aceruloplasminemia (an iron metabolic disorder), endocrine diseases such as diabetes, autoimmune diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA), and psoriasis, and various cancers (e.g., lymphoma).

Following is a non-limiting list of polypeptides which can be attached to the microtube of the invention in order to treat pathologies requiring polypeptide therapy. Phenylalanine hydroxylase [(PAH); GenBank Accession Nos. NM\_000277.1 (nucleic acid sequence) and NP\_000268.1 (SEQ ID NO:3; amino acid sequence)] for treating phenylketonuria (PKU), dystrophin [(DMD); GenBank Accession Nos. NM\_000109.2 (nucleic acid sequence) and NP\_000100.2 (SEQ ID NO:4; amino acid sequence)] for treating Duchenne (DMD) and Becker (BMD) Muscular Dystrophies, beta-glucosidase [(GBA); GenBank Accession Nos. NM\_001005741.1 (nucleic acid sequence) and NP\_001005741.1 (amino acid sequence; SEQ ID NO:5)] for treating Gaucher disease, insulin [GenBank Accession Nos. NM\_000207.1 (nucleic acid sequence) and NP\_000198.1 (amino acid sequence; SEQ ID NO:6)] for treating diabetes, and ceruloplasmin ferroxidase [(CP); GenBank Accession Nos. NM\_000096.1 (nucleic acid sequence) and NP\_000087.1 (SEQ ID NO:7; amino acid sequence)] for treating aceruloplasminemia, CD20 monoclonal antibodies for treating non-Hodgkin's lymphoma and autoimmune disease (Yazawa N, et al., 2005, Proc Natl Acad Sci USA. 102:15178-83) and T-cell receptor peptides for treating of multiple sclerosis (MS), rheumatoid arthritis (RA), and psoriasis (Vandenbark A A, et al., 2001, Neurochem Res. 26:713-30).

Targeted delivery of a drug molecule to a tissue-of-interest is desired in various pathologies, especially in cases where the effect of the drug is deleterious to non-diseased tissues or when high concentrations of drug molecules are required to achieve a therapeutic effect on the diseased tissue (the tissue-of-interest). Thus, for example it is highly desired to have a targeted delivery of a chemotherapy agent or a radiation seed particle to the liver in case of hepatic cancer, or an angiogenic factor to coronary blood vessels, heart or carotid blood vessels in case of ischemia.

According to an embodiment of the invention, for targeted delivery of a drug molecule to a tissue-of-interest via the opening of the microtube (at the targeted tissue), the microtube of the invention is designed such that the electrospun shell is semi-permeable (i.e., prevents passage of the drug molecule but enables the penetration of water or a physiological solution therethrough) and the coat over the internal surface of the shell is attached to the drug molecule.

Such a microtube can be implanted in a subject such that the distal end of the microtube is implanted in or in close proximity to the tissue-of-interest. As used herein the term "proximity" refers to being in a cavity defined by the tissue, for example, if the tissue in which the drug is released is a blood vessel (artery or vein) the cavity is a lumen of such a blood vessel, or if the tissue in which the medication is released is a heart chamber, then the cavity is an atrium or a ventricle. It will be appreciated that the other end of the

microtube can be also implanted in proximity to the tissue-of-interest. Alternatively, the proximal end of the microtube can be either sealed using e.g., a laser beam to prevent delivery of the drug to undesired cells/tissues of the subject, or if needed, could be placed outside the body, or subcutaneously such that the microtube can be replenished with additional drug molecules using extra thin needles (e.g., which can penetrate a 5  $\mu$ m lumen of the microtube).

Once the microtube of some embodiments of the invention (e.g., a microtube with a semi permeable shell and a drug molecule attached to the coat over the internal surface of the shell) is implanted in the subject it can be filled with a physiological fluid (e.g., of the subject) which is capable of dissolving the water-soluble polymer of the coat over the internal surface of the shell to thereby release the drug molecule therefrom. The released drug molecule flows by capillary forces within the microtube until reaching the end of the open lumen, which is in proximity of the tissue-of-interest.

If needed, the microtube according to this embodiment of the invention, can be also replenished with additional drug molecules or other molecules which can increase the effect of the drug molecule released by the microtube. For example, if the drug molecule attached to the microtube is an angiogenic factor, a solution saturated with gasses (e.g., oxygen) can be administered to the microtube (e.g., after implantation in the subject) to thereby increase the anti-ischemic effect of the angiogenic factor.

Targeted delivery of a drug to a tissue-of-interest can be also effected using a microtube in which the shell enables diffusion of the drug molecule therethrough and accordingly, the drug molecule can be released through the shell pores and/or the distal opening of the microtube at the desired tissue.

The invention further envisages the use of the microtube of the invention, which include a molecule-of-interest attached thereto, for guiding cell growth ex vivo or in vivo. For example, neuronal cells can be placed near or in direct contact with the microtube which is attached to necessary growth factors and nutrients needed for neuronal growth. It will be appreciated that once an initial neuronal growth has occurred ex vivo, such a system (i.e., the microtube and the neuronal cells) can be implanted in a subject in need thereof (e.g., a subject with degenerated, damaged or injured neuronal cells) to thereby enable neuronal growth and guidance.

The microtube of some embodiments of the invention can be included in a kit/article of manufacture along with a packaging material and/or instructions for use in any of the above described methods or applications.

As used herein the term "about" refers to  $\pm 10\%$ .

The terms "comprises", "comprising", "includes", "including", "having" and their conjugates mean "including but not limited to". This term encompasses the terms "consisting of" and "consisting essentially of".

The phrase "consisting essentially of" means that the composition or method may include additional ingredients and/or steps, but only if the additional ingredients and/or steps do not materially alter the basic and novel characteristics of the claimed composition or method.

As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.

Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for

convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases "ranging/ranges between" a first indicate number and a second indicate number and "ranging/ranges from" a first indicate number "to" a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.

As used herein the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.

An electrospraying apparatus can include a controller programmed with parameters as described herein or measuring output and automatically modifying. Controller can be hardware, software, firmware, with CPU, volatile memory, optional non-volatile memory.

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.

Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.

## EXAMPLES

Reference is now made to the following examples, which together with the above descriptions, illustrate some embodiments of the invention in a non limiting fashion.

Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Md. (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual

Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed. (1994); "Current Protocols in Immunology" Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, Conn. (1994); Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", W.H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; "Oligonucleotide Synthesis" Gait, M. J., ed. (1984); "Nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., eds. (1985); "Transcription and Translation" Hames, B. D., and Higgins S. J., Eds. (1984); "Animal Cell Culture" Freshney, R. I., ed. (1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in Enzymology" Vol. 1-317, Academic Press; "PCR Protocols: A Guide To Methods And Applications", Academic Press, San Diego, Calif. (1990); Marshak et al., "Strategies for Protein Purification and Characterization—A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.

#### General Materials and Experimental Methods

##### Enzymes and Solutions—

The compositions of the shell and core solutions are given in Table 3, hereinbelow. All polymers and solvents were purchased from Sigma-Aldrich and were used as is. Alkaline phosphatase (AP) and beta-galactosidase ( $\beta$ -GAL) from *E. coli* were also purchased from Sigma-Aldrich. AP cleaves monophosphate esters and has a molecular weight of about 80,000 Da.  $\beta$ -GAL is a tetrameric enzyme of 465,396 Da consisting of four identical subunits each (Zabin I., et al., 1980) and catalyzes the hydrolysis of the terminal galactosidyl group of  $\beta$ -galactosides. Both enzymes were initially dissolved in water and then mixed with the core solution.

TABLE 3

Two types of core-shell microtubes: composition of the solutions

Type	Shell solution	Core solution
1	10% PCL 80 K; in $\text{CHCl}_3$ :DMF (90:10 by weight)	4% (w/w) PEG 600 K + 0.0733 mg/ml AP or 2.38 units/ml $\beta$ -GAL; in ethanol: $\text{H}_2\text{O}$ (26:74 by weight)
2	10% PCL 80 K + 1% PEG 6 K; in $\text{CHCl}_3$ :DMF (90:10 by weight)	4% (w/w) PEG 600 K + 0.0733 mg/ml AP or 2.38 units/ml $\beta$ -GAL; in ethanol: $\text{H}_2\text{O}$ (26:74 by weight)

Table 3. Microtubes were formed by co-electrospinning of the shell solution (a first polymeric solution for forming the shell) and a core solution (a second polymeric solution for forming the coat over the internal surface of the shell).

##### Electrospinning—

Hollow microtubes (core-shell hollow fibers) were fabricated by a co-electrospinning process using the set up

described by Sun et al. 2003 and Zussman et al. 2006. All experiments were conducted at room temperature (about 22° C.) and a relative humidity of about 35%. The spinning parameters were as follow: the electrostatic field used was approximately 0.44 kV/cm and the distance between the spinneret and collector plate was 16 cm. The flow rates of both the core and shell solutions were controlled by two syringe pumps and were 3.5 ml/hour for the shell solution and 1 ml/hour for the core solution. The fibers were collected as a strip on the edge of a vertical rotating wheel (Theron A., et al., 2001) having a velocity of 1.2 m/second. For fluorescence microscopy, a few fibers were collected directly onto a microscope slide

##### Imaging—

Images of the fibers were obtained using a Leo Gemini high resolution scanning electron microscope (HRSEM) at an acceleration voltage of 3 kV and a sample to detector distance of 3-5 mm. The specimens were coated with a thin gold film to increase their conductivity. Fluorescence microscope Leica DM IRE2 at excitation and emission wavelengths of 359 and 361 nm, respectively, was used for the imaging of fibers filled with fluorescent product.

##### Measurement of the Enzyme Activity—

To measure enzyme activity, pieces of mat were weighed and dipped in assay solution according to Table 4, hereinbelow. At each time of sampling, the solution was mixed with a vortex mixer, and 1 ml of the assay mixture was transferred to spectrophotometer cuvette. The absorbance of the solution was measured in a Perkins-Elmer spectrophotometer at a wavelength of 410 nm. For both enzymatic reactions, the substrates are colorless but the products, para-nitrophenol for AP and ortho-nitrophenol for 13-GAL, are yellow with an absorption maximum at 410 nm. After the absorbance was measured, the liquid was returned to the assay vessel. Units, activity and relative activity are defined as follow:

$$\text{Unit} = \frac{\Delta A}{\Delta t} \cdot 1000 \quad (1)$$

$$\text{Activity of the mat} = \text{unit} \cdot C \text{ where } C = \frac{\text{mass of total mat}}{\text{mass of piece}} \quad (2)$$

$$\text{Relative Activity (\%)} = \frac{\text{Activity of the mat}}{\text{Activity of the core solution}} \cdot 100 \quad (3)$$

Where:  $\Delta A$  is the difference is the absorbance at difference times,  $\Delta t$ , difference between  $t_1$  and  $t_2$  (two time points) taken in the linear region of the reaction curve, and  $C$  is a normalization factor which takes into account the different weight of each piece.

For the fluorescence microscope imaging a drop of the assay solution was put directly on the microscope slide on which a few fibers had been deposited. The fluorescent substrates were methylumbelliferyl-phosphate for alkaline phosphatase (AP) and methylumbelliferyl-galactoside for beta-galactosidase ( $\beta$ -GAL). These were used at the same concentrations as their nitro-phenyl analogs.

TABLE 4

Composition of the assays				
Enzyme	Substrate	Buffer	H <sub>2</sub> O	Products
AP	0.7 mg/ml p-nitrophenyl-phosphate (MW = 217 Da) 1 ml 4-methylumbelliferyl-phosphate: fluorescence microscopy	TRIS-HCl buffer 1.5 ml	0.5 ml	p-nitrophenol + PO <sub>4</sub>  4-methylumbelliferone + PO <sub>4</sub>
β-GAL	4 mg/ml o-nitrophenyl-β-D-galactoside 0.2 ml (MW = 301 Da) 4-methylumbelliferyl-β-D-galactoside: fluorescence microscopy	Z-buffer 0.7 ml	0.3 ml	o-nitrophenol + galactose  4-methylumbelliferone + galactose

Table 4.

## Example 1

## Attachment of Enzymes to Electrospun Microtubes

## Experimental Results

## Formation of Micro-Tubes—

Two types of electrospun hollow fibers have been fabricated with the polymers listed in Table 3, hereinabove. The resultant fibers are hollow structures, namely micro-tubes, as previously described by the present inventors (Dror, Y et al., 2007 and PCT/IB2007/054001, which is fully incorporated herein by reference). The hollow nature of these structures and the different morphologies of the tube walls are demonstrated in the high resolution scanning electron microscope (HRSEM) micrographs presented in FIGS. 1a-d. Type 1 fibers are made with only PCL in the shell and exhibit a rough surface due to the rapid evaporation of the solvent (FIGS. 1a and c). However, this roughness doesn't affect the intact nature of the walls. As PEG is added to the shell solution (Type 2), the walls become increasingly porous (FIGS. 1b and d) and pores can be seen even in the interior surface of the tubes (FIG. 1b). PEG and PCL are partially miscible due to favorable, but weak, intermolecular polar-interactions (Coleman M M, et al., 1991). During fiber solidification along with the evaporation of the solvents, the concentration of the components increases and phase separation takes place. However, since the PEG has a surfactant-like character it deposits an adherent film around the PCL domains resulting in the formation of pores rather than forming solid domains of PEG.

After electrospinning the tubes form a fibrous non-woven, aligned or non-aligned mat. When the mat material is placed in an aqueous environment, the coat over the internal surface of the shell dissolves and the enzymes are released (through desorption) and become active on their substrate(s). For a further description of the desorption process see FIG. 8 and Example 8 hereinbelow. This arrangement of material allows for flow-through technologies without subjecting the enzyme to the external environment and without the need for chemical attachment and can prevent loss of the entrapped enzyme.

## Enzymes Attached to Fibers Maintain Normal Biological Activity—

The kinetics of the enzymatic reaction for alkaline phosphatase was measured as described in the experimental section and is presented in FIGS. 2a-b. The enzymatic reaction with the fibers was compared to the free enzyme in the core solution (before electrospinning) and normalized with respect to the weight of the analyzed pieces. The results

strongly indicate that the enzyme attached in the fiber (e.g., encapsulated) maintains its biological activity after electrospinning and exhibits a reaction curve similar to the free enzyme. The curves are characteristic of enzymatic reactions when there is large excess of substrate. The colored product, p-nitrophenol, diffuses out of the fibers into the surrounding medium as shown in FIG. 2c (Type 1). The reaction rates of the enzyme attached (e.g., contained within) the microtubes are slightly reduced in comparison to the free enzyme. Without being bound by any theory, it is possible that the reaction rates are reduced because of the following reasons: (1) the substrate has to diffuse into the fibers in order to reach the active site of the enzyme; and/or (2) the enzyme has to diffuse outside; (3) the product has to diffuse outside in order to be detected; (4) some enzyme activity was lost during the spinning process itself. The attainment of maximum reaction velocity occurs more rapidly with Type 2 fibers, undoubtedly due to their highly porous character. Upon closer examination of the initial kinetics, it can be seen that Type 1 fibers, which do not contain PEG in the shell, exhibit a linear reaction rate that is much reduced (inset—FIG. 2b, marked by dark arrows) than Type 2 fibers (which include PEG in the shell polymer, and consequently, pores in the microtube shell). Without being bound by any theory, the initial low rate seems to result from the time required for the penetration of the substrate into the fibers since these fibers have a less porous morphology and are more hydrophobic. In the porous fibers (Type 2) the penetration of the substrate is barely hampered since the presence of PEG facilitates the wetting of the outer surface of the fibers and thereby allows the access of the aqueous substrate.

Altogether, these results demonstrate that enzymes attached to (e.g., encapsulated within) electrospun microtubes maintain their enzymatic activity.

Thus, the present technology overcomes both the problem of fiber dissolution and subsequent leaching of the enzyme and the exposure of the enzyme to harmful solvents.

## Example 2

## Electrospun Microtubes can Release Enzymes Attached Thereto

## Experimental Results

## Enzyme can be Leached Out of the Electrospun Microtubes—

In order to determine whether the substrate diffuses into the fibers or the enzyme diffuses out of the fibers, 3 specimens containing alkaline phosphatase (AP) were cut out

from the non-woven mat and placed in buffer. The buffer from the first sample was taken immediately and assayed (initial rinse). For the second and third samples the buffer was taken and assayed after 24 hours and 72 hours, respectively. The first sample was tested in order to evaluate if any removable enzyme resides on the outer surface of the fibers after the spinning. The relative activity of the escaped enzyme in the buffers for the two types of fibers is presented in FIG. 3. The results clearly indicate that a significant fraction of the enzyme has leached out of the fibers within the first 24 hours. Hence it can be concluded that the reaction monitored for the mat (the electrospun microtubes) is a result of both in-fiber and out-fiber reactions. Interestingly however, for Type 1 fibers, which do not contain PEG in the shell, 82% of enzyme has diffused outside the fibers within 24 hours (compared to the mat). For Type 2 fibers, which are more hydrophilic due to PEG, the leaching of the enzyme is less although by no means negligible. The results also point out, as was already mentioned, that Type 2 fibers are the most active system and attains 55% of the activity of the free enzyme.

#### Alkaline Phosphatase can Migrate to the Outer Surface of the Microtubes During Electrospinning—

Moreover, it is clear that some enzyme is located on the outer surface of the fibers (i.e., attached to the microtube shell) and can immediately enter the surrounding buffer upon rinsing. The migration of the enzyme to the outer surface of the fibers during the spinning is more pronounced in Type 2 and is probably due to PEG which might serve as hydrophilic conduit for the enzyme. It has been already found (Reznik S N, et al., 2006) that in the core-shell process all charges immediately accumulate at the outer surface of the shell in the drop. Ions are preferentially subjected to this migration as the electric field is applied. In the present case, the protein, which is a charged molecule, can also migrate to the outer surface during electrospinning. This may explain the relatively large quantity of enzyme that is released by rinsing.

Altogether, these results demonstrate that type 2 fibers attain more enzymatic activity as compared to type 1 fibers. In addition, the enzyme within the type 2 fibers (which include PEG in the shell) is present in both the outer surface and the inner surface of the microtubes. Thus, these results demonstrate that the even though the enzyme is mixed with the core solution, it is capable of migrating into the outer surface of the shell during the electrospinning process.

### Example 3

#### Electrospun Microtubes can Serve as Microreactors

##### Experimental Results

#### $\beta$ -Galactosidase Remains within the Hollow Fiber Micro-Reactor—

The kinetics of the  $\beta$ -GAL reaction were determined as described hereinabove for AP and the results are presented in FIGS. 4a-b. Briefly, pieces of mat (electrospun microtubes) were immersed in buffer for a quick rinse, 24 or 72 hours to determine if there is any leaching of the enzyme (FIG. 5, shown are results of Type 2 as an example). Two striking differences between the AP and  $\beta$ -GAL series were observed (FIG. 6): (i) the  $\beta$ -GAL reaction rate of the Type 1 mat is much slower relative to that found for AP, and the activity of AP in the type 1 mat is slower relative to that found for the activity of the free enzyme in the core solution (prior to electrospinning). In type 2, conversely, the activity of the  $\beta$ -GAL is higher than that of AP and the reaction velocity of

the  $\beta$ -GAL enzyme is comparable to the free enzyme. This intense response of Type 2 is attributed to the high porosity of these fibers and their hydrophilic nature; (ii) the results shown in FIG. 5 for Type 2 fibers demonstrate that the  $\beta$ -GAL enzyme doesn't diffuse out of the fibers even after 72 hours even though Type 2 might be thought to be the more likely to allow the enzyme to escape. That is, the reaction takes place only within the fibers. Thus, for  $\beta$ -GAL, the hollow fibers act as a micro-reactor; the substrate which enters the "reactor" through the entire porous shell is cleaved by the encapsulated enzyme and the reaction product then diffuses out into the surrounding medium. Thus, without being bound by any theory it seems that the reduction in the reaction rate for Type 1 is related solely to the slow diffusion of the substrate into the fibers. The size of the enzyme seems to affect both the amount of enzyme that can migrate during the spinning to the outer surface of the fibers and its subsequent escape into the surrounding medium. In the case of  $\beta$ -GAL only a small amount of enzyme was detected in the rinsing buffer for Type 2 while for Type 1 no enzyme was detected at all (data not shown). As was argued before, in the fibers which do not contain PEG in the shell (Type 1) an additional moderate slope at the very beginning of the reaction can be observed (FIG. 4b-inset, marked by dark arrow) due to the relatively high hydrophobicity of the surface which hinders the access of the aqueous dissolved substrate.

Altogether, these results demonstrate that the Type 1 system results in lowered enzymatic activity, especially for large proteins such as  $\beta$ -GAL, which cannot diffuse through the shell pores. The fact that Type 1 fibers are hydrophobic and non-porous and thus inhibit the entrance of these substrates seems to make Type 1 fibers less efficacious for their use as flow-through reactors. This is in contrast to the remarkably efficient system obtained with Type 2 fibers.

#### The Enzymatic Reaction Occurs within Type I Micro-tubes (Hollow Fibers)—

Visual evidence that the enzymatic reaction occurs within the type 1 fibers was obtained by using a substrate in which one of the products is fluorescent. For both AP and 13-GAL enzymes the substrates used liberate 4-methylumbelliferone after hydrolysis which allows imaging by fluorescence microscopy. As is clearly seen in FIGS. 7a-b, the interior of the fibers is fluorescent while the surrounding medium is dark. Thus, these results clearly show that both enzymatic reactions (of AP and  $\beta$ -GAL), in fact, take place within the fibers. It is important to emphasize that, in contrast to the mat immersion experiments, this method is very sensitive and enables the detection of very small amounts of product which accumulates within a relatively short time. Indeed, these images were acquired within 1-2 minutes after the substrate was applied, a time scale which is larger than the characteristic time [about 10 seconds, as was calculated by the present inventors (Dror Y., et al., 2007)] of the diffusion through the micro-tubes wall. Hence, these results are not in contradiction to those of the mat immersion experiments in which the kinetics were followed over a much longer period during which both the product and the enzyme (in the AP case) can diffuse outside the fibers. In FIG. 7b short slugs (sections) of fluorescent liquid are observed. This phenomenon has been previously found in such fibers (Dror Y., et al., 2007).

The results shown in Examples 1-3 demonstrate the direct incorporation of enzymes into micro-tubes fabricated by co-electrospinning by introduction of the enzymes into the aqueous core solution of the microtube (e.g., PEO). The shell solution in this case was made of PCL dissolved in

mixture of chloroform and DMF. The separation between the outer organic and inner aqueous phases was found to preserve enzyme activity during and after spinning when the electrospun fibers (mats) were subsequently placed in an aqueous environment.

Two types of micro-tubes were fabricated which differ in their shell morphology. Type 2 shells were produced by adding PEG to the shell solution. By using a mixture of PEG and PCL in the shell, pores were formed during the solidification process and this, in turn, directly affected the transfer of molecules into and out of the fibers. As a consequence, the more porous fibers (Type 2) exhibited higher rates of enzymatic reaction. In addition two enzymes differing in their molecular weight were incorporated: AP and  $\beta$ -GAL. The difference in the molecular weight between the enzymes was well reflected in the kinetics of the enzymatic reactions for both types of micro-tubes. While AP could diffuse outside the fibers,  $\beta$ -GAL remained in the fibers without any leaching of the enzyme and the progress of the reaction depended only on the arrival of the substrate from the surroundings. Thus, the AP fibers act as an enzyme release device in which the release rate can be tailored by modifying the morphology of the shell and, on the other hand, the  $\beta$ -GAL fibers act as an enzymatic micro-reactor with an efficient provision of the substrate through the entire surface area and efficient discharge of the product. Thus, by manipulating the morphology of the shell, the substrate supply and product release rate can be controlled. This method of encapsulation can be used when a separation between the enzyme and an external aqueous environment is desired (e.g. with living tissue to avoid immunological reactions). The remarkable retention of the enzyme activity for  $\beta$ -GAL Type 2 fibers clearly demonstrates that this approach preserves the activity of the enzyme.

Another advantage of the core-shell fiber method is the small volume within the micro-tubes which enables the quick buildup of the product. This is important for enzymes working in sequence where the local concentration of the product of the first reaction serves as the substrate for a subsequent reaction. In this regard, these nanotubes are somewhat analogous to living cells except that any manner of enzymes may be added to the fibers without regard to their biological origin. Another advantage of this system is that unlike living cells, there is no discrimination as to which type of small molecules may enter these tubes. For example, phosphorylated molecules (like p-nitrophenyl phosphate) which do not enter *Escherichia coli* cells can enter the microtubes described herein.

#### Example 4

##### Use of the Electrospun Microtubes as Microreactors for Chemical Transitions

##### The Microtubes of the Invention as Reactions for Multi-Step Enzymatic Processes—

In order to synthesize or catabolize molecules which require multi-step enzymatic processes the present inventors have devised electrospun microtubes which include the enzymes participating in the multi-step enzymatic process, attached thereto, as follows.

For a biochemical pathway which involves the conversion of A to E via compounds B, C and D, the second polymeric solution for forming the coat over the internal surface of the shell (also referred to as a core solution) is mixed with the following enzymes: the enzyme that converts the starting substrate A to intermediate compound B, the enzyme that

converts B to C, the enzyme that converts C to D, and the enzyme that converts D to the end product E (see for example, FIG. 9). It should be noted that due to the proximity of the enzymes to each other in the microtube (which can be a closed micro-reactor), the local concentrations of each of the intermediate molecules, i.e., compounds B, C, and D is relatively high, which enables the kinetics of the reactions to occur, similarly to their concentrations in cells or cell compartments (e.g., mitochondria). The shell solution is made from hydrophobic polymers (water insoluble polymers), with or without the addition of PEG.

Thus, the microtube of the invention enables higher local concentrations of intermediate compounds which can not be reached from the same starting material (substrate A) if an open system (such as any solid substrate to which an enzyme is immobilized) is used.

The creation of micro- and nano-fibers containing enzymes simulates the cellular structure because two or more different enzymes involved in a particular synthesis or degradation can be put into proximity of one another. The interior of the tube is quite parallel to that of cells except that the borders of the tube are made from a water insoluble substance whereas living cells are encompassed by lipid membranes. In addition the microtubes are much longer than cells but quite similar in other dimensions to a bacterial cell. In the electrospun fibers, any small molecule can pass through the water insoluble barrier (pores can be made) regardless of its chemistry with the only provision that the small molecule be water soluble.

Thus, the present technology allows the entrapment of high concentrations of an enzyme or several enzymes within a confined space. Single or multi-step reactions can then take place where the product of one reaction is the substrate of a second and the second enzyme is spatially nearby. While such multi-step reactions can occur in an open system, the time necessary to reach the end product is orders of magnitude greater than within the microtube of the invention.

##### The Microtubes of the Invention can Include Enzymes from Different Species—

Another very important advantage of these electrospun fibers is that there is no limitation of which enzymes can be embedded. In nature, cells contain enzymes useful for their growth and reproduction. Organisms have not been designed or selected for industrial processes desired by humans. The microtubes of the invention allow any desired combination of enzymes to be brought together. This might mean that enzymes from totally different organisms (e.g. flies and humans) could be placed together for some use while in nature no organism exists with this combination.

##### The Microtubes of the Invention as Micro-Reactors for the Production of Molecules which are Intermediate Compounds of a Natural Process—

The enzymes encapsulated might be those carrying out part of pathway making the end product a substance that is usually an intermediate molecule in living organisms. This allows one to synthesize molecules that cannot be obtained in any amount from living material because the concentration of intermediates in cells is usually very low (in the order of 10  $\mu$ M or less). For example, to synthesize indole-glycerol phosphate which is an intermediate in tryptophan synthesis within the cells of lower organisms, the enzymes that participate in the conversion of anthranilate (an inexpensive compound) to indole-glycerol phosphate should be included in the microtube, while the enzymes that continue the synthesis of tryptophan from indole-glycerol phosphate are excluded from the microtube. In summary, many combinations of enzymes from different organisms may be put



35

together without any genetic engineering and partial sets of enzymes can also be used. The number of possible useful combinations is therefore very large.

Thus, the microtubes of the invention can be used as enzymatic micro-reactors where the inner space enables a confined but free reaction space. The substrate diffuses through the shell to the inner space where the enzymatic reaction takes place and the product can then diffuse out.

#### Example 5

##### The Electrospun Microtubes as Biosensors

Since the electrospun microtubes of the invention are insoluble in aqueous solutions, they can provide an excellent tool for the construction of biosensors.

Since any enzyme or combination of enzymes can be encapsulated in the electrospun microtubes, a variety of biosensors can be devised. For example, enzymes that are sensitive to heavy metals exhibit loss of activity in the presence of heavy metals. Another example, firefly luciferase, for example can be electrospun with its luciferin cofactor and any reaction affecting ATP production can be used in conjunction with light output the signal.

#### Example 6

##### The Electrospun Microtubes for Flow-Through Applications

###### Water Purification or Detoxification—

The electrospun microtubes of the invention, which are made of a water-insoluble outer shell, enable the flow of liquids. It will be appreciated that enzymes embedded in such microtubes can be used to purify the liquid flowing past the microtubes as molecules diffuse in and out of them.

Thus the present inventors have devised water purification or detoxification apparatuses, as follows. The second polymeric solution which forms the coat over the internal surface of the shell (also referred to as a core solution) [which is made of water-soluble polymer(s)] includes enzymes which remove a toxic moiety from water, such as the gene product of the *atzA* gene from *Pseudomonas* ADP that removes the chlorine from atrazine, a toxic substance. The shell solution [which is made of water-insoluble polymer(s)] is designed so as to enable water flow within the microtube. The effluent would thereby be rendered free of atrazine and safe for animal and human consumption.

###### Dialysis—

The microtubes of the invention can be used in various applications which remove certain compounds, such as dialysis procedures on humans. Thus, the electrospun microtubes can be made using a shell polymer which prevents the diffusion of enzymes therethrough, yet enables passage of water and substances that need to be purified. It will be appreciated that such microtubes can be also implanted into a subject in need thereof (e.g., a subject in need of dialysis), and due to the structure of a closed conduit, which prevents passage of embedded enzymes through the shell, there is no immune response to the implanted conduit.

#### Example 7

##### The Electrospun Microtubes for Enzyme Therapy

Since the electrospun microtubes of the invention are insoluble in aqueous solutions, they should provide excel-

36

lent tool for the construction of material for enzyme therapy. Some individuals lack certain enzymes, usually as a result of their being homozygous for recessive alleles that lead to synthesis of an inactive enzyme. Gene therapy attempts to introduce the missing active gene which thereby leads to the production of an active enzyme. However, this technique is still quite inefficient. A different way of treating such patients is enzyme therapy, in which the missing enzyme is exogenously supplied to the subject. The main drawbacks of the second method is that injection of enzymes often leads to the formation of antibodies against them and the half-life of the enzymes within the body may be quite short.

Thus, the present inventors have devised an apparatus for enzyme therapy, as follows. Briefly, the electrospun microtubes which include a water-insoluble shell can include enzymes which are needed for enzyme therapy, and be further implanted in a subject in need thereof.

###### Enzyme Therapy for PKU—

Phenylketonuria (PKU) occurs in slightly less than 1 per 10000 individuals and is an autosomal recessive genetic disease caused by homozygosity of alleles encoding defective enzymes. Phenylalanine and tyrosine are amino acids that are found in most proteins. In humans, the source of these two amino acids is dietary protein. In normal individuals, excess phenylalanine is converted to tyrosine. Excess tyrosine, in turn, is broken down to fumarate and acetoacetate. Both tyrosine and phenylalanine are essential for human protein synthesis. In addition, tyrosine is the precursor of melanin (skin and eye pigment) and for certain hormone like substances such as thyroxine. Phenylketonuria is caused by the lack of the enzyme (phenylalanine 4-monooxygenase EC 1.14.16.1) that converts phenylalanine to tyrosine. The result of this defect is the accumulation of phenylalanine in the blood along with a number of compounds that are derived from it (e.g. phenylpyruvic acid and phenyllactic acid). The result is brain damage (and an IQ of 30-70) as some of these compounds are toxic. The current method of preventing deterioration of the disease is to limit the intake of phenylalanine. The present inventors have envisaged that PKU can be treated by implanting electrospun microtubes containing the missing enzyme, phenylalanine hydroxylase (PAH; GenBank Accession No. NP\_00026), in a subject diagnosed with PKU, and thereby enabling the breakdown of excess phenylalanine in the subject. It will be appreciated that in this case, the microtube can be designed so as to enable release of enzyme from the inner surface through the outer shell (e.g., using PEG in the outer shell) or alternatively can be designed such that the enzyme is entrapped (or remains) within the microtubes and effects its activity there (e.g., by diffusion of the substrate or end-product through the shell pores, or microtube opening(s)). As phenylalanine hydroxylase can be phosphorylated (with a molecular weight of consists of 50,000 Da) or dephosphorylated (with a molecular weight of 49,000 Da), the size of the pores in the shell should enable passage (by diffusion) of each of these forms (e.g., about 5 nm in diameter). Microtubes can be made with smaller pores that will prevent the loss of the enzyme which will remain within the microtube.

#### Example 8

##### The Desorption Process

FIG. 8 schematically depicts the desorption of a molecule-of-interest to the microtube of the invention. After the electrospinning process, the molecule-of-interest (e.g., a

protein, an enzyme) is adsorbed to the inner side of the microtubes. As mentioned, the porosity of the microtubes can be controlled (e.g., adding PEG to the shell polymer), therefore the shell consists of nanopores (see #3 in FIG. 8) with an opening to the outer surface of the microtube, which herein the pores are considered to have a cylindrical shape. When immersing the microtubes in a solution (e.g., a tissue culture medium, a physiological solution or any buffer) most nanopores opening are accessible to the solution.

Once the microtubes are immersed in the solution the nanopores are filled by the solution through capillary rise (see arrow #1 in FIG. 8). It will be appreciated that the time of the capillary rise depends on the solution rheological properties (viscosity and surface tension), the wetting angle and the geometry of the nanopore (length and radius). The solution penetrates to the microtube and start wetting and filling its entire inner volume. Desorption of the molecule-of-interest from the microtube wall depends mainly on the rate of the release of the molecule-of-interest from the polymer of the second polymeric solution. Finally, the molecule-of-interest (e.g., protein/enzymes) diffuses (see arrow #2 in FIG. 8) into the solution and released to the surroundings of the microtubes (assuming that the major release is through the microtubes envelope).

Note that the geometry (radius and length) of the nanopore is controllable, by adjusting the shell thickness, or by blending, more PEG to the shell polymer. Therefore, the release from or confinement in the microtube of the invention is controllable, e.g., in certain cases the molecule-of-interest is released from the microtube, whereas in other cases, the molecule-of-interest remains in the inner volume of the microtube. As shown in FIG. 2a, a molecule-of-interest is released from the microtube of the invention in a controlled manner, which can be extended beyond 2500, minutes, e.g., for several days and months.

Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.

## REFERENCES

Additional References are Cited in Text

- (1) Xie, J.; Hsieh, Y. L. *J. Mater. Sci.* 2003, 38, 2125-2133.
- (2) Zhang, Y. Z.; Wang, X.; Lim, C. T.; Ramakrishna, S. *Biomacromolecules* 2006, 7, 1049-1057.
- (3) Jiang, H.; Hu, Y.; Zhao, P.; Li, Y.; Zhu, K. *J. Biomed. Mater. Res. Part B: Appl. Biomater.* 2006, 79B, 50-57.
- (4) Patel, A. C.; Li, S.; Yuan, J. M.; Wei, Y. *Nano Letters* 2006, 6, 1042-1046.
- (5) Salalha, W.; Kuhn, J.; Dror, Y.; Zussman, E. *Nanotechnology* 2006, 17, 4675-4681.
- (6) Sun, Z.; Zussman, E.; Yarin, A. L.; Wendorff, J. H.; Greiner, A. *Adv. Mater.* 2003, 15, 1929-1932.
- (7) Ye, P.; Xu, Z. K.; Wu, J.; Innocent, C.; Seta, P. *Macromolecules* 2006, 39, 1041-1045.
- (8) Jia, H.; Zhu, G.; Vugrinovich, B.; Kataphinan, W.; Reneker, D. H.; Wang, P. *Biotechnol. Prog.* 2002, 18, 1027-1032.
- (9) Kim, T. G.; Park, T. G. *Biotechnol. Prog.* 2006, 22, 1108-1113.
- (10) Huang, X. J.; Xu, Z. K.; Wan, L. S.; Innocent, C.; Seta, P. *Macromol. Rapid Commun.* 2006, 27, 1341-1345.
- (11) Wu, L.; Yuan, X.; Sheng, J. J. *Membr. Sci.* 2005, 250, 167-173.
- (12) Jiang, H.; Fang, D.; Hsiao, B. S.; Chu, B.; Chen, W. *Biomacromolecules* 2004, 4, 326-333.
- (13) Zeng, J.; Aigner, A.; Czubayko, F.; Kissel, T.; Wendorff, J. H.; Greiner, A. *Biomacromolecules* 2005, 6, 1484-1488.
- (14) Herricks, T. E.; Kim, S. H.; Kim, J.; Li, D.; Kwak, J. H.; Grate, J. W.; Kim, S. H.; Xia, Y. J. *Mater. Chem.* 2005, 15, 3241-3245.
- (15) Dror, Y.; Salalha, W.; Avrahami, R.; Zussman, E.; Yarin, A. L.; Dersch, R.; Greiner, A.; Wendorff, J. H. 2007, *Small* 3:1064-73.
- (16) Zabin, I.; Flower, A. V. *b-Galactosidase, the Lactose Permease Protein and Thiogalactoside Transacetylase*; in *The Operon* pp 89-121, Cold Spring Harbor Laboratory: NY, 1980.
- (17) Zussman, E.; Yarin, A. L.; Bazilevsky, V.; Avrahami, R.; Feldman, M. *Adv. Mater.* 2006, 18, 348-353.
- (18) Theron, A.; Zussman, E.; Yarin, A. L. *Nanotechnology* 2001, 12, 384.
- (19) Coleman, M. M.; Graf, J. F.; Painter, P. C. *Specific Interactions and the Miscibility of Polymer Blends*; Technomic Publishing Company: Pennsylvania, 1991.
- (20) Reznik, S. N.; Yarin, A. L.; Zussman, E.; Bercovici, L. *Physics of Fluids* 2006, 18, 1-13.
- (21) D. H. Reneker, A. L. Yarin, E. Zussman, H. Xu, *Advances in Applied Mechanics* 2006, 40.
- (22) S. Ramakrishna, K. Fujihara, W.-e. Teo, Lim, T. C., Z. Ma, *An Introduction to Electrospinning and Nanofibers*, 1 ed., World Scientific Publishing Company, 2005.
- (23) D. Li, Y. N. Xia, *Advanced Materials* 2004, 16, 1151.

## SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 9

<210> SEQ ID NO 1

<211> LENGTH: 524

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

Met Ile Ser Pro Phe Leu Val Leu Ala Ile Gly Thr Cys Leu Thr Asn  
1 5 10 15

Ser 60	Leu 61	Val 62	Pro 20	Glu 63	Lys 64	Glu 65	Lys 66	Asp 25	Pro 67	Lys 68	Tyr 69	Trp 70	Arg 30	Asp 71	Gln 72
Ala 31	Gln 32	Glu 33	Thr 34	Leu 35	Lys 36	Tyr 37	Ala 40	Leu 41	Glu 42	Leu 43	Gln 44	Lys 45	Leu 46	Asn 47	Thr 48
Asn 51	Val 52	Ala 53	Lys 54	Asn 55	Val 56	Ile 55	Met 56	Phe 57	Leu 58	Gly 59	Asp 60	Gly 61	Met 62	Gly 63	Val 64
Ser 65	Thr 66	Val 67	Thr 68	Ala 69	Ala 70	Arg 71	Ile 72	Leu 73	Lys 74	Gly 75	Gln 76	Leu 77	His 78	His 79	Asn 80
Pro 81	Gly 82	Glu 83	Glu 84	Thr 85	Arg 86	Leu 87	Glu 88	Met 89	Asp 90	Lys 91	Phe 92	Pro 93	Phe 94	Val 95	Ala 96
Leu 101	Ser 102	Lys 103	Thr 104	Tyr 105	Asn 106	Thr 107	Asn 108	Ala 105	Gln 109	Val 110	Pro 111	Asp 112	Ser 113	Ala 114	Gly 115
Thr 116	Ala 117	Thr 118	Ala 119	Tyr 120	Leu 121	Cys 122	Gly 123	Val 124	Lys 125	Ala 126	Asn 127	Glu 128	Gly 129	Thr 130	Val 131
Gly 132	Val 133	Ser 134	Ala 135	Ala 136	Thr 137	Glu 138	Arg 139	Ser 140	Arg 141	Cys 142	Asn 143	Thr 144	Thr 145	Gln 146	Gly 147
Asn 148	Glu 149	Val 150	Thr 151	Ser 152	Ile 153	Leu 154	Arg 155	Trp 156	Ala 157	Lys 158	Asp 159	Ala 160	Gly 161	Lys 162	Ser 163
Val 164	Gly 165	Ile 166	Val 167	Thr 168	Thr 169	Thr 170	Arg 171	Val 172	Asn 173	His 174	Ala 175	Thr 176	Pro 177	Ser 178	Ala 179
Ala 181	Tyr 182	Ala 183	His 184	Ser 185	Ala 186	Asp 187	Arg 188	Asp 189	Trp 190	Tyr 191	Ser 192	Asp 193	Asn 194	Glu 195	Met 196
Pro 197	Pro 198	Glu 199	Ala 200	Leu 201	Ser 202	Gln 203	Gly 204	Cys 205	Lys 206	Asp 207	Ile 208	Ala 209	Tyr 210	Gln 211	Leu 212
Met 213	His 214	Asn 215	Ile 216	Arg 217	Asp 218	Ile 219	Asp 220	Val 221	Ile 222	Met 223	Gly 224	Gly 225	Gly 226	Arg 227	Lys 228
Tyr 229	Met 230	Tyr 231	Pro 232	Lys 233	Asn 234	Lys 235	Thr 236	Asp 237	Val 238	Glu 239	Tyr 240	Glu 241	Ser 242	Asp 243	Glu 244
Lys 245	Ala 246	Arg 247	Gly 248	Thr 249	Arg 250	Leu 251	Asp 252	Gly 253	Leu 254	Asp 255	Leu 256	Val 257	Asp 258	Thr 259	Trp 260
Lys 261	Ser 262	Phe 263	Lys 264	Pro 265	Arg 266	Tyr 267	Lys 268	His 269	Ser 270	His 271	Phe 272	Ile 273	Trp 274	Asn 275	Arg 276
Thr 277	Glu 278	Leu 279	Leu 280	Thr 281	Leu 282	Asp 283	Pro 284	His 285	Asn 286	Val 287	Asp 288	Tyr 289	Leu 290	Leu 291	Gly 292
Leu 293	Phe 294	Glu 295	Pro 296	Gly 297	Asp 298	Met 299	Gln 300	Tyr 301	Glu 302	Leu 303	Asn 304	Arg 305	Asn 306	Asn 307	Val 308
Thr 309	Asp 310	Pro 311	Ser 312	Leu 313	Ser 314	Glu 315	Met 316	Val 317	Val 318	Val 319	Ala 320	Ile 321	Gln 322	Ile 323	Leu 324
Arg 325	Lys 326	Asn 327	Pro 328	Lys 329	Gly 330	Phe 331	Phe 332	Leu 333	Leu 334	Val 335	Glu 336	Gly 337	Gly 338	Arg 339	Ile 340
Asp 341	His 342	Gly 343	His 344	His 345	Glu 346	Gly 347	Lys 348	Ala 349	Lys 350	Gln 351	Ala 352	Leu 353	His 354	Glu 355	Ala 356
Val 357	Glu 358	Met 359	Asp 360	Arg 361	Ala 362	Ile 363	Gly 364	Gln 365	Ala 366	Gly 367	Ser 368	Leu 369	Thr 370	Ser 371	Ser 372
Glu 373	Asp 374	Thr 375	Leu 376	Thr 377	Val 378	Val 379	Thr 380	Ala 381	Asp 382	His 383	Ser 384	His 385	Val 386	Phe 387	Thr 388
Phe 389	Gly 390	Gly 391	Tyr 392	Thr 393	Pro 394	Arg 395	Gly 396	Asn 397	Ser 398	Ile 399	Phe 400	Gly 401	Leu 402	Ala 403	Pro 404
Met 405	Leu 406	Ser 407	Asp 408	Thr 409	Asp 410	Lys 411	Lys 412	Pro 413	Phe 414	Thr 415	Ala 416				

-continued

---

```

Met Val Asp Tyr Ala His Asn Asn Tyr Gln Ala Gln Ser Ala Val Pro
  435                      440                      445

Leu Arg His Glu Thr His Gly Gly Glu Asp Val Ala Val Phe Ser Lys
  450                      455                      460

Gly Pro Met Ala His Leu Leu His Gly Val His Glu Gln Asn Tyr Val
  465                      470                      475                      480

Pro His Val Met Ala Tyr Ala Ala Cys Ile Gly Ala Asn Leu Gly His
  485                      490                      495

Cys Ala Pro Ala Ser Ser Ala Gly Ser Leu Ala Ala Gly Pro Leu Leu
  500                      505                      510

Leu Ala Leu Ala Leu Tyr Pro Leu Ser Val Leu Phe
  515                      520

```

```

<210> SEQ ID NO 2
<211> LENGTH: 1024
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 2

```

```

Met Thr Met Ile Thr Asp Ser Leu Ala Val Val Leu Gln Arg Arg Asp
  1           5           10           15

Trp Glu Asn Pro Gly Val Thr Gln Leu Asn Arg Leu Ala Ala His Pro
  20           25           30

Pro Phe Ala Ser Trp Arg Asn Ser Glu Glu Ala Arg Thr Asp Arg Pro
  35           40           45

Ser Gln Gln Leu Arg Ser Leu Asn Gly Glu Trp Arg Phe Ala Trp Phe
  50           55           60

Pro Ala Pro Glu Ala Val Pro Glu Ser Trp Leu Glu Cys Asp Leu Pro
  65           70           75           80

Glu Ala Asp Thr Val Val Val Pro Ser Asn Trp Gln Met His Gly Tyr
  85           90           95

Asp Ala Pro Ile Tyr Thr Asn Val Thr Tyr Pro Ile Thr Val Asn Pro
  100          105          110

Pro Phe Val Pro Thr Glu Asn Pro Thr Gly Cys Tyr Ser Leu Thr Phe
  115          120          125

Asn Val Asp Glu Ser Trp Leu Gln Glu Gly Gln Thr Arg Ile Ile Phe
  130          135          140

Asp Gly Val Asn Ser Ala Phe His Leu Trp Cys Asn Gly Arg Trp Val
  145          150          155          160

Gly Tyr Gly Gln Asp Ser Arg Leu Pro Ser Glu Phe Asp Leu Ser Ala
  165          170          175

Phe Leu Arg Ala Gly Glu Asn Arg Leu Ala Val Met Val Leu Arg Trp
  180          185          190

Ser Asp Gly Ser Tyr Leu Glu Asp Gln Asp Met Trp Arg Met Ser Gly
  195          200          205

Ile Phe Arg Asp Val Ser Leu Leu His Lys Pro Thr Thr Gln Ile Ser
  210          215          220

Asp Phe His Val Ala Thr Arg Phe Asn Asp Asp Phe Ser Arg Ala Val
  225          230          235          240

Leu Glu Ala Glu Val Gln Met Cys Gly Glu Leu Arg Asp Tyr Leu Arg
  245          250          255

Val Thr Val Ser Leu Trp Gln Gly Glu Thr Gln Val Ala Ser Gly Thr
  260          265          270

Ala Pro Phe Gly Gly Glu Ile Ile Asp Glu Arg Gly Gly Tyr Ala Asp
  275          280          285

```

Arg	Val	Thr	Leu	Arg	Leu	Asn	Val	Glu	Asn	Pro	Lys	Leu	Trp	Ser	Ala
290						295						300			
Glu	Ile	Pro	Asn	Leu	Tyr	Arg	Ala	Val	Val	Glu	Leu	His	Thr	Ala	Asp
305						310						315			
Gly	Thr	Leu	Ile	Glu	Ala	Glu	Ala	Cys	Asp	Val	Gly	Phe	Arg	Glu	Val
325						330						335			
Arg	Ile	Glu	Asn	Gly	Leu	Leu	Leu	Leu	Asn	Gly	Lys	Pro	Leu	Leu	Ile
340						345						350			
Arg	Gly	Val	Asn	Arg	His	Glu	His	His	Pro	Leu	His	Gly	Gln	Val	Met
355						360						365			
Asp	Glu	Gln	Thr	Met	Val	Gln	Asp	Ile	Leu	Leu	Met	Lys	Gln	Asn	Asn
370						375						380			
Phe	Asn	Ala	Val	Arg	Cys	Ser	His	Tyr	Pro	Asn	His	Pro	Leu	Trp	Tyr
385						390						395			
Thr	Leu	Cys	Asp	Arg	Tyr	Gly	Leu	Tyr	Val	Val	Asp	Glu	Ala	Asn	Ile
405						410						415			
Glu	Thr	His	Gly	Met	Val	Pro	Met	Asn	Arg	Leu	Thr	Asp	Asp	Pro	Arg
420						425						430			
Trp	Leu	Pro	Ala	Met	Ser	Glu	Arg	Val	Thr	Arg	Met	Val	Gln	Arg	Asp
435						440						445			
Arg	Asn	His	Pro	Ser	Val	Ile	Ile	Trp	Ser	Leu	Gly	Asn	Glu	Ser	Gly
450						455						460			
His	Gly	Ala	Asn	His	Asp	Ala	Leu	Tyr	Arg	Trp	Ile	Lys	Ser	Val	Asp
465						470						475			
Pro	Ser	Arg	Pro	Val	Gln	Tyr	Glu	Gly	Gly	Gly	Ala	Asp	Thr	Thr	Ala
485						490						495			
Thr	Asp	Ile	Ile	Cys	Pro	Met	Tyr	Ala	Arg	Val	Asp	Glu	Asp	Gln	Pro
500						505						510			
Phe	Pro	Ala	Val	Pro	Lys	Trp	Ser	Ile	Lys	Lys	Trp	Leu	Ser	Leu	Pro
515						520						525			
Gly	Glu	Thr	Arg	Pro	Leu	Ile	Leu	Cys	Glu	Tyr	Ala	His	Ala	Met	Gly
530						535						540			
Asn	Ser	Leu	Gly	Gly	Phe	Ala	Lys	Tyr	Trp	Gln	Ala	Phe	Arg	Gln	Tyr
545						550						555			
Pro	Arg	Leu	Gln	Gly	Gly	Phe	Val	Trp	Asp	Trp	Val	Asp	Gln	Ser	Leu
565						570						575			
Ile	Lys	Tyr	Asp	Glu	Asn	Gly	Asn	Pro	Trp	Ser	Ala	Tyr	Gly	Gly	Asp
580						585						590			
Phe	Gly	Asp	Thr	Pro	Asn	Asp	Arg	Gln	Phe	Cys	Met	Asn	Gly	Leu	Val
595						600						605			
Phe	Ala	Asp	Arg	Thr	Pro	His	Pro	Ala	Leu	Thr	Glu	Ala	Lys	His	Gln
610						615						620			
Gln	Gln	Phe	Phe	Gln	Phe	Arg	Leu	Ser	Gly	Gln	Thr	Ile	Glu	Val	Thr
625						630						635			
Ser	Glu	Tyr	Leu	Phe	Arg	His	Ser	Asp	Asn	Glu	Leu	Leu	His	Trp	Met
645						650						655			
Val	Ala	Leu	Asp	Gly	Lys	Pro	Leu	Ala	Ser	Gly	Glu	Val	Pro	Leu	Asp
660						665						670			
Val	Ala	Pro	Gln	Gly	Lys	Gln	Leu	Ile	Glu	Leu	Pro	Glu	Leu	Pro	Gln
675						680						685			
Pro	Glu	Ser	Ala	Gly	Gln	Leu	Trp	Leu	Thr	Val	Arg	Val	Val	Gln	Pro
690						695						700			

-continued

---

```

Asn Ala Thr Ala Trp Ser Glu Ala Gly His Ile Ser Ala Trp Gln Gln
705                      710                      715                      720

Trp Arg Leu Ala Glu Asn Leu Ser Val Thr Leu Pro Ala Ala Ser His
                      725                      730                      735

Ala Ile Pro His Leu Thr Thr Ser Glu Met Asp Phe Cys Ile Glu Leu
                      740                      745                      750

Gly Asn Lys Arg Trp Gln Phe Asn Arg Gln Ser Gly Phe Leu Ser Gln
                      755                      760                      765

Met Trp Ile Gly Asp Lys Lys Gln Leu Leu Thr Pro Leu Arg Asp Gln
770                      775                      780

Phe Thr Arg Ala Pro Leu Asp Asn Asp Ile Gly Val Ser Glu Ala Thr
785                      790                      795                      800

Arg Ile Asp Pro Asn Ala Trp Val Glu Arg Trp Lys Ala Ala Gly His
                      805                      810                      815

Tyr Gln Ala Glu Ala Ala Leu Leu Gln Cys Thr Ala Asp Thr Leu Ala
                      820                      825                      830

Asp Ala Val Leu Ile Thr Thr Ala His Ala Trp Gln His Gln Gly Lys
                      835                      840                      845

Thr Leu Phe Ile Ser Arg Lys Thr Tyr Arg Ile Asp Gly Ser Gly Gln
850                      855                      860

Met Ala Ile Thr Val Asp Val Glu Val Ala Ser Asp Thr Pro His Pro
865                      870                      875                      880

Ala Arg Ile Gly Leu Asn Cys Gln Leu Ala Gln Val Ala Glu Arg Val
                      885                      890                      895

Asn Trp Leu Gly Leu Gly Pro Gln Glu Asn Tyr Pro Asp Arg Leu Thr
900                      905                      910

Ala Ala Cys Phe Asp Arg Trp Asp Leu Pro Leu Ser Asp Met Tyr Thr
915                      920                      925

Pro Tyr Val Phe Pro Ser Glu Asn Gly Leu Arg Cys Gly Thr Arg Glu
930                      935                      940

Leu Asn Tyr Gly Pro His Gln Trp Arg Gly Asp Phe Gln Phe Asn Ile
945                      950                      955                      960

Ser Arg Tyr Ser Gln Gln Gln Leu Met Glu Thr Ser His Arg His Leu
                      965                      970                      975

Leu His Ala Glu Glu Gly Thr Trp Leu Asn Ile Asp Gly Phe His Met
980                      985                      990

Gly Ile Gly Gly Asp Asp Ser Trp Ser Pro Ser Val Ser Ala Glu Phe
995                      1000                      1005

Gln Leu Ser Ala Gly Arg Tyr His Tyr Gln Leu Val Trp Cys Gln
1010                      1015                      1020

```

Lys

```

<210> SEQ ID NO 3
<211> LENGTH: 452
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

&lt;400&gt; SEQUENCE: 3

```

Met Ser Thr Ala Val Leu Glu Asn Pro Gly Leu Gly Arg Lys Leu Ser
1          5          10          15

Asp Phe Gly Gln Glu Thr Ser Tyr Ile Glu Asp Asn Cys Asn Gln Asn
20          25          30

Gly Ala Ile Ser Leu Ile Phe Ser Leu Lys Glu Glu Val Gly Ala Leu
35          40          45

```

[illegible]

-continued

---

```

<210> SEQ ID NO 4
<211> LENGTH: 3677
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

Met Glu Asp Glu Arg Glu Asp Val Gln Lys Lys Thr Phe Thr Lys Trp
 1             5             10             15

Val Asn Ala Gln Phe Ser Lys Phe Gly Lys Gln His Ile Glu Asn Leu
 20             25             30

Phe Ser Asp Leu Gln Asp Gly Arg Arg Leu Leu Asp Leu Leu Glu Gly
 35             40             45

Leu Thr Gly Gln Lys Leu Pro Lys Glu Lys Gly Ser Thr Arg Val His
 50             55             60

Ala Leu Asn Asn Val Asn Lys Ala Leu Arg Val Leu Gln Asn Asn Asn
 65             70             75             80

Val Asp Leu Val Asn Ile Gly Ser Thr Asp Ile Val Asp Gly Asn His
 85             90             95

Lys Leu Thr Leu Gly Leu Ile Trp Asn Ile Ile Leu His Trp Gln Val
100            105            110

Lys Asn Val Met Lys Asn Ile Met Ala Gly Leu Gln Gln Thr Asn Ser
115            120            125

Glu Lys Ile Leu Leu Ser Trp Val Arg Gln Ser Thr Arg Asn Tyr Pro
130            135            140

Gln Val Asn Val Ile Asn Phe Thr Thr Ser Trp Ser Asp Gly Leu Ala
145            150            155            160

Leu Asn Ala Leu Ile His Ser His Arg Pro Asp Leu Phe Asp Trp Asn
165            170            175

Ser Val Val Cys Gln Gln Ser Ala Thr Gln Arg Leu Glu His Ala Phe
180            185            190

Asn Ile Ala Arg Tyr Gln Leu Gly Ile Glu Lys Leu Leu Asp Pro Glu
195            200            205

Asp Val Asp Thr Thr Tyr Pro Asp Lys Lys Ser Ile Leu Met Tyr Ile
210            215            220

Thr Ser Leu Phe Gln Val Leu Pro Gln Gln Val Ser Ile Glu Ala Ile
225            230            235            240

Gln Glu Val Glu Met Leu Pro Arg Pro Pro Lys Val Thr Lys Glu Glu
245            250            255

His Phe Gln Leu His His Gln Met His Tyr Ser Gln Gln Ile Thr Val
260            265            270

Ser Leu Ala Gln Gly Tyr Glu Arg Thr Ser Ser Pro Lys Pro Arg Phe
275            280            285

Lys Ser Tyr Ala Tyr Thr Gln Ala Ala Tyr Val Thr Thr Ser Asp Pro
290            295            300

Thr Arg Ser Pro Phe Pro Ser Gln His Leu Glu Ala Pro Glu Asp Lys
305            310            315            320

Ser Phe Gly Ser Ser Leu Met Glu Ser Glu Val Asn Leu Asp Arg Tyr
325            330            335

Gln Thr Ala Leu Glu Glu Val Leu Ser Trp Leu Leu Ser Ala Glu Asp
340            345            350

Thr Leu Gln Ala Gln Gly Glu Ile Ser Asn Asp Val Glu Val Val Lys
355            360            365

Asp Gln Phe His Thr His Glu Gly Tyr Met Met Asp Leu Thr Ala His
370            375            380

```



-continued

---

Gln	Gly	Arg	Val	Gly	Asn	Ile	Leu	Gln	Leu	Gly	Ser	Lys	Leu	Ile	Gly	385	390	395	400
Thr	Gly	Lys	Leu	Ser	Glu	Asp	Glu	Glu	Thr	Glu	Val	Gln	Glu	Gln	Met	405	410	415	
Asn	Leu	Leu	Asn	Ser	Arg	Trp	Glu	Cys	Leu	Arg	Val	Ala	Ser	Met	Glu	420	425	430	
Lys	Gln	Ser	Asn	Leu	His	Arg	Val	Leu	Met	Asp	Leu	Gln	Asn	Gln	Lys	435	440	445	
Leu	Lys	Glu	Leu	Asn	Asp	Trp	Leu	Thr	Lys	Thr	Glu	Glu	Arg	Thr	Arg	450	455	460	
Lys	Met	Glu	Glu	Glu	Pro	Leu	Gly	Pro	Asp	Leu	Glu	Asp	Leu	Lys	Arg	465	470	475	480
Gln	Val	Gln	Gln	His	Lys	Val	Leu	Gln	Glu	Asp	Leu	Glu	Gln	Glu	Gln	485	490	495	
Val	Arg	Val	Asn	Ser	Leu	Thr	His	Met	Val	Val	Val	Val	Asp	Glu	Ser	500	505	510	
Ser	Gly	Asp	His	Ala	Thr	Ala	Ala	Leu	Glu	Glu	Gln	Leu	Lys	Val	Leu	515	520	525	
Gly	Asp	Arg	Trp	Ala	Asn	Ile	Cys	Arg	Trp	Thr	Glu	Asp	Arg	Trp	Val	530	535	540	
Leu	Leu	Gln	Asp	Ile	Leu	Leu	Lys	Trp	Gln	Arg	Leu	Thr	Glu	Glu	Gln	545	550	555	560
Cys	Leu	Phe	Ser	Ala	Trp	Leu	Ser	Glu	Lys	Glu	Asp	Ala	Val	Asn	Lys	565	570	575	
Ile	His	Thr	Thr	Gly	Phe	Lys	Asp	Gln	Asn	Glu	Met	Leu	Ser	Ser	Leu	580	585	590	
Gln	Lys	Leu	Ala	Val	Leu	Lys	Ala	Asp	Leu	Glu	Lys	Lys	Lys	Gln	Ser	595	600	605	
Met	Gly	Lys	Leu	Tyr	Ser	Leu	Lys	Gln	Asp	Leu	Leu	Ser	Thr	Leu	Lys	610	615	620	
Asn	Lys	Ser	Val	Thr	Gln	Lys	Thr	Glu	Ala	Trp	Leu	Asp	Asn	Phe	Ala	625	630	635	640
Arg	Cys	Trp	Asp	Asn	Leu	Val	Gln	Lys	Leu	Glu	Lys	Ser	Thr	Ala	Gln	645	650	655	
Ile	Ser	Gln	Ala	Val	Thr	Thr	Thr	Gln	Pro	Ser	Leu	Thr	Gln	Thr	Thr	660	665	670	
Val	Met	Glu	Thr	Val	Thr	Thr	Val	Thr	Thr	Arg	Glu	Gln	Ile	Leu	Val	675	680	685	
Lys	His	Ala	Gln	Glu	Glu	Leu	Pro	Pro	Pro	Pro	Pro	Gln	Lys	Lys	Arg	690	695	700	
Gln	Ile	Thr	Val	Asp	Ser	Glu	Ile	Arg	Lys	Arg	Leu	Asp	Val	Asp	Ile	705	710	715	720
Thr	Glu	Leu	His	Ser	Trp	Ile	Thr	Arg	Ser	Glu	Ala	Val	Leu	Gln	Ser	725	730	735	
Pro	Glu	Phe	Ala	Ile	Phe	Arg	Lys	Glu	Gly	Asn	Phe	Ser	Asp	Leu	Lys	740	745	750	
Glu	Lys	Val	Asn	Ala	Ile	Glu	Arg	Glu	Lys	Ala	Glu	Lys	Phe	Arg	Lys	755	760	765	
Leu	Gln	Asp	Ala	Ser	Arg	Ser	Ala	Gln	Ala	Leu	Val	Glu	Gln	Met	Val	770	775	780	
Asn	Glu	Gly	Val	Asn	Ala	Asp	Ser	Ile	Lys	Gln	Ala	Ser	Glu	Gln	Leu	785	790	795	800
Asn	Ser	Arg	Trp	Ile	Glu	Phe	Cys	Gln	Leu	Leu	Ser	Glu	Arg	Leu	Asn				

-continued

805										810					815				
Trp	Leu	Glu	Tyr	Gln	Asn	Asn	Ile	Ile	Ala	Phe	Tyr	Asn	Gln	Leu	Gln				
820										825					830				
Gln	Leu	Glu	Gln	Met	Thr	Thr	Thr	Ala	Glu	Asn	Trp	Leu	Lys	Ile	Gln				
835										840					845				
Pro	Thr	Thr	Pro	Ser	Glu	Pro	Thr	Ala	Ile	Lys	Ser	Gln	Leu	Lys	Ile				
850										855					860				
Cys	Lys	Asp	Glu	Val	Asn	Arg	Leu	Ser	Gly	Leu	Gln	Pro	Gln	Ile	Glu				
865										870					875				
Arg	Leu	Lys	Ile	Gln	Ser	Ile	Ala	Leu	Lys	Glu	Lys	Gly	Gln	Gly	Pro				
885										890					895				
Met	Phe	Leu	Asp	Ala	Asp	Phe	Val	Ala	Phe	Thr	Asn	His	Phe	Lys	Gln				
900										905					910				
Val	Phe	Ser	Asp	Val	Gln	Ala	Arg	Glu	Lys	Glu	Leu	Gln	Thr	Ile	Phe				
915										920					925				
Asp	Thr	Leu	Pro	Pro	Met	Arg	Tyr	Gln	Glu	Thr	Met	Ser	Ala	Ile	Arg				
930										935					940				
Thr	Trp	Val	Gln	Gln	Ser	Glu	Thr	Lys	Leu	Ser	Ile	Pro	Gln	Leu	Ser				
945										950					955				
Val	Thr	Asp	Tyr	Glu	Ile	Met	Glu	Gln	Arg	Leu	Gly	Glu	Leu	Gln	Ala				
965										970					975				
Leu	Gln	Ser	Ser	Leu	Gln	Glu	Gln	Gln	Ser	Gly	Leu	Tyr	Tyr	Leu	Ser				
980										985					990				
Thr	Thr	Val	Lys	Glu	Met	Ser	Lys	Lys	Ala	Pro	Ser	Glu	Ile	Ser	Arg				
995										1000					1005				
Lys	Tyr	Gln	Ser	Glu	Phe	Glu	Glu	Ile	Glu	Gly	Arg	Trp	Lys	Lys					
1010										1015					1020				
Leu	Ser	Ser	Gln	Leu	Val	Glu	His	Cys	Gln	Lys	Leu	Glu	Glu	Gln					
1025										1030					1035				
Met	Asn	Lys	Leu	Arg	Lys	Ile	Gln	Asn	His	Ile	Gln	Thr	Leu	Lys					
1040										1045					1050				
Lys	Trp	Met	Ala	Glu	Val	Asp	Val	Phe	Leu	Lys	Glu	Glu	Trp	Pro					
1055										1060					1065				
Ala	Leu	Gly	Asp	Ser	Glu	Ile	Leu	Lys	Lys	Gln	Leu	Lys	Gln	Cys					
1070										1075					1080				
Arg	Leu	Leu	Val	Ser	Asp	Ile	Gln	Thr	Ile	Gln	Pro	Ser	Leu	Asn					
1085										1090					1095				
Ser	Val	Asn	Glu	Gly	Gly	Gln	Lys	Ile	Lys	Asn	Glu	Ala	Glu	Pro					
1100										1105					1110				
Glu	Phe	Ala	Ser	Arg	Leu	Glu	Thr	Glu	Leu	Lys	Glu	Leu	Asn	Thr					
1115										1120					1125				
Gln	Trp	Asp	His	Met	Cys	Gln	Gln	Val	Tyr	Ala	Arg	Lys	Glu	Ala					
1130										1135					1140				
Leu	Lys	Gly	Gly	Leu	Glu	Lys	Thr	Val	Ser	Leu	Gln	Lys	Asp	Leu					
1145										1150					1155				
Ser	Glu	Met	His	Glu	Trp	Met	Thr	Gln	Ala	Glu	Glu	Glu	Tyr	Leu					
1160										1165					1170				
Glu	Arg	Asp	Phe	Glu	Tyr	Lys	Thr	Pro	Asp	Glu	Leu	Gln	Lys	Ala					
1175										1180					1185				
Val	Glu	Glu	Met	Lys	Arg	Ala	Lys	Glu	Glu	Ala	Gln	Gln	Lys	Glu					
1190										1195					1200				
Ala	Lys	Val	Lys	Leu	Leu	Thr	Glu	Ser	Val	Asn	Ser	Val	Ile	Ala					
1205										1210					1215				

-continued

---

Gln Ala	Pro Pro	Val Ala	Gln	Glu Ala	Leu Lys	Lys	Glu Leu	Glu
1220			1225			1230		
Thr Leu	Thr Thr	Asn Tyr	Gln	Trp Leu	Cys Thr	Arg	Leu Asn	Gly
1235			1240			1245		
Lys Cys	Lys Thr	Leu Glu	Glu	Val Trp	Ala Cys	Trp	His Glu	Leu
1250			1255			1260		
Leu Ser	Tyr Leu	Glu Lys	Ala	Asn Lys	Trp Leu	Asn	Glu Val	Glu
1265			1270			1275		
Phe Lys	Leu Lys	Thr Thr	Glu	Asn Ile	Pro Gly	Gly	Ala Glu	Glu
1280			1285			1290		
Ile Ser	Glu Val	Leu Asp	Ser	Leu Glu	Asn Leu	Met	Arg His	Ser
1295			1300			1305		
Glu Asp	Asn Pro	Asn Gln	Ile	Arg Ile	Leu Ala	Gln	Thr Leu	Thr
1310			1315			1320		
Asp Gly	Gly Val	Met Asp	Glu	Leu Ile	Asn Glu	Glu	Leu Glu	Thr
1325			1330			1335		
Phe Asn	Ser Arg	Trp Arg	Glu	Leu His	Glu Glu	Ala	Val Arg	Arg
1340			1345			1350		
Gln Lys	Leu Leu	Glu Gln	Ser	Ile Gln	Ser Ala	Gln	Glu Thr	Glu
1355			1360			1365		
Lys Ser	Leu His	Leu Ile	Gln	Glu Ser	Leu Thr	Phe	Ile Asp	Lys
1370			1375			1380		
Gln Leu	Ala Ala	Tyr Ile	Ala	Asp Lys	Val Asp	Ala	Ala Gln	Met
1385			1390			1395		
Pro Gln	Glu Ala	Gln Lys	Ile	Gln Ser	Asp Leu	Thr	Ser His	Glu
1400			1405			1410		
Ile Ser	Leu Glu	Glu Met	Lys	Lys His	Asn Gln	Gly	Lys Glu	Ala
1415			1420			1425		
Ala Gln	Arg Val	Leu Ser	Gln	Ile Asp	Val Ala	Gln	Lys Lys	Leu
1430			1435			1440		
Gln Asp	Val Ser	Met Lys	Phe	Arg Leu	Phe Gln	Lys	Pro Ala	Asn
1445			1450			1455		
Phe Glu	Gln Arg	Leu Gln	Glu	Ser Lys	Met Ile	Leu	Asp Glu	Val
1460			1465			1470		
Lys Met	His Leu	Pro Ala	Leu	Glu Thr	Lys Ser	Val	Glu Gln	Glu
1475			1480			1485		
Val Val	Gln Ser	Gln Leu	Asn	His Cys	Val Asn	Leu	Tyr Lys	Ser
1490			1495			1500		
Leu Ser	Glu Val	Lys Ser	Glu	Val Glu	Met Val	Ile	Lys Thr	Gly
1505			1510			1515		
Arg Gln	Ile Val	Gln Lys	Lys	Gln Thr	Glu Asn	Pro	Lys Glu	Leu
1520			1525			1530		
Asp Glu	Arg Val	Thr Ala	Leu	Lys Leu	His Tyr	Asn	Glu Leu	Gly
1535			1540			1545		
Ala Lys	Val Thr	Glu Arg	Lys	Gln Gln	Leu Glu	Lys	Cys Leu	Lys
1550			1555			1560		
Leu Ser	Arg Lys	Met Arg	Lys	Glu Met	Asn Val	Leu	Thr Glu	Trp
1565			1570			1575		
Leu Ala	Ala Thr	Asp Met	Glu	Leu Thr	Lys Arg	Ser	Ala Val	Glu
1580			1585			1590		
Gly Met	Pro Ser	Asn Leu	Asp	Ser Glu	Val Ala	Trp	Gly Lys	Ala
1595			1600			1605		

-continued

---

Thr	Gln	Lys	Glu	Ile	Glu	Lys	Gln	Lys	Val	His	Leu	Lys	Ser	Ile
1610						1615					1620			
Thr	Glu	Val	Gly	Glu	Ala	Leu	Lys	Thr	Val	Leu	Gly	Lys	Lys	Glu
1625						1630					1635			
Thr	Leu	Val	Glu	Asp	Lys	Leu	Ser	Leu	Leu	Asn	Ser	Asn	Trp	Ile
1640						1645					1650			
Ala	Val	Thr	Ser	Arg	Ala	Glu	Glu	Trp	Leu	Asn	Leu	Leu	Leu	Glu
1655						1660					1665			
Tyr	Gln	Lys	His	Met	Glu	Thr	Phe	Asp	Gln	Asn	Val	Asp	His	Ile
1670						1675					1680			
Thr	Lys	Trp	Ile	Ile	Gln	Ala	Asp	Thr	Leu	Leu	Asp	Glu	Ser	Glu
1685						1690					1695			
Lys	Lys	Lys	Pro	Gln	Gln	Lys	Glu	Asp	Val	Leu	Lys	Arg	Leu	Lys
1700						1705					1710			
Ala	Glu	Leu	Asn	Asp	Ile	Arg	Pro	Lys	Val	Asp	Ser	Thr	Arg	Asp
1715						1720					1725			
Gln	Ala	Ala	Asn	Leu	Met	Ala	Asn	Arg	Gly	Asp	His	Cys	Arg	Lys
1730						1735					1740			
Leu	Val	Glu	Pro	Gln	Ile	Ser	Glu	Leu	Asn	His	Arg	Phe	Ala	Ala
1745						1750					1755			
Ile	Ser	His	Arg	Ile	Lys	Thr	Gly	Lys	Ala	Ser	Ile	Pro	Leu	Lys
1760						1765					1770			
Glu	Leu	Glu	Gln	Phe	Asn	Ser	Asp	Ile	Gln	Lys	Leu	Leu	Glu	Pro
1775						1780					1785			
Leu	Glu	Ala	Glu	Ile	Gln	Gln	Gly	Val	Asn	Leu	Lys	Glu	Glu	Asp
1790						1795					1800			
Phe	Asn	Lys	Asp	Met	Asn	Glu	Asp	Asn	Glu	Gly	Thr	Val	Lys	Glu
1805						1810					1815			
Leu	Leu	Gln	Arg	Gly	Asp	Asn	Leu	Gln	Gln	Arg	Ile	Thr	Asp	Glu
1820						1825					1830			
Arg	Lys	Arg	Glu	Glu	Ile	Lys	Ile	Lys	Gln	Gln	Leu	Leu	Gln	Thr
1835						1840					1845			
Lys	His	Asn	Ala	Leu	Lys	Asp	Leu	Arg	Ser	Gln	Arg	Arg	Lys	Lys
1850						1855					1860			
Ala	Leu	Glu	Ile	Ser	His	Gln	Trp	Tyr	Gln	Tyr	Lys	Arg	Gln	Ala
1865						1870					1875			
Asp	Asp	Leu	Leu	Lys	Cys	Leu	Asp	Asp	Ile	Glu	Lys	Lys	Leu	Ala
1880						1885					1890			
Ser	Leu	Pro	Glu	Pro	Arg	Asp	Glu	Arg	Lys	Ile	Lys	Glu	Ile	Asp
1895						1900					1905			
Arg	Glu	Leu	Gln	Lys	Lys	Lys	Glu	Glu	Leu	Asn	Ala	Val	Arg	Arg
1910						1915					1920			
Gln	Ala	Glu	Gly	Leu	Ser	Glu	Asp	Gly	Ala	Ala	Met	Ala	Val	Glu
1925						1930					1935			
Pro	Thr	Gln	Ile	Gln	Leu	Ser	Lys	Arg	Trp	Arg	Glu	Ile	Glu	Ser
1940						1945					1950			
Lys	Phe	Ala	Gln	Phe	Arg	Arg	Leu	Asn	Phe	Ala	Gln	Ile	His	Thr
1955						1960					1965			
Val	Arg	Glu	Glu	Thr	Met	Met	Val	Met	Thr	Glu	Asp	Met	Pro	Leu
1970						1975					1980			
Glu	Ile	Ser	Tyr	Val	Pro	Ser	Thr	Tyr	Leu	Thr	Glu	Ile	Thr	His
1985						1990					1995			
Val	Ser	Gln	Ala	Leu	Leu	Glu	Val	Glu	Gln	Leu	Leu	Asn	Ala	Pro

-continued

2000	2005	2010
Asp Leu Cys Ala Lys Asp Phe 2015	Glu Asp Leu Phe 2020	Lys Gln Glu Glu 2025
Ser Leu Lys Asn Ile Lys Asp 2030	Ser Leu Gln Gln 2035	Ser Ser Gly Arg 2040
Ile Asp Ile Ile His Ser Lys 2045	Lys Thr Ala Ala 2050	Leu Gln Ser Ala 2055
Thr Pro Val Glu Arg Val Lys 2060	Leu Gln Glu Ala 2065	Leu Ser Gln Leu 2070
Asp Phe Gln Trp Glu Lys Val 2075	Asn Lys Met Tyr 2080	Lys Asp Arg Gln 2085
Gly Arg Phe Asp Arg Ser Val 2090	Glu Lys Trp Arg 2095	Arg Phe His Tyr 2100
Asp Ile Lys Ile Phe Asn Gln 2105	Trp Leu Thr Glu 2110	Ala Glu Gln Phe 2115
Leu Arg Lys Thr Gln Ile Pro 2120	Glu Asn Trp Glu 2125	His Ala Lys Tyr 2130
Lys Trp Tyr Leu Lys Glu Leu 2135	Gln Asp Gly Ile 2140	Gly Gln Arg Gln 2145
Thr Val Val Arg Thr Leu Asn 2150	Ala Thr Gly Glu 2155	Glu Ile Ile Gln 2160
Gln Ser Ser Lys Thr Asp Ala 2165	Ser Ile Leu Gln 2170	Glu Lys Leu Gly 2175
Ser Leu Asn Leu Arg Trp Gln 2180	Glu Val Cys Lys 2185	Gln Leu Ser Asp 2190
Arg Lys Lys Arg Leu Glu Glu 2195	Gln Lys Asn Ile 2200	Leu Ser Glu Phe 2205
Gln Arg Asp Leu Asn Glu Phe 2210	Val Leu Trp Leu 2215	Glu Glu Ala Asp 2220
Asn Ile Ala Ser Ile Pro Leu 2225	Glu Pro Gly Lys 2230	Glu Gln Gln Leu 2235
Lys Glu Lys Leu Glu Gln Val 2240	Lys Leu Leu Val 2245	Glu Glu Leu Pro 2250
Leu Arg Gln Gly Ile Leu Lys 2255	Gln Leu Asn Glu 2260	Thr Gly Gly Pro 2265
Val Leu Val Ser Ala Pro Ile 2270	Ser Pro Glu Glu 2275	Gln Asp Lys Leu 2280
Glu Asn Lys Leu Lys Gln Thr 2285	Asn Leu Gln Trp 2290	Ile Lys Val Ser 2295
Arg Ala Leu Pro Glu Lys Gln 2300	Gly Glu Ile Glu 2305	Ala Gln Ile Lys 2310
Asp Leu Gly Gln Leu Glu Lys 2315	Lys Leu Glu Asp 2320	Leu Glu Glu Gln 2325
Leu Asn His Leu Leu Leu Trp 2330	Leu Ser Pro Ile 2335	Arg Asn Gln Leu 2340
Glu Ile Tyr Asn Gln Pro Asn 2345	Gln Glu Gly Pro 2350	Phe Asp Val Gln 2355
Glu Thr Glu Ile Ala Val Gln 2360	Ala Lys Gln Pro 2365	Asp Val Glu Glu 2370
Ile Leu Ser Lys Gly Gln His 2375	Leu Tyr Lys Glu 2380	Lys Pro Ala Thr 2385
Gln Pro Val Lys Arg Lys Leu 2390	Glu Asp Leu Ser 2395	Ser Glu Trp Lys 2400

-continued

---

Ala Val	Asn Arg	Leu Leu	Gln	Glu Leu	Arg Ala	Lys	Gln Pro	Asp	
2405			2410			2415			
Leu Ala	Pro Gly	Leu Thr	Thr	Ile Gly	Ala Ser	Pro	Thr Gln	Thr	
2420			2425			2430			
Val Thr	Leu Val	Thr Gln	Pro	Val Val	Thr Lys	Glu	Thr Ala	Ile	
2435			2440			2445			
Ser Lys	Leu Glu	Met Pro	Ser	Ser Leu	Met Leu	Glu	Val Pro	Ala	
2450			2455			2460			
Leu Ala	Asp Phe	Asn Arg	Ala	Trp Thr	Glu Leu	Thr	Asp Trp	Leu	
2465			2470			2475			
Ser Leu	Leu Asp	Gln Val	Ile	Lys Ser	Gln Arg	Val	Met Val	Gly	
2480			2485			2490			
Asp Leu	Glu Asp	Ile Asn	Glu	Met Ile	Ile Lys	Gln	Lys Ala	Thr	
2495			2500			2505			
Met Gln	Asp Leu	Glu Gln	Arg	Arg Pro	Gln Leu	Glu	Glu Leu	Ile	
2510			2515			2520			
Thr Ala	Ala Gln	Asn Leu	Lys	Asn Lys	Thr Ser	Asn	Gln Glu	Ala	
2525			2530			2535			
Arg Thr	Ile Ile	Thr Asp	Arg	Ile Glu	Arg Ile	Gln	Asn Gln	Trp	
2540			2545			2550			
Asp Glu	Val Gln	Glu His	Leu	Gln Asn	Arg Arg	Gln	Gln Leu	Asn	
2555			2560			2565			
Glu Met	Leu Lys	Asp Ser	Thr	Gln Trp	Leu Glu	Ala	Lys Glu	Glu	
2570			2575			2580			
Ala Glu	Gln Val	Leu Gly	Gln	Ala Arg	Ala Lys	Leu	Glu Ser	Trp	
2585			2590			2595			
Lys Glu	Gly Pro	Tyr Thr	Val	Asp Ala	Ile Gln	Lys	Lys Ile	Thr	
2600			2605			2610			
Glu Thr	Lys Gln	Leu Ala	Lys	Asp Leu	Arg Gln	Trp	Gln Thr	Asn	
2615			2620			2625			
Val Asp	Val Ala	Asn Asp	Leu	Ala Leu	Lys Leu	Leu	Arg Asp	Tyr	
2630			2635			2640			
Ser Ala	Asp Asp	Thr Arg	Lys	Val His	Met Ile	Thr	Glu Asn	Ile	
2645			2650			2655			
Asn Ala	Ser Trp	Arg Ser	Ile	His Lys	Arg Val	Ser	Glu Arg	Glu	
2660			2665			2670			
Ala Ala	Leu Glu	Glu Thr	His	Arg Leu	Leu Gln	Gln	Phe Pro	Leu	
2675			2680			2685			
Asp Leu	Glu Lys	Phe Leu	Ala	Trp Leu	Thr Glu	Ala	Glu Thr	Thr	
2690			2695			2700			
Ala Asn	Val Leu	Gln Asp	Ala	Thr Arg	Lys Glu	Arg	Leu Leu	Glu	
2705			2710			2715			
Asp Ser	Lys Gly	Val Lys	Glu	Leu Met	Lys Gln	Trp	Gln Asp	Leu	
2720			2725			2730			
Gln Gly	Glu Ile	Glu Ala	His	Thr Asp	Val Tyr	His	Asn Leu	Asp	
2735			2740			2745			
Glu Asn	Ser Gln	Lys Ile	Leu	Arg Ser	Leu Glu	Gly	Ser Asp	Asp	
2750			2755			2760			
Ala Val	Leu Leu	Gln Arg	Arg	Leu Asp	Asn Met	Asn	Phe Lys	Trp	
2765			2770			2775			
Ser Glu	Leu Arg	Lys Lys	Ser	Leu Asn	Ile Arg	Ser	His Leu	Glu	
2780			2785			2790			

-continued

---

Ala	Ser	Ser	Asp	Gln	Trp	Lys	Arg	Leu	His	Leu	Ser	Leu	Gln	Glu
2795						2800					2805			
Leu	Leu	Val	Trp	Leu	Gln	Leu	Lys	Asp	Asp	Glu	Leu	Ser	Arg	Gln
2810						2815					2820			
Ala	Pro	Ile	Gly	Gly	Asp	Phe	Pro	Ala	Val	Gln	Lys	Gln	Asn	Asp
2825						2830					2835			
Val	His	Arg	Ala	Phe	Lys	Arg	Glu	Leu	Lys	Thr	Lys	Glu	Pro	Val
2840						2845					2850			
Ile	Met	Ser	Thr	Leu	Glu	Thr	Val	Arg	Ile	Phe	Leu	Thr	Glu	Gln
2855						2860					2865			
Pro	Leu	Glu	Gly	Leu	Glu	Lys	Leu	Tyr	Gln	Glu	Pro	Arg	Glu	Leu
2870						2875					2880			
Pro	Pro	Glu	Glu	Arg	Ala	Gln	Asn	Val	Thr	Arg	Leu	Leu	Arg	Lys
2885						2890					2895			
Gln	Ala	Glu	Glu	Val	Asn	Thr	Glu	Trp	Glu	Lys	Leu	Asn	Leu	His
2900						2905					2910			
Ser	Ala	Asp	Trp	Gln	Arg	Lys	Ile	Asp	Glu	Thr	Leu	Glu	Arg	Leu
2915						2920					2925			
Gln	Glu	Leu	Gln	Glu	Ala	Thr	Asp	Glu	Leu	Asp	Leu	Lys	Leu	Arg
2930						2935					2940			
Gln	Ala	Glu	Val	Ile	Lys	Gly	Ser	Trp	Gln	Pro	Val	Gly	Asp	Leu
2945						2950					2955			
Leu	Ile	Asp	Ser	Leu	Gln	Asp	His	Leu	Glu	Lys	Val	Lys	Ala	Leu
2960						2965					2970			
Arg	Gly	Glu	Ile	Ala	Pro	Leu	Lys	Glu	Asn	Val	Ser	His	Val	Asn
2975						2980					2985			
Asp	Leu	Ala	Arg	Gln	Leu	Thr	Thr	Leu	Gly	Ile	Gln	Leu	Ser	Pro
2990						2995					3000			
Tyr	Asn	Leu	Ser	Thr	Leu	Glu	Asp	Leu	Asn	Thr	Arg	Trp	Lys	Leu
3005						3010					3015			
Leu	Gln	Val	Ala	Val	Glu	Asp	Arg	Val	Arg	Gln	Leu	His	Glu	Ala
3020						3025					3030			
His	Arg	Asp	Phe	Gly	Pro	Ala	Ser	Gln	His	Phe	Leu	Ser	Thr	Ser
3035						3040					3045			
Val	Gln	Gly	Pro	Trp	Glu	Arg	Ala	Ile	Ser	Pro	Asn	Lys	Val	Pro
3050						3055					3060			
Tyr	Tyr	Ile	Asn	His	Glu	Thr	Gln	Thr	Thr	Cys	Trp	Asp	His	Pro
3065						3070					3075			
Lys	Met	Thr	Glu	Leu	Tyr	Gln	Ser	Leu	Ala	Asp	Leu	Asn	Asn	Val
3080						3085					3090			
Arg	Phe	Ser	Ala	Tyr	Arg	Thr	Ala	Met	Lys	Leu	Arg	Arg	Leu	Gln
3095						3100					3105			
Lys	Ala	Leu	Cys	Leu	Asp	Leu	Leu	Ser	Leu	Ser	Ala	Ala	Cys	Asp
3110						3115					3120			
Ala	Leu	Asp	Gln	His	Asn	Leu	Lys	Gln	Asn	Asp	Gln	Pro	Met	Asp
3125						3130					3135			
Ile	Leu	Gln	Ile	Ile	Asn	Cys	Leu	Thr	Thr	Ile	Tyr	Asp	Arg	Leu
3140						3145					3150			
Glu	Gln	Glu	His	Asn	Asn	Leu	Val	Asn	Val	Pro	Leu	Cys	Val	Asp
3155						3160					3165			
Met	Cys	Leu	Asn	Trp	Leu	Leu	Asn	Val	Tyr	Asp	Thr	Gly	Arg	Thr
3170						3175					3180			
Gly	Arg	Ile	Arg	Val	Leu	Ser	Phe	Lys	Thr	Gly	Ile	Ile	Ser	Leu

-continued

---

3185	3190	3195
Cys Lys Ala His Leu Glu Asp 3200 3205	Lys Tyr Arg Tyr Leu Phe Lys Gln 3210	
Val Ala Ser Ser Thr Gly Phe 3215 3220	Cys Asp Gln Arg Arg Leu Gly Leu 3225	
Leu Leu His Asp Ser Ile Gln 3230 3235	Ile Pro Arg Gln Leu Gly Glu Val 3240	
Ala Ser Phe Gly Gly Ser Asn 3245 3250	Ile Glu Pro Ser Val Arg Ser Cys 3255	
Phe Gln Phe Ala Asn Asn Lys 3260 3265	Pro Glu Ile Glu Ala Ala Leu Phe 3270	
Leu Asp Trp Met Arg Leu Glu 3275 3280	Pro Gln Ser Met Val Trp Leu Pro 3285	
Val Leu His Arg Val Ala Ala 3290 3295	Ala Glu Thr Ala Lys His Gln Ala 3300	
Lys Cys Asn Ile Cys Lys Glu 3305 3310	Cys Pro Ile Ile Gly Phe Arg Tyr 3315	
Arg Ser Leu Lys His Phe Asn 3320 3325	Tyr Asp Ile Cys Gln Ser Cys Phe 3330	
Phe Ser Gly Arg Val Ala Lys 3335 3340	Gly His Lys Met His Tyr Pro Met 3345	
Val Glu Tyr Cys Thr Pro Thr 3350 3355	Thr Ser Gly Glu Asp Val Arg Asp 3360	
Phe Ala Lys Val Leu Lys Asn 3365 3370	Lys Phe Arg Thr Lys Arg Tyr Phe 3375	
Ala Lys His Pro Arg Met Gly 3380 3385	Tyr Leu Pro Val Gln Thr Val Leu 3390	
Glu Gly Asp Asn Met Glu Thr 3395 3400	Pro Val Thr Leu Ile Asn Phe Trp 3405	
Pro Val Asp Ser Ala Pro Ala 3410 3415	Ser Ser Pro Gln Leu Ser His Asp 3420	
Asp Thr His Ser Arg Ile Glu 3425 3430	His Tyr Ala Ser Arg Leu Ala Glu 3435	
Met Glu Asn Ser Asn Gly Ser 3440 3445	Tyr Leu Asn Asp Ser Ile Ser Pro 3450	
Asn Glu Ser Ile Asp Asp Glu 3455 3460	His Leu Leu Ile Gln His Tyr Cys 3465	
Gln Ser Leu Asn Gln Asp Ser 3470 3475	Pro Leu Ser Gln Pro Arg Ser Pro 3480	
Ala Gln Ile Leu Ile Ser Leu 3485 3490	Glu Ser Glu Glu Arg Gly Glu Leu 3495	
Glu Arg Ile Leu Ala Asp Leu 3500 3505	Glu Glu Glu Asn Arg Asn Leu Gln 3510	
Ala Glu Tyr Asp Arg Leu Lys 3515 3520	Gln Gln His Glu His Lys Gly Leu 3525	
Ser Pro Leu Pro Ser Pro Pro 3530 3535	Glu Met Met Pro Thr Ser Pro Gln 3540	
Ser Pro Arg Asp Ala Glu Leu 3545 3550	Ile Ala Glu Ala Lys Leu Leu Arg 3555	
Gln His Lys Gly Arg Leu Glu 3560 3565	Ala Arg Met Gln Ile Leu Glu Asp 3570	
His Asn Lys Gln Leu Glu Ser 3575 3580	Gln Leu His Arg Leu Arg Gln Leu 3585	



-continued

---

Leu Glu Gln Pro Gln Ala Glu Ala Lys Val Asn Gly Thr Thr Val  
 3590 3595 3600  
 Ser Ser Pro Ser Thr Ser Leu Gln Arg Ser Asp Ser Ser Gln Pro  
 3605 3610 3615  
 Met Leu Leu Arg Val Val Gly Ser Gln Thr Ser Asp Ser Met Gly  
 3620 3625 3630  
 Glu Glu Asp Leu Leu Ser Pro Pro Gln Asp Thr Ser Thr Gly Leu  
 3635 3640 3645  
 Glu Glu Val Met Glu Gln Leu Asn Asn Ser Phe Pro Ser Ser Arg  
 3650 3655 3660  
 Gly Arg Asn Thr Pro Gly Lys Pro Met Arg Glu Asp Thr Met  
 3665 3670 3675

<210> SEQ ID NO 5  
 <211> LENGTH: 536  
 <212> TYPE: PRT  
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 5

Met Glu Phe Ser Ser Pro Ser Arg Glu Glu Cys Pro Lys Pro Leu Ser  
 1 5 10 15  
 Arg Val Ser Ile Met Ala Gly Ser Leu Thr Gly Leu Leu Leu Leu Gln  
 20 25 30  
 Ala Val Ser Trp Ala Ser Gly Ala Arg Pro Cys Ile Pro Lys Ser Phe  
 35 40 45  
 Gly Tyr Ser Ser Val Val Cys Val Cys Asn Ala Thr Tyr Cys Asp Ser  
 50 55 60  
 Phe Asp Pro Pro Thr Phe Pro Ala Leu Gly Thr Phe Ser Arg Tyr Glu  
 65 70 75 80  
 Ser Thr Arg Ser Gly Arg Arg Met Glu Leu Ser Met Gly Pro Ile Gln  
 85 90 95  
 Ala Asn His Thr Gly Thr Gly Leu Leu Leu Thr Leu Gln Pro Glu Gln  
 100 105 110  
 Lys Phe Gln Lys Val Lys Gly Phe Gly Gly Ala Met Thr Asp Ala Ala  
 115 120 125  
 Ala Leu Asn Ile Leu Ala Leu Ser Pro Pro Ala Gln Asn Leu Leu Leu  
 130 135 140  
 Lys Ser Tyr Phe Ser Glu Glu Gly Ile Gly Tyr Asn Ile Ile Arg Val  
 145 150 155 160  
 Pro Met Ala Ser Cys Asp Phe Ser Ile Arg Thr Tyr Thr Tyr Ala Asp  
 165 170 175  
 Thr Pro Asp Asp Phe Gln Leu His Asn Phe Ser Leu Pro Glu Glu Asp  
 180 185 190  
 Thr Lys Leu Lys Ile Pro Leu Ile His Arg Ala Leu Gln Leu Ala Gln  
 195 200 205  
 Arg Pro Val Ser Leu Leu Ala Ser Pro Trp Thr Ser Pro Thr Trp Leu  
 210 215 220  
 Lys Thr Asn Gly Ala Val Asn Gly Lys Gly Ser Leu Lys Gly Gln Pro  
 225 230 235 240  
 Gly Asp Ile Tyr His Gln Thr Trp Ala Arg Tyr Phe Val Lys Phe Leu  
 245 250 255  
 Asp Ala Tyr Ala Glu His Lys Leu Gln Phe Trp Ala Val Thr Ala Glu  
 260 265 270  
 Asn Glu Pro Ser Ala Gly Leu Leu Ser Gly Tyr Pro Phe Gln Cys Leu

-continued

275	280	285
Gly Phe Thr Pro Glu His	Gln Arg Asp Phe Ile	Ala Arg Asp Leu Gly
290	295	300
Pro Thr Leu Ala Asn Ser	Thr His His Asn Val	Arg Leu Leu Met Leu
305	310	315
Asp Asp Gln Arg Leu Leu	Leu Pro His Trp Ala	Lys Val Val Leu Thr
325	330	335
Asp Pro Glu Ala Ala Lys	Tyr Val His Gly Ile	Ala Val His Trp Tyr
340	345	350
Leu Asp Phe Leu Ala Pro	Ala Lys Ala Thr Leu	Gly Glu Thr His Arg
355	360	365
Leu Phe Pro Asn Thr Met	Leu Phe Ala Ser Glu	Ala Cys Val Gly Ser
370	375	380
Lys Phe Trp Glu Gln Ser	Val Arg Leu Gly Ser	Trp Asp Arg Gly Met
385	390	395
Gln Tyr Ser His Ser Ile	Ile Thr Asn Leu Leu	Tyr His Val Val Gly
405	410	415
Trp Thr Asp Trp Asn Leu	Ala Leu Asn Pro Glu	Gly Gly Pro Asn Trp
420	425	430
Val Arg Asn Phe Val Asp	Ser Pro Ile Ile Val	Asp Ile Thr Lys Asp
435	440	445
Thr Phe Tyr Lys Gln Pro	Met Phe Tyr His Leu	Gly His Phe Ser Lys
450	455	460
Phe Ile Pro Glu Gly Ser	Gln Arg Val Gly Leu	Val Ala Ser Gln Lys
465	470	475
Asn Asp Leu Asp Ala Val	Ala Leu Met His Pro	Asp Gly Ser Ala Val
485	490	495
Val Val Val Leu Asn Arg	Ser Ser Lys Asp Val	Pro Leu Thr Ile Lys
500	505	510
Asp Pro Ala Val Gly Phe	Leu Glu Thr Ile Ser	Pro Gly Tyr Ser Ile
515	520	525
His Thr Tyr Leu Trp Arg	Arg Gln	
530	535	
<210> SEQ ID NO 6		
<211> LENGTH: 110		
<212> TYPE: PRT		
<213> ORGANISM: Homo sapiens		
<400> SEQUENCE: 6		
Met Ala Leu Trp Met Arg	Leu Leu Pro Leu Leu	Ala Leu Leu Ala Leu
1	5	10
Trp Gly Pro Asp Pro Ala	Ala Ala Phe Val Asn	Gln His Leu Cys Gly
20	25	30
Ser His Leu Val Glu Ala	Leu Tyr Leu Val Cys	Gly Glu Arg Gly Phe
35	40	45
Phe Tyr Thr Pro Lys Thr	Arg Arg Glu Ala Glu	Asp Leu Gln Val Gly
50	55	60
Gln Val Glu Leu Gly Gly	Gly Pro Gly Ala Gly	Ser Leu Gln Pro Leu
65	70	75
Ala Leu Glu Gly Ser Leu	Gln Lys Arg Gly Ile	Val Glu Gln Cys Cys
85	90	95
Thr Ser Ile Cys Ser Leu	Tyr Gln Leu Glu Asn	Tyr Cys Asn
100	105	110

-continued

---

```

<210> SEQ ID NO 7
<211> LENGTH: 1065
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 7

Met Lys Ile Leu Ile Leu Gly Ile Phe Leu Phe Leu Cys Ser Thr Pro
 1             5             10             15

Ala Trp Ala Lys Glu Lys His Tyr Tyr Ile Gly Ile Ile Glu Thr Thr
 20             25             30

Trp Asp Tyr Ala Ser Asp His Gly Glu Lys Lys Leu Ile Ser Val Asp
 35             40             45

Thr Glu His Ser Asn Ile Tyr Leu Gln Asn Gly Pro Asp Arg Ile Gly
 50             55             60

Arg Leu Tyr Lys Lys Ala Leu Tyr Leu Gln Tyr Thr Asp Glu Thr Phe
 65             70             75             80

Arg Thr Thr Ile Glu Lys Pro Val Trp Leu Gly Phe Leu Gly Pro Ile
 85             90             95

Ile Lys Ala Glu Thr Gly Asp Lys Val Tyr Val His Leu Lys Asn Leu
100            105            110

Ala Ser Arg Pro Tyr Thr Phe His Ser His Gly Ile Thr Tyr Tyr Lys
115            120            125

Glu His Glu Gly Ala Ile Tyr Pro Asp Asn Thr Thr Asp Phe Gln Arg
130            135            140

Ala Asp Asp Lys Val Tyr Pro Gly Glu Gln Tyr Thr Tyr Met Leu Leu
145            150            155            160

Ala Thr Glu Glu Gln Ser Pro Gly Glu Gly Asp Gly Asn Cys Val Thr
165            170            175

Arg Ile Tyr His Ser His Ile Asp Ala Pro Lys Asp Ile Ala Ser Gly
180            185            190

Leu Ile Gly Pro Leu Ile Ile Cys Lys Lys Asp Ser Leu Asp Lys Glu
195            200            205

Lys Glu Lys His Ile Asp Arg Glu Phe Val Val Met Phe Ser Val Val
210            215            220

Asp Glu Asn Phe Ser Trp Tyr Leu Glu Asp Asn Ile Lys Thr Tyr Cys
225            230            235            240

Ser Glu Pro Glu Lys Val Asp Lys Asp Asn Glu Asp Phe Gln Glu Ser
245            250            255

Asn Arg Met Tyr Ser Val Asn Gly Tyr Thr Phe Gly Ser Leu Pro Gly
260            265            270

Leu Ser Met Cys Ala Glu Asp Arg Val Lys Trp Tyr Leu Phe Gly Met
275            280            285

Gly Asn Glu Val Asp Val His Ala Ala Phe Phe His Gly Gln Ala Leu
290            295            300

Thr Asn Lys Asn Tyr Arg Ile Asp Thr Ile Asn Leu Phe Pro Ala Thr
305            310            315            320

Leu Phe Asp Ala Tyr Met Val Ala Gln Asn Pro Gly Glu Trp Met Leu
325            330            335

Ser Cys Gln Asn Leu Asn His Leu Lys Ala Gly Leu Gln Ala Phe Phe
340            345            350

Gln Val Gln Glu Cys Asn Lys Ser Ser Ser Lys Asp Asn Ile Arg Gly
355            360            365

Lys His Val Arg His Tyr Tyr Ile Ala Ala Glu Glu Ile Ile Trp Asn
370            375            380

```

-continued

---

Tyr	Ala	Pro	Ser	Gly	Ile	Asp	Ile	Phe	Thr	Lys	Glu	Asn	Leu	Thr	Ala	385	390	395	400
Pro	Gly	Ser	Asp	Ser	Ala	Val	Phe	Phe	Glu	Gln	Gly	Thr	Thr	Arg	Ile	405	410	415	
Gly	Gly	Ser	Tyr	Lys	Lys	Leu	Val	Tyr	Arg	Glu	Tyr	Thr	Asp	Ala	Ser	420	425	430	
Phe	Thr	Asn	Arg	Lys	Glu	Arg	Gly	Pro	Glu	Glu	Glu	His	Leu	Gly	Ile	435	440	445	
Leu	Gly	Pro	Val	Ile	Trp	Ala	Glu	Val	Gly	Asp	Thr	Ile	Arg	Val	Thr	450	455	460	
Phe	His	Asn	Lys	Gly	Ala	Tyr	Pro	Leu	Ser	Ile	Glu	Pro	Ile	Gly	Val	465	470	475	480
Arg	Phe	Asn	Lys	Asn	Asn	Glu	Gly	Thr	Tyr	Tyr	Ser	Pro	Asn	Tyr	Asn	485	490	495	
Pro	Gln	Ser	Arg	Ser	Val	Pro	Pro	Ser	Ala	Ser	His	Val	Ala	Pro	Thr	500	505	510	
Glu	Thr	Phe	Thr	Tyr	Glu	Trp	Thr	Val	Pro	Lys	Glu	Val	Gly	Pro	Thr	515	520	525	
Asn	Ala	Asp	Pro	Val	Cys	Leu	Ala	Lys	Met	Tyr	Tyr	Ser	Ala	Val	Asp	530	535	540	
Pro	Thr	Lys	Asp	Ile	Phe	Thr	Gly	Leu	Ile	Gly	Pro	Met	Lys	Ile	Cys	545	550	555	560
Lys	Lys	Gly	Ser	Leu	His	Ala	Asn	Gly	Arg	Gln	Lys	Asp	Val	Asp	Lys	565	570	575	
Glu	Phe	Tyr	Leu	Phe	Pro	Thr	Val	Phe	Asp	Glu	Asn	Glu	Ser	Leu	Leu	580	585	590	
Leu	Glu	Asp	Asn	Ile	Arg	Met	Phe	Thr	Thr	Ala	Pro	Asp	Gln	Val	Asp	595	600	605	
Lys	Glu	Asp	Glu	Asp	Phe	Gln	Glu	Ser	Asn	Lys	Met	His	Ser	Met	Asn	610	615	620	
Gly	Phe	Met	Tyr	Gly	Asn	Gln	Pro	Gly	Leu	Thr	Met	Cys	Lys	Gly	Asp	625	630	635	640
Ser	Val	Val	Trp	Tyr	Leu	Phe	Ser	Ala	Gly	Asn	Glu	Ala	Asp	Val	His	645	650	655	
Gly	Ile	Tyr	Phe	Ser	Gly	Asn	Thr	Tyr	Leu	Trp	Arg	Gly	Glu	Arg	Arg	660	665	670	
Asp	Thr	Ala	Asn	Leu	Phe	Pro	Gln	Thr	Ser	Leu	Thr	Leu	His	Met	Trp	675	680	685	
Pro	Asp	Thr	Glu	Gly	Thr	Phe	Asn	Val	Glu	Cys	Leu	Thr	Thr	Asp	His	690	695	700	
Tyr	Thr	Gly	Gly	Met	Lys	Gln	Lys	Tyr	Thr	Val	Asn	Gln	Cys	Arg	Arg	705	710	715	720
Gln	Ser	Glu	Asp	Ser	Thr	Phe	Tyr	Leu	Gly	Glu	Arg	Thr	Tyr	Tyr	Ile	725	730	735	
Ala	Ala	Val	Glu	Val	Glu	Trp	Asp	Tyr	Ser	Pro	Gln	Arg	Glu	Trp	Glu	740	745	750	
Lys	Glu	Leu	His	His	Leu	Gln	Glu	Gln	Asn	Val	Ser	Asn	Ala	Phe	Leu	755	760	765	
Asp	Lys	Gly	Glu	Phe	Tyr	Ile	Gly	Ser	Lys	Tyr	Lys	Lys	Val	Val	Tyr	770	775	780	
Arg	Gln	Tyr	Thr	Asp	Ser	Thr	Phe	Arg	Val	Pro	Val	Glu	Arg	Lys	Ala	785	790	795	800

Glu	Glu	Glu	His	Leu	Gly	Ile	Leu	Gly	Pro	Gln	Leu	His	Ala	Asp	Val	
805																
Gly	Asp	Lys	Val	Lys	Ile	Ile	Phe	Lys	Asn	Met	Ala	Thr	Arg	Pro	Tyr	
820																
Ser	Ile	His	Ala	His	Gly	Val	Gln	Thr	Glu	Ser	Ser	Thr	Val	Thr	Pro	
835																
Thr	Leu	Pro	Gly	Glu	Thr	Leu	Thr	Tyr	Val	Trp	Lys	Ile	Pro	Glu	Arg	
850																
Ser	Gly	Ala	Gly	Thr	Glu	Asp	Ser	Ala	Cys	Ile	Pro	Trp	Ala	Tyr	Tyr	
865																
Ser	Thr	Val	Asp	Gln	Val	Lys	Asp	Leu	Tyr	Ser	Gly	Leu	Ile	Gly	Pro	
885																
Leu	Ile	Val	Cys	Arg	Arg	Pro	Tyr	Leu	Lys	Val	Phe	Asn	Pro	Arg	Arg	
900																
Lys	Leu	Glu	Phe	Ala	Leu	Leu	Phe	Leu	Val	Phe	Asp	Glu	Asn	Glu	Ser	
915																
Trp	Tyr	Leu	Asp	Asp	Asn	Ile	Lys	Thr	Tyr	Ser	Asp	His	Pro	Glu	Lys	
930																
Val	Asn	Lys	Asp	Asp	Glu	Glu	Phe	Ile	Glu	Ser	Asn	Lys	Met	His	Ala	
945																
Ile	Asn	Gly	Arg	Met	Phe	Gly	Asn	Leu	Gln	Gly	Leu	Thr	Met	His	Val	
965																
Gly	Asp	Glu	Val	Asn	Trp	Tyr	Leu	Met	Gly	Met	Gly	Asn	Glu	Ile	Asp	
980																
Leu	His	Thr	Val	His	Phe	His	Gly	His	Ser	Phe	Gln	Tyr	Lys	His	Arg	
995																
Gly	Val	Tyr	Ser	Ser	Asp	Val	Phe	Asp	Ile	Phe	Pro	Gly	Thr	Tyr		
1010																
Gln	Thr	Leu	Glu	Met	Phe	Pro	Arg	Thr	Pro	Gly	Ile	Trp	Leu	Leu		
1025																
His	Cys	His	Val	Thr	Asp	His	Ile	His	Ala	Gly	Met	Glu	Thr	Thr		
1040																
Tyr	Thr	Val	Leu	Gln	Asn	Glu	Asp	Thr	Lys	Ser	Gly					
1055																
1060																
1065																
<210> SEQ ID NO 8																
<211> LENGTH: 471																
<212> TYPE: PRT																
<213> ORGANISM: Escherichia coli																
<400> SEQUENCE: 8																
Met	Lys	Gln	Ser	Thr	Ile	Ala	Leu	Ala	Leu	Leu	Pro	Leu	Leu	Phe	Thr	
1																
5																
Pro	Val	Thr	Lys	Ala	Arg	Thr	Pro	Glu	Met	Pro	Val	Leu	Glu	Asn	Arg	
20																
25																
30																
Ala	Ala	Gln	Gly	Asp	Ile	Thr	Ala	Pro	Gly	Gly	Ala	Arg	Arg	Leu	Thr	
35																
40																
45																
Gly	Asp	Gln	Thr	Ala	Ala	Leu	Arg	Asp	Ser	Leu	Ser	Asp	Lys	Pro	Ala	
50																
55																
60																
Lys	Asn	Ile	Ile	Leu	Leu	Ile	Gly	Asp	Gly	Met	Gly	Asp	Ser	Glu	Ile	
65																
70																
75																
80																
Thr	Ala	Ala	Arg	Asn	Tyr	Ala	Glu	Gly	Ala	Gly	Gly	Phe	Phe	Lys	Gly	
85																
90																
95																
Ile	Asp	Ala	Leu	Pro	Leu	Thr	Gly	Gln	Tyr	Thr	His	Tyr	Ala	Leu	Asn	
100																
105																
110																

-continued

---

Lys Lys Thr Gly Lys Pro Asp Tyr Val Thr Asp Ser Ala Ala Ser Ala  
 115 120 125  
 Thr Ala Trp Ser Thr Gly Val Lys Thr Tyr Asn Gly Ala Leu Gly Val  
 130 135 140  
 Asp Ile His Glu Lys Asp His Pro Thr Ile Leu Glu Met Ala Lys Ala  
 145 150 155 160  
 Ala Gly Leu Ala Thr Gly Asn Val Ser Thr Ala Glu Leu Gln Asp Ala  
 165 170 175  
 Thr Pro Ala Ala Leu Val Ala His Val Thr Ser Arg Lys Cys Tyr Gly  
 180 185 190  
 Pro Ser Ala Thr Ser Glu Lys Cys Pro Gly Asn Ala Leu Glu Lys Gly  
 195 200 205  
 Gly Lys Gly Ser Ile Thr Glu Gln Leu Leu Asn Ala Arg Ala Asp Val  
 210 215 220  
 Thr Leu Gly Gly Gly Ala Lys Thr Phe Ala Glu Thr Ala Thr Ala Gly  
 225 230 235 240  
 Glu Trp Gln Gly Lys Thr Leu Arg Glu Gln Ala Gln Ala Arg Gly Tyr  
 245 250 255  
 Gln Leu Val Ser Asp Ala Ala Ser Leu Asn Ser Val Thr Glu Ala Asn  
 260 265 270  
 Gln Gln Lys Pro Leu Leu Gly Leu Phe Ala Asp Gly Asn Met Pro Val  
 275 280 285  
 Arg Trp Leu Gly Pro Lys Ala Thr Tyr His Gly Asn Ile Asp Lys Pro  
 290 295 300  
 Ala Val Thr Cys Thr Pro Asn Pro Gln Arg Asn Asp Ser Val Pro Thr  
 305 310 315 320  
 Leu Ala Gln Met Thr Asp Lys Ala Ile Glu Leu Leu Ser Lys Asn Glu  
 325 330 335  
 Lys Gly Phe Phe Leu Gln Val Glu Gly Ala Ser Ile Asp Lys Gln Asp  
 340 345 350  
 His Ala Ala Asn Pro Cys Gly Gln Ile Gly Glu Thr Val Asp Leu Asp  
 355 360 365  
 Glu Ala Val Gln Arg Ala Leu Glu Phe Ala Lys Lys Glu Gly Asn Thr  
 370 375 380  
 Leu Val Ile Val Thr Ala Asp His Ala His Ala Ser Gln Ile Val Ala  
 385 390 395 400  
 Pro Asp Thr Lys Ala Pro Gly Leu Thr Gln Ala Leu Asn Thr Lys Asp  
 405 410 415  
 Gly Ala Val Met Val Met Ser Tyr Gly Asn Ser Glu Glu Asp Ser Gln  
 420 425 430  
 Glu His Thr Gly Ser Gln Leu Arg Ile Ala Ala Tyr Gly Pro His Ala  
 435 440 445  
 Ala Asn Val Val Gly Leu Thr Asp Gln Thr Asp Leu Phe Tyr Thr Met  
 450 455 460  
 Lys Ala Ala Leu Gly Leu Lys  
 465 470

&lt;210&gt; SEQ ID NO 9

&lt;211&gt; LENGTH: 1024

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Escherichia coli

&lt;400&gt; SEQUENCE: 9

Met Thr Met Ile Thr Asp Ser Leu Ala Val Val Leu Gln Arg Arg Asp

-continued

---

1	5	10	15
Trp Glu Asn Pro Gly Val Thr Gln Leu Asn Arg Leu Ala Ala His Pro	20	25	30
Pro Phe Ala Ser Trp Arg Asn Ser Glu Glu Ala Arg Thr Asp Arg Pro	35	40	45
Ser Gln Gln Leu Arg Ser Leu Asn Gly Glu Trp Arg Phe Ala Trp Phe	50	55	60
Pro Ala Pro Glu Ala Val Pro Glu Ser Trp Leu Glu Cys Asp Leu Pro	65	70	75
Glu Ala Asp Thr Val Val Val Pro Ser Asn Trp Gln Met His Gly Tyr	85	90	95
Asp Ala Pro Ile Tyr Thr Asn Val Thr Tyr Pro Ile Thr Val Asn Pro	100	105	110
Pro Phe Val Pro Thr Glu Asn Pro Thr Gly Cys Tyr Ser Leu Thr Phe	115	120	125
Asn Val Asp Glu Ser Trp Leu Gln Glu Gly Gln Thr Arg Ile Ile Phe	130	135	140
Asp Gly Val Asn Ser Ala Phe His Leu Trp Cys Asn Gly Arg Trp Val	145	150	155
Gly Tyr Gly Gln Asp Ser Arg Leu Pro Ser Glu Phe Asp Leu Ser Ala	165	170	175
Phe Leu Arg Ala Gly Glu Asn Arg Leu Ala Val Met Val Leu Arg Trp	180	185	190
Ser Asp Gly Ser Tyr Leu Glu Asp Gln Asp Met Trp Arg Met Ser Gly	195	200	205
Ile Phe Arg Asp Val Ser Leu Leu His Lys Pro Thr Thr Gln Ile Ser	210	215	220
Asp Phe His Val Ala Thr Arg Phe Asn Asp Asp Phe Ser Arg Ala Val	225	230	235
Leu Glu Ala Glu Val Gln Met Cys Gly Glu Leu Arg Asp Tyr Leu Arg	245	250	255
Val Thr Val Ser Leu Trp Gln Gly Glu Thr Gln Val Ala Ser Gly Thr	260	265	270
Ala Pro Phe Gly Gly Glu Ile Ile Asp Glu Arg Gly Gly Tyr Ala Asp	275	280	285
Arg Val Thr Leu Arg Leu Asn Val Glu Asn Pro Lys Leu Trp Ser Ala	290	295	300
Glu Ile Pro Asn Leu Tyr Arg Ala Val Val Glu Leu His Thr Ala Asp	305	310	315
Gly Thr Leu Ile Glu Ala Glu Ala Cys Asp Val Gly Phe Arg Glu Val	325	330	335
Arg Ile Glu Asn Gly Leu Leu Leu Leu Asn Gly Lys Pro Leu Leu Ile	340	345	350
Arg Gly Val Asn Arg His Glu His His Pro Leu His Gly Gln Val Met	355	360	365
Asp Glu Gln Thr Met Val Gln Asp Ile Leu Leu Met Lys Gln Asn Asn	370	375	380
Phe Asn Ala Val Arg Cys Ser His Tyr Pro Asn His Pro Leu Trp Tyr	385	390	395
Thr Leu Cys Asp Arg Tyr Gly Leu Tyr Val Val Asp Glu Ala Asn Ile	405	410	415
Glu Thr His Gly Met Val Pro Met Asn Arg Leu Thr Asp Asp Pro Arg	420	425	430

-continued

---

Trp	Leu	Pro	Ala	Met	Ser	Glu	Arg	Val	Thr	Arg	Met	Val	Gln	Arg	Asp
	435						440					445			
Arg	Asn	His	Pro	Ser	Val	Ile	Ile	Trp	Ser	Leu	Gly	Asn	Glu	Ser	Gly
	450					455					460				
His	Gly	Ala	Asn	His	Asp	Ala	Leu	Tyr	Arg	Trp	Ile	Lys	Ser	Val	Asp
	465				470					475					480
Pro	Ser	Arg	Pro	Val	Gln	Tyr	Glu	Gly	Gly	Gly	Ala	Asp	Thr	Thr	Ala
			485						490					495	
Thr	Asp	Ile	Ile	Cys	Pro	Met	Tyr	Ala	Arg	Val	Asp	Glu	Asp	Gln	Pro
		500						505					510		
Phe	Pro	Ala	Val	Pro	Lys	Trp	Ser	Ile	Lys	Lys	Trp	Leu	Ser	Leu	Pro
	515						520					525			
Gly	Glu	Thr	Arg	Pro	Leu	Ile	Leu	Cys	Glu	Tyr	Ala	His	Ala	Met	Gly
	530					535					540				
Asn	Ser	Leu	Gly	Gly	Phe	Ala	Lys	Tyr	Trp	Gln	Ala	Phe	Arg	Gln	Tyr
	545				550					555					560
Pro	Arg	Leu	Gln	Gly	Gly	Phe	Val	Trp	Asp	Trp	Val	Asp	Gln	Ser	Leu
			565						570					575	
Ile	Lys	Tyr	Asp	Glu	Asn	Gly	Asn	Pro	Trp	Ser	Ala	Tyr	Gly	Gly	Asp
		580						585					590		
Phe	Gly	Asp	Thr	Pro	Asn	Asp	Arg	Gln	Phe	Cys	Met	Asn	Gly	Leu	Val
	595						600					605			
Phe	Ala	Asp	Arg	Thr	Pro	His	Pro	Ala	Leu	Thr	Glu	Ala	Lys	His	Gln
	610					615					620				
Gln	Gln	Phe	Phe	Gln	Phe	Arg	Leu	Ser	Gly	Gln	Thr	Ile	Glu	Val	Thr
	625				630					635					640
Ser	Glu	Tyr	Leu	Phe	Arg	His	Ser	Asp	Asn	Glu	Leu	Leu	His	Trp	Met
			645					650						655	
Val	Ala	Leu	Asp	Gly	Lys	Pro	Leu	Ala	Ser	Gly	Glu	Val	Pro	Leu	Asp
		660						665					670		
Val	Ala	Pro	Gln	Gly	Lys	Gln	Leu	Ile	Glu	Leu	Pro	Glu	Leu	Pro	Gln
	675					680						685			
Pro	Glu	Ser	Ala	Gly	Gln	Leu	Trp	Leu	Thr	Val	Arg	Val	Val	Gln	Pro
	690				695						700				
Asn	Ala	Thr	Ala	Trp	Ser	Glu	Ala	Gly	His	Ile	Ser	Ala	Trp	Gln	Gln
	705				710					715					720
Trp	Arg	Leu	Ala	Glu	Asn	Leu	Ser	Val	Thr	Leu	Pro	Ala	Ala	Ser	His
			725						730					735	
Ala	Ile	Pro	His	Leu	Thr	Thr	Ser	Glu	Met	Asp	Phe	Cys	Ile	Glu	Leu
		740						745					750		
Gly	Asn	Lys	Arg	Trp	Gln	Phe	Asn	Arg	Gln	Ser	Gly	Phe	Leu	Ser	Gln
	755					760						765			
Met	Trp	Ile	Gly	Asp	Lys	Lys	Gln	Leu	Leu	Thr	Pro	Leu	Arg	Asp	Gln
	770				775						780				
Phe	Thr	Arg	Ala	Pro	Leu	Asp	Asn	Asp	Ile	Gly	Val	Ser	Glu	Ala	Thr
	785				790					795					800
Arg	Ile	Asp	Pro	Asn	Ala	Trp	Val	Glu	Arg	Trp	Lys	Ala	Ala	Gly	His
			805						810					815	
Tyr	Gln	Ala	Glu	Ala	Ala	Leu	Leu	Gln	Cys	Thr	Ala	Asp	Thr	Leu	Ala
		820						825					830		
Asp	Ala	Val	Leu	Ile	Thr	Thr	Ala	His	Ala	Trp	Gln	His	Gln	Gly	Lys
	835						840					845			



-continued

---

Thr Leu Phe Ile Ser Arg Lys Thr Tyr Arg Ile Asp Gly Ser Gly Gln  
 850 855 860  
 Met Ala Ile Thr Val Asp Val Glu Val Ala Ser Asp Thr Pro His Pro  
 865 870 875 880  
 Ala Arg Ile Gly Leu Asn Cys Gln Leu Ala Gln Val Ala Glu Arg Val  
 885 890 895  
 Asn Trp Leu Gly Leu Gly Pro Gln Glu Asn Tyr Pro Asp Arg Leu Thr  
 900 905 910  
 Ala Ala Cys Phe Asp Arg Trp Asp Leu Pro Leu Ser Asp Met Tyr Thr  
 915 920 925  
 Pro Tyr Val Phe Pro Ser Glu Asn Gly Leu Arg Cys Gly Thr Arg Glu  
 930 935 940  
 Leu Asn Tyr Gly Pro His Gln Trp Arg Gly Asp Phe Gln Phe Asn Ile  
 945 950 955 960  
 Ser Arg Tyr Ser Gln Gln Gln Leu Met Glu Thr Ser His Arg His Leu  
 965 970 975  
 Leu His Ala Glu Glu Gly Thr Trp Leu Asn Ile Asp Gly Phe His Met  
 980 985 990  
 Gly Ile Gly Gly Asp Asp Ser Trp Ser Pro Ser Val Ser Ala Glu Phe  
 995 1000 1005  
 Gln Leu Ser Ala Gly Arg Tyr His Tyr Gln Leu Val Trp Cys Gln  
 1010 1015 1020  
 Lys

---

What is claimed is:

1. A microtube comprising:

an electrospun shell,

an electrospun coat polymer over an internal surface of  
 said shell and a molecule-of-interest attached to the  
 microtube,

wherein said electrospun shell comprises pores,

wherein said electrospun shell is formed of a first poly-  
 meric solution comprising a first solvent and said  
 electrospun coat is formed of a second polymeric  
 solution comprising a second solvent,

wherein said second solvent of said second polymeric  
 solution is incapable of dissolving the polymer of said  
 first polymeric solution,

wherein said first polymeric solution solidifies faster than  
 said second polymeric solution,

wherein said second polymeric solution is capable of  
 wetting said internal surface of said shell during or  
 following solidification of said first polymeric solution,

wherein said electrospun shell comprises a polymer  
 selected from the group consisting of poly (ε-caprolac-  
 tone) (PCL), polyamide, poly(siloxane), poly(silicone),  
 poly(ethylene), poly(vinyl pyrrolidone), poly(2-hy-  
 droxy ethylmethacrylate), poly(N-vinyl pyrrolidone),  
 poly(methyl methacrylate), poly(vinyl alcohol), poly  
 (acrylic acid), poly(vinyl acetate), polyacrylamide,  
 poly(ethylene-co-vinyl acetate), poly(methacrylic  
 acid), polylactide, polyglycolide, poly(lactide-cogly-  
 colide), polyanhydride, polyorthoester, poly(carbon-  
 ate), poly(acrylo nitrile), polyaniline, polyvinyl carba-  
 zole, polystyrene, poly(vinyl phenol),  
 polyhydroxyacid, poly(caprolactone), polyanhydride,  
 polyhydroxyalkanoate, and polyurethane, and whereas  
 said electrospun coat comprises a polymer selected  
 from the group consisting of poly(acrylic acid), poly

(vinyl acetate), polyacrylamide, poly(ethylene-co-vinyl  
 acetate), poly(ethylene glycol), poly(methacrylic acid),  
 polylactide polyglycolide, poly(lactide-coglycolide),  
 polyanhydride, polyorthoester, poly(carbonate), poly  
 (ethylene oxide), polyaniline, polyvinyl carbazole,  
 polystyrene, poly(vinyl phenol), and polyhydroxyacid,  
 wherein said polymer of said first polymeric solution and  
 said polymer of said second polymeric solution are  
 different,

wherein said molecule-of-interest is selected from the  
 group consisting of: a polypeptide, a polynucleotide, a  
 carbohydrate, a polysaccharide, a lipid, a drug mol-  
 ecule, and a small molecule, and

wherein said small molecule is selected from the group  
 consisting of a nucleotide base, an amino acid, a  
 nucleotide, an antibiotic, and a vitamin.

2. The microtube of claim 1, wherein said first solvent of  
 said first polymeric solution evaporates faster than said  
 second solvent of said second polymeric solution.

3. The microtube of claim 1, wherein said second solvent  
 of said second polymeric solution is capable of evaporating  
 through said internal surface of said shell.

4. The microtube of claim 1, wherein a thickness of said  
 shell is from about 100 nm to about 20 micrometer.

5. The microtube of claim 1, wherein an internal diameter  
 of the microtube is from about 50 nm to about 20 microm-  
 eter.

6. The microtube of claim 1, wherein said first and said  
 second polymeric solutions are selected from the group  
 consisting of: 10% poly (ε-caprolactone) (PCL) in chloro-  
 form (CHCl<sub>3</sub>) and dimethylformamide (DMF) (80:20 by  
 weight) as said first polymeric solution and 4% poly(ethyl-  
 ene oxide) (PEO) in water (H<sub>2</sub>O) and ethanol (60:40 by  
 weight) as said second polymeric solution, 10% PCL in  
 CHCl<sub>3</sub> and DMF (80:20 by weight) as said first polymeric

85

solution and 6% PEO in H<sub>2</sub>O and ethanol (60:40 by weight) as said second polymeric solution, 9% PCL in CHCl<sub>3</sub> and DMF (90:10 by weight) as said first polymeric solution and 7% PEO in H<sub>2</sub>O as said second polymeric solution, 10% PCL in CHCl<sub>3</sub> and DMF (80:20 by weight) as said first polymeric solution and 9% poly(vinyl alcohol) (PVA) in water and ethanol (50:50 by weight) as said second polymeric solution, and 10% PCL in CHCl<sub>3</sub> and DMF (90:10 by weight) as the first polymeric solution and 4% (by weight) PEO in ethanol:H<sub>2</sub>O (26:74 by weight) as a second polymeric solution.

7. The microtube of claim 1, wherein said microtube is filled with a liquid.

8. The microtube of claim 1, wherein said molecule-of-interest is attached to said coat over said internal surface of said shell.

9. The microtube of claim 1, wherein said cell or said membrane-coated particle-of-interest is attached to said shell of the microtube.

86

10. The microtube of claim 1, wherein said first polymeric solution further comprises polyethylene glycol (PEG).

11. The microtube of claim 1, wherein said shell prevents diffusion of the molecule-of-interest therethrough.

12. A microfluidic device comprising a plurality of the microtubes of claim 1.

13. The microtube of claim 1, wherein said microtube is a single or separated microtube.

14. The microtube of claim 1, wherein said microtube comprises a plurality of microtubes.

15. The microtube of claim 14, wherein said plurality of microtubes form an aligned array.

16. The microtube of claim 7, wherein said liquid is blood.

17. The microtube of claim 1, wherein said polymer comprises a co-polymer.

18. The microtube of claim 1, wherein said polymer comprises a blend of polymers.

\* \* \* \* \*